

ean
congress

4th Congress of the
European Academy
of Neurology

Lisbon
2018

June 16 – 19

Neurogenetics

Unravelling hidden diseases.



Final Programme

THE WAY WE SEE IT, EVEN GREY MATTERS.

LET'S GIVE IT MEANING.
TOGETHER.

JOIN
EAN TODAY
ean.org/membership

Driving Excellence in Neurology.

Be part of one of humankind's most ambitious projects to help uncover the workings of the nervous system. EAN connects 45,000 specialists in neurology in 47 countries across Europe. Promoting excellence, cutting-edge science and innovative therapies for a better life for more than 430 million patients in Europe alone. Read more on ean.org

Great Minds.



General Information

Welcome Message	03
About EAN	04
Board and Committees	05
EAN Membership Information	06
Educational grants Information	07
Resident and Research Fellow Section (EAN-RRFS)	09
Congress Grants	10
Appreciation and thanks	12
Continuing Medical Education, Accreditation	13
Instructions for Speakers and Presenters	14
Information from A-Z	14
Floor plans	24
EAN Business meeting overview	28
ePoster and ePresentation Overview	31
Networking Programme and Other Activities	36
Timetable/Session Overview	42

Scientific Programme

Saturday, 16 June 2018

Educational Sessions	50, 56, 58, 61, 62
Focused Workshops	51, 52
Special Sessions	52, 58, 61
Symposia	53, 54
Teaching Courses	59, 60, 61
Oral Sessions	64

Sunday, 17 June 2018

Educational Sessions	70, 71, 76, 79
Focused Workshops	71, 72
Presidential Symposium	75
Special Sessions	73, 76, 77
Teaching Courses	77
Oral Sessions	80

Monday, 18 June 2018

Educational Sessions	86, 91, 92, 94
Focused Workshops	87, 88
Special Sessions	89
Symposia	90
Teaching Courses	92
Oral Sessions	96

Tuesday, 19 June 2018

Educational Sessions	106, 107, 108, 109
Highlight + Breaking News	108
Special Sessions	107
Symposia	106
Teaching Courses	109
Oral Sessions	112

Industry Sponsored Programme

Acknowledgements	119
Exhibitors and Exhibition Floor Plan	120
Satellite Symposia Programmes	126
3-Days Satellite Sessions	153
Forum Talk Programmes	157
Index	161

OUR UNIVERSE IS MADE UP OF 86 BILLION NEURONS.

LET'S EXPLORE IT.
TOGETHER.

Driving Excellence in Neurology.

Be part of one of humankind's most ambitious projects to help uncover the workings of the nervous system. EAN connects 45,000 specialists in neurology in 47 countries across Europe. Promoting excellence, cutting-edge science and innovative therapies for a better life for more than 430 million patients in Europe alone. Read more on ean.org

Great Minds.



Welcome

On behalf of the European Academy of Neurology and the Portuguese Society of Neurology, we are pleased to you to the 4th Congress of the European Academy of Neurology (EAN) taking place in Lisbon, Portugal from June 16-19, 2018.

The overarching theme for the Lisbon congress is 'Neurogenetics – Unravelling hidden diseases'. Diagnosis and treatment are increasingly using genetic methods and one purpose of the congress is to highlight clinically useful aspects of genetic medicine in Neurology. But as always, progress in all fields of neurology will be presented and participants will be updated about recent developments and news in clinical neurology. The selection of the educational programme is meanwhile organised within a newly adapted 5-year EAN educational curriculum. This curriculum is covering all important aspects a neurologist should learn and update in this period.

Lisbon is a modern town, easily accessible from almost everywhere, where you can enjoy the hospitality of its people, walking around town exploring culture, arts and food. The charming capital of Portugal is located by the wide estuary of Tagus River where you will find scenic views from almost every corner. Here, you can absorb the unique scent of the near Mediterranean, mild and pleasant climate of early summer and the peculiar luminosity of a blue sky reflected on its white ancient houses in historic areas. Lisbon is dominated by its castle, more than one thousand years old, with a unique view. This is a city full of history where you may feel the ambiance of the old Arab neighborhood of Alfama and Mouraria, where Fado, the national sentimental song, was born. Needless to say, that it was from Lisbon, that the navigators left to discover the world and you can meet history at several museums and monuments.

EAN and the Portuguese Society of Neurology cordially welcome the European neurological community to celebrate the strength and beauty of our field and to get inspired by meeting with colleagues and friends.



Paul Boon
Chair
Programme Committee
of the European
Academy of Neurology



Günther Deuschl
President
European Academy
of Neurology



Joaquim Ferreira
Chair
Local Organising
Committee



Join us to promote
excellence in neurology!

About EAN

The European Academy of Neurology (EAN) has been founded in 2014 on the initiative of the European Neurological Society (ENS) and the European Federation of Neurological Societies (EFNS), who both considered it essential to have one joint professional and scientific Neurology organisation in Europe. EAN shall provide the essential infrastructure together with the organisational framework for the support and development of neurological education and research in Europe.

The Aim of EAN is Excellence in Neurology in Europe

EAN is a non-profit organisation and identifies itself with the following five values:

- Professionalism. EAN will strive to reach the highest scientific standards and to deliver unbiased information in its research and educational activities.
- High ethical standards. EAN will apply high ethical standards in all its activities within science, education, communication, and administration, complying with applicable regulations and codes of ethics.
- Involvement. EAN will strive to involve its members and collaborators in the organisation of research, education and liaison activities.
- Independence. EAN will operate as a professional and scientific organisation, independent from the political or commercial interests of external companies or organisations.
- Transparency. EAN will provide transparency in the organisation of all its scientific and administrative activities.

EAN is an organisation of:

- 47 European national neurological societies
- 900 individual members
- 10 corresponding member societies

EAN consists of:

- an Assembly of Delegates of institutional and individual delegates
- elected officers
- 4 committees (+ 3 sub-committees)
- 31 Scientific Panels

Committees

EAN Board

Günther Deuschl, Germany
President

Franz Fazekas, Austria
President elect

Didier Leys, France
Secretary General

Marianne de Visser, The Netherlands
Treasurer

Antonio Federico, Italy
Chair Scientific Committee

David B. Vodušek, Slovenia
Chair Communication Committee

Hannah Cock, UK
Chair Education Committee

Paul A.J.M. Boon, Belgium
Chair Programme Committee

Per Soelberg Sørensen, Denmark
Member at Large

Programme Committee

Paul A.J.M. Boon, Belgium, (*Chair*)
Joaquim Ferreira, Portugal, (*Co-Chair*)

Valeria Caso, Italy
Hannah Cock, UK (*Chair Education Committee*)
Marianne Dieterich, Germany
Antonio Federico, Italy (*Chair Scientific Committee*)
Ivan Rektor, Czech Republic
Philip Scheltens, The Netherlands
Aksel Siva, Turkey
Riccardo Soffietti, Italy
Claudia Sommer, Germany (*Chair Teaching Course sub-Committee*)
Guido Stoll, Germany
Pille Taba, Estonia (*MDS-ES representative*)

Local Organising Committee

Joaquim Ferreira, (*Chair*)

Mamede de Carvalho, Manuel Correia, Rui Costa, José Ferro,
Victor Oliveira, Ana Amélia Nogueira Pinto, Isabel Pavão Martins

Teaching Course sub-Committee

Claudia Sommer, Germany, (*Chair*)
Anish Bahra, United Kingdom
Theodor Landis, Switzerland
Elena R. Lebedeva, Russian Federation
Milija Mijajlovic, Serbia
Viktoria Papp, Denmark (*RRFS Representative*)
Erich Schmutzhard, Austria
Pille Taba, Estonia (*MDS-ES representative*)

Membership Information

EAN Membership Information

Become an EAN individual member and benefit from the following:

- reduced membership fee at the annual congresses
- active and passive voting rights at the Assembly of Delegates of the EAN
- possibility to participate in EAN Committees and Scientific Panels
- free online access to the online learning platform eBrain
- free online access to the European Journal of Neurology
- free online access to the guidelines
- access to educational grants (if applicable)
- right to purchase the *European Journal of Neurology* (EJN) at a reduced rate
- a membership certificate
- monthly mailshots of the EAN electronic newsletter
- one free Teaching Course at EAN annual congresses
- free access to VIP area at EAN annual congresses
- free professional photo taken at Congress
- free access to selected congress webcasts on the website after the congress
- AAN shared Membership:

If you are an AAN Member, you are eligible of a 10% discount off your EAN Individual Membership fee. In reverse, EAN Individual members receive a 10% discount when applying for AAN membership.



Individual Membership Categories:

Full Individual Member: Neurologists who are nationals of any EAN member country; and/or neurologists practicing in any EAN member country including neurologists in training.

Resident and Research Fellow (RRF): Physicians in training can become individual members of EAN via the EAN Resident and Research Fellow Section at a reduced fee. Residency has to be proven annually by a signed confirmation of the physician in charge of the residency programme



Corresponding Individual Member:

- Neurologists who are nationals of and practice in countries other than EAN member countries
- Health Professionals and/or Scientists of other specialties or professions related to Neurology

Undergraduate Student:

Undergraduate medical students can become individual members. They need to explain their special interest in neurology and the purpose why they request membership.

Fellow of EAN (FEAN)

The title 'Fellow of the EAN' acknowledges a limited number of neurologists who are full individual members and who deserve a special recognition of the EAN because of

- a scientific achievement that places them within the European leaders in their field, or
- significant and continuing service in a leadership position for of a European or World society for neurology or neurological subspecialty society, or
- a service for neurological patients that is considered exceptional

Fellow of the EAN is a title honouring special service to neurology and the Society.



Please apply by sending your application form and CV (in English) to the EAN Head Office:
membership@ean.org
Forms can be downloaded online or be sent to upon request.

Honorary Members and Service Award 2018

Mark Hallett, Bethesda, USA and Alistar Compston, Cambridge, UK will be awarded the EAN Honorary Membership during the Opening.

Amadou Gallo Diop, Dakar, Senegal and Riad Gouider, Tunis, Tunisia will receive the EAN Service Award during the EAN Assembly of Delegates

Educational Grants Information

Clinical Fellowship 2019



Application Deadline: October 31, 2018

The purpose of this award is to provide a well-defined observational clinical practice, service structure or technical experience to support training. The grant is to support a visit of six weeks duration.

Each grant is amounting to € 1,500.-/month (plus travel expenses of up to € 300.-)

A list of approved hosting departments (and details for interested hosts of how to apply) is available on www.ean.org

Candidates from all EAN member (and corresponding member) countries are eligible to apply. Applicants must be current residents with a minimum of 2 years training in neurology, or have obtained their board certificate/completed training within the last 3 years at the time of application; be fluent in English or the local language (host department).

Awardees from previous years are no more qualified.

All applicants must be Full member or RRFS member at time of application.

All application documents must be submitted by October 31, 2018 by email to Ms. Magda Dohnalová: dohnalova@ean.org

Application is open between 1 August and 31 October 2018

EAN Research Fellowship 2019



Application deadline: August 31, 2018

The purpose is to support training and experience for European Neurologists in any area of basic or clinical or applied research in neuroscience. The research work must be carried out at a European academic neurological department outside the country of residence. All applications should

demonstrate experience/ training of clear value to the home department/individual beyond that available in their own countries/ institutions.

Successful applicants will be awarded € 2,000.- per month.

Research training fellowship: Expected to be of typically 12 months and no less than 6 months, to lead either to completion of a higher degree, a grant application or peer-reviewed publication.

Research experience fellowship: Expected to be of typically and no more than 6 months duration for individuals who might otherwise not have the opportunity to gain high quality research experience; more experienced clinicians/researchers requiring training in a specific research methodology or technique not currently available in their own country and of clear value to home department will also be considered.

Candidates from EAN member countries and affiliated to a European academic neurological department with a minimum of 2 years neurology training, up to a maximum of 5 years beyond their final degree (PhD, MD, or equivalent) at the time of application are eligible to apply.

All applicants must be Full member or RRFS member at time of application.

Applicants and hosts are expected to have consulted and worked together on any application to maximise the likelihood of success.

All application documents must be submitted by August 31, 2018 by email to Ms. Julia Mayer: fellowship@ean.org

Application Deadline: August 31, 2018

EAN Spring School 2019

May 2019



Application deadline: January 31, 2019

Dedicated to clinical neurologists in training who did not yet complete their residency/ clinical speciality training who wish to boost their knowledge and to get the chance to enable personal contacts among participants and faculty members

Preliminary Programme:

1. Stroke
2. Higher cortical functions
3. Neurorehabilitation

Structure: morning plenary sessions and case-based workshops in the afternoons.

Educational Grants Information

All applicants must be neurologists in training (not yet completed residency/ clinical speciality training) who will have had at least 2 years of clinical experience by the time of the course, and who are able to attend the full course. Participants nominated for attendance by their national neurological societies will be prioritised, but individual applications are also welcome up to the full capacity. Awardees from previous years are no more qualified.

All applicants must be Full member or RRFS member at time of application.

Accommodation, tuition, board and programme are sponsored by the EAN. Participants pay for their travel only.

All application documents must be submitted by January 31, 2019 by email to Ms. Magda Dohnalová: dohnalova@ean.org

Application open between 1 October 2018 and 31 January 2019

EAN Autumn School 2018
November 8-11, 2018



Application deadline: July 31, 2018

Increase your knowledge of clinical neurology! Experienced neurologists and sub-specialists will illustrate how they approach specific clinical presentations, including an update on relevant diagnostic and treatment approaches for key conditions in the relevant areas.

Preliminary Programme:

1. Episodic Loss of consciousness
2. Gait Disorders
3. Tremor (jointly organised with MDS-ES)

Structure: morning plenary sessions and hands-on/case-based clinical workshops (video and patient presentations) for 20 persons each in the afternoons.

Location: Loutraki, Greece (1,5h from Athens airport)

All applicants must be neurologists in training (not yet completed residency/ clinical speciality training) who will have had at least 2 years of clinical experience by the time of the course, and who are able to attend the full course.

All applicants must be Full member or RRFS member at time of application.

Accommodation, tuition, board and programme are sponsored by the EAN. Participants pay for their travel only.

All application documents must be submitted by July 31, 2018 by email to Ms. Magda Dohnalová: dohnalova@ean.org

Application open between 1 June and 31 July 2018

EAN Regional Teaching Courses (RTC) and EAN-Day

EAN-RTCs are specially designed for the purpose to bring neurological standards directly to the countries in the East or Sub-Saharan Africa to avoid that our colleagues in training have to travel to distant congresses. RTCs provide basic teaching in neurology and thus also establish friendly relations with all colleagues.

These courses are held in English language and have a duration of 3 days.

4 plenary session will be held each morning and will deal with each of the three main topics of the RTC, i.e. focus on one main topic per day. Small tuitional groups in the afternoon are set up to enhance the hand-on learning (case-based videoclips, Hands-on course, Workshops). Organisers are either National Neurological Societies or Neurological University departments.

The next EAN RTC will be in Struga, Macedonia, September 14-16, 2018

The EAN-Day aims at bringing excellent teaching and special recognition by EAN to our National Neurological Member Societies (and Corresponding Member Societies). This day takes place directly prior or after a National Neurological Society meeting.

Three plenary sessions will take place in the morning addressing 3 different topics.

After a lunch break, there will be rotating workshops on the same 3 topics, case-based video clips or hands-on courses for participants to work and learn in smaller groups.

The language is English.

All Guidance documents and application forms can be found online: www.ean.org- LEARN- Educational events

Education & RRFS

CME Articles



Each month a CME article is published in the *European Journal of Neurology* and on the EAN website. Answer 5 article-related questions correctly and receive a certificate recommending one hour of CME.

Please log-in on the EAN website for free-of-charge access to all e-learning features and the online version of the *European Journal of Neurology*.

eBrain



ebrain represents the world's largest, most comprehensive web-based training resource in clinical neuroscience designed to support training and continuous professional development for clinical neuroscience trainees, consultants and non-specialists. It is free-of-charge for EAN members. Please log-in on www.ean.org to have direct access. If you need help, please come to the EAN booth/LEARN, or contact education@ean.org

The multimedia-rich, engaging materials are designed to enhance traditional learning, support existing teaching methods and provide a valuable reference point that is accessible anytime, anywhere.

The online training content comprises approximately 20 modules of e-learning, with each of the 550+ individual lessons taking around 20 minutes to complete.

Guideline papers

Included in the EJoN, the Handbook as well as FREE OF CHARGE for EAN members via the Guideline Reference Center on the EAN website.

Resident and Research Fellow Section



RRFS represents the junior generation of neurologists within EAN. Our members are physicians currently working as a resident in Neurology, research fellow, PhD student or neurologist with not more than 3 years of practice after completion of the residence training. Application for membership can be done directly at the EAN booth or be sent to rrfs@ean.org, further information is provided on the EAN homepage.

The aims of RRFS are to support neurology trainees in their clinical training or research, to promote network between European junior neurologists and different generations of neurologists.

Activities of the Resident and Research Fellow Section during the Congress

Join us at the RRFS booth

During the congress, RRFS members are available at the LEARN and HOME area of the EAN booth in order to provide up-to-date information about membership, education and travel/EBN grants and other congress activities.

RRFS special session

Sunday, June 17, 8.00 - 9.30h, room Oslo
Resident and Research Fellow Section Round Table Discussion

This is the ideal opportunity to

- Learn about academic career and research opportunities around Europe
- Get expert advices on laboratory and clinical research
- Meet experts from different parts of Europe and improve the professional European network
- Get to know opinion leaders' careers and how they got there

Participants will meet worldwide renowned professors around Europe covering different field of interests as well as basic and clinical neuroscience.

Table 1 - José M Ferro, Lisbon, Portugal
(Main interest: stroke)

Table 2 - Klaus Viktor Toyka, Würzburg, Germany
(Main interest: Disease models of neuro-immunological and degenerative disorders of the nervous system)

Table 3 - Hannah Cock, London, United Kingdom
(Main interest: epilepsy)

Table 4 - Eva Kubala Havrdová, Prague, Czech Republic
(Main interest: multiple sclerosis)

RRFS & Congress Grants

Following the successful session last year, the special session of RRFS is held as a round table discussion. As participants found it most helpful and interesting to have direct discussions with the speaker, participants and speakers will directly sit down at four round tables with each Professor from different parts of Europe and with different fields of interest and the participants will then circulate between the round tables.

RRFS General Assembly

Monday, June 18, 14.15 - 15.15h, room 0.01
All RRFS members are invited to join the RRFS General Assembly.

RRFS annual hospital visit

Monday, June 18, 18:15h

This year, the traditional hospital visit is organised on Monday, June 18. Participants will be introduced to the local neurology education while visiting the Neurology Department of the Centro Hospitalar Lisboa Norte - Hospital de Santa Maria (Santa Maria University Hospital/North Lisbon Hospitalary Center).

Afterwards, transfer will be organised to the EAN "Meet your neurology network" event that will take place in the Museu Nacional de Arte Antiga (reduced entrance fee for all hospital visit participants).

Registration is necessary due to limited places. If you would like to join us, send an email to rrfs@ean.org.



Congress Grants

Bursaries

The 4th EAN Congress offered 240 bursaries consisting of free registration and up to four nights of hotel accommodation.

Eligible were PhD (neurology) students, residents of neurology or certified clinical neurologists (with no more than 3 years practice since completing training) who are working in Europe and whose abstract had been accepted.

It was also possible for colleagues in training from Algeria, Egypt, Jordan, Lebanon, Libya, Mauretania, Morocco, Palestine, Syria and Tunisia as well as from sub-Saharan countries belonging to the HINARI Group A list of countries as established by WHO (www.who.int/hinari/eligibility/en/) to apply for bursaries.

Applications were accompanied by a letter from the chairperson of the applicant's department confirming that they are in training. Only one bursary per abstract was awarded.

Bursary recipients were selected by the Programme Committee based on abstract evaluation.

Bursaries will be available for EAN RRFS and full members only.

The bursaries were co-sponsored by an educational grant from MDS-ES.

Applications for the 5th EAN congress Oslo 2019 can be submitted by the time of the abstract submission deadline: **23 January 2019**.

Investigator Award

All free presentations (oral presentations, posters) selected for presentation at the 4th EAN Congress 2018 will automatically take part in the selection of an Investigator Award. The award for the 20 best presentations will be a registration to the 5th EAN Congress in Oslo, Norway, a diploma and the winners will be announced in EAN Pages. The award will be given to the first author who needs to be the person to present the work at the congress. The EAN Scientific Panels together with the Scientific Committee and the Programme Committee will be responsible for the evaluation process before as well as during the congress.

Congress Grants

Tournament for Neurologists in Training

A tournament for neurologists in training will take place. The tournament will be carried out in two groups. One on basic neurological science, Sunday, June 17, 2018 (see page 80) and one on clinical related research on Monday, June 18, 2018 (see page 96).

Eligible were PhD (neurology) students, residents of neurology or certified clinical neurologists (with no more than 3 years practice since completing training) working in Europe and whose abstract has been accepted.

Selection of candidates: The EAN Programme Committee has selected 6 candidates for each tournament group based on the contents of the abstracts submitted. The clinical subjects had to be received from authors who work in Europe and thus carry out their projects in Europe. For the basic science session, clinical relevance was weighted.

Financial support: Candidates selected for the tournament have received a bursary consisting of free registration to the Congress, up to four nights hotel accommodation, and a travel grant.

Presentation: Each selected candidate is allotted 10 minutes for presentation of his/her paper plus five minutes for discussion with the jury.

Jury: Members of the Programme, the Scientific and the Teaching Course Committees.

Evaluation: Candidates will be judged not only on the scientific value of the work presented, but also on the quality of the oral presentation and the way the candidate responds to the questions of the jury.

Prize: The winner of each group will receive a prize consisting of: Free registration at the 5th EAN Congress in Oslo 2019, up to four nights hotel accommodation as well as a travel grant. The prize is not transferable and will not be paid off in cash.

Two runner-up prizes in each, the clinical and basic tournament will be awarded. They will consist of a certificate and a free registration to the 5th EAN Congress in Oslo 2019.

IN OUR
PROFESSION,
PERCEPTION IS KEY.

LET'S TRAIN IT. TOGETHER.

JOIN
AND TAKE
ADVANTAGE
OF RRFs
ean.org/rrfs

Whichever path you're on, boost your career by getting involved in our international community!

Great Minds.



Appreciation and thanks

We would like to thank the reviewers of the submitted abstracts for their invaluable help and assistance:

A

Federica Agosta, Italy
 Diana Aguiar de Sousa, Portugal
 Yuri Alekseenko, Belarus
 Pasquale Annunziata, Italy
 Fabio Antonaci, Italy
 Angelo Antonini, Italy
 Zohar Argov, Israel
 Nadine Attal, France

B

Shakya Bhattacharjee, UK
 Paul Boon, Belgium
 Thomas Brandt, Germany
 Geir Brathen, Norway
 Filipe Brogueira Rodrigues, UK
 Wallace Brownlee, UK
 Jean Marc Burgunder, Switzerland

C

Pasquale Calabrese, Switzerland
 Stefano Cappa, Italy
 Valeria Caso, Italy
 Declan Chard, UK
 Hannah Cock, UK
 Carlo Colosimo, Italy
 Giancarlo Comi, Italy
 Pamela Correia, Switzerland
 Ana Cristina Duque Santos, Portugal
 Laszlo Csiba, Hungary
 Anna Czlonkowska, Poland

D

Maxwell Damian, UK
 Marianne de Visser, The Netherlands
 Vida Demarin, Hungary
 Günther Deuschl, Germany
 Giovanni Di Liberto, Switzerland
 Marianne Dieterich, Germany
 Karin Diserens, Switzerland
 João Luís Oliveira Durães, Portugal
 Raffaele Dubbioso, Italy
 Andreij Dubenko, Ukraine
 Francois Ducray, France

E

Edvard Ehler, Czech Republic
 Stefan Evers, Germany

F

Franz Fazekas, Austria
 Antonio Federico, Italy
 Luigi Ferini-Strambi, Italy
 José Ferro, Portugal
 Massimo Filippi, Italy
 Alessandro Filla, Italy

G

Thomas Gattringer, Austria
 Raquel Gil-Gouveia, Portugal
 Raquel Gutiérrez Zúñiga, Spain

H

Mario Habek, Hungary
 Hans-Peter Hartung, Germany
 Wolfgang Heide, Germany
 Raimund Helbok, Austria
 Max J. Hilz, Germany

K

Ulf Kallweit, Germany
 Reetta Kälviäinen, Finland
 Vincent Keereman, Belgium
 Michael Khalil, Austria
 Nina Khizanishvili, Germany
 Thomas Klopstock, Germany
 Christian Krarup, Denmark
 Jera Kruja, Albania
 Jan Kuks, The Netherlands

L

Lieven Lagae, Belgium
 Maurizio Leone, Italy
 Vitalie Lisnic, Moldova

M

Monica Margoni, Italy
 Hugh Markus, UK
 Geert Mayer, Germany
 Patrik Michel, Switzerland

O

Stefan Oberndorfer, Austria
 Oana Maria Obrisca, Romania
 David Oliver, UK
 Irina Orban, Romania
 Serefnur Öztürk, Turkey

P

Eleftherios Papathanasiou, Cyprus
 Viktoria Papp, Denmark
 Simon Podnar, Slovenia
 Werner Poewe, Austria
 Maura Pugliatti, Italy

R

Olivier Rascol, France
 Radu Razvan, Romania
 Heinz Reichmann, Germany
 Ivan Rektor, Czech Republic
 Roberta Rudá, Italy
 Marina Ruiz Piñero, Spain

S

Maria José Sá, Portugal
 Simona Sacco, Italy
 Anna Sauerbier, UK
 Philip Scheltens, The Netherlands
 Erich Schmutzhard, Austria
 Stefan Schwab, Germany
 Alessandro Simonati, Italy
 Aksel Siva, Turkey
 Riccardo Soffietti, Italy
 Aleksandra Sokołowska, Poland
 Claudia Sommer, Germany
 Israel Steiner, Israel
 Guido Stoll, Germany
 Walter Struhal, Austria

T

Pille Taba, Estonia
 Miguel Tábuas-Pereira, Portugal
 Radu Tanasescu, Romania
 Maarten Titulaer, The Netherlands
 Antonio Toscano, Italy
 Klaus Toyka, Germany
 Marie Trad, France

U

Iris Unterberger, Austria

V

José Valdueza, Germany
 Josep Valls-Solé, Spain
 Domizia Vecchio, Italy
 David B. Vodušek, Slovenia
 Tim von Oertzen, Austria
 Pieter Vos, The Netherlands

Continuing Medical Education

Continuing Medical Education (CME Information)

Purpose

The purpose of the 4th EAN Congress is to offer a forum for clinical and basic discussion on a variety of neurological topics including presentations of current research and available treatments.

Learning Objectives

Through Plenary Symposia, Symposia, Focused Workshops, Teaching Courses, Case-based workshops, Hands-on Courses, controversy sessions, Career development Sessions, Interactive sessions and special sessions, participants will be better able to:

1. Describe the pathophysiology and neurobiology of neurological diseases
2. Discuss the diagnostic approaches and tools available for neurological diseases
3. Discuss the pharmacological and non-pharmacological treatment options available for neurological diseases

Target Audience

The target audience includes clinicians, researchers, post-doc fellows, medical residents, students and other healthcare professionals with an interest in the current research and diagnosis and treatment of neurological diseases. Kindly note that in the description of some courses the target audience is separately disclosed.

Financial disclosure information

It is the policy of the European Academy of Neurology to ensure objectivity, independence and balance in all congress activities. All participants are required to disclose any real or apparent conflict(s) of interest that can have a direct bearing on the subject matter of the activity. Financial disclosure information will be provided on the presentations and/or abstracts.

EACCME Accreditation statement

EACCME EVENT CODE: LEE17-00902

The 4th Congress of the European Academy of Neurology is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS): <http://www.uems.net>.

The Congress of the European Academy of Neurology (Saturday, Sunday, Monday, Tuesday) is designated for a maximum of 24 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

These points are accepted by several national societies, and thus they are claimed in these countries.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Ethical MedTech has endorsed the congress

CME Certificates and Attendance Tracking Report

If you need a report of your attendance in sessions, please use the EAN website and app and evaluate all sessions that you have attended. From Thursday, 21 June, onwards you will receive a certificate including a report of all sessions you have attended and evaluated.



CME Certificates will only be provided to participants who have evaluated the sessions attended during the congress. Evaluation is possible until Wednesday, 20 June 2018, 23.59 CET.

Please see page 18, "Evaluation" for further information.

Instructions for Speakers and Presenters | Information from A to Z

Instructions for Speakers and Presenters

Speakers' Service Centre

All speakers are requested to hand in their presentations (PowerPoint only) via a USB compatible memory stick at the Speakers' Service Centre (SSC) at least three hours before the beginning of the session. The SSC is located on the press gallery next to the entrance of Auditorium II and the EAN Members' Lounge on the first floor (Foyer D).

Speakers will have the opportunity to check their presentations on PCs available in the SSC.

The speakers' service centre (SSC) is supported by



ePresentations and ePosters

All posters will be presented electronically only. Within the ePoster area (located in Hall 4 and Hall 5) there are 22 poster screens (and 25 computer stations next to Hall 4) available throughout the whole congress, where presenters and audience are invited to interact with each other. You will be able to contact all presenters and meet with them at any time at one of the poster screens to discuss his/her work. In addition, there will be scheduled sessions, taking place Saturday to Monday from 12.30 - 13.15 and 13.30 - 14.15.

All ePoster and ePresentation sessions will be discussed with a chairperson. The chairperson will be present and discuss each presentation with the presenter and the audience. In **ePoster sessions** (45 minutes) up to 15 presentations are scheduled at the dedicated poster screens. Each presenter will have 2 minutes of presentation time and approximately 1 minute of discussion.

ePresentation sessions will be 45 minutes long as well and accommodate up to 10 presentations. Each presenter will have 3 minutes of presentation time and 2 minutes of discussion.

Please make sure that you are present at your screen at the beginning of your session. Please see page 31 or the Interactive Programme Planner (IPP) for details and exact session times. For better audio quality, please pick up a receiver and ear-phones from the ePoster desk before the session. Different sessions will have different channels, indicated next to each poster screen.

Poster Desk

Technicians and hosts will be available throughout the congress in the ePoster area (Hall 4).

Information from A to Z

Abstracts

All accepted abstracts will be published as a supplement to the *European Journal of Neurology*. There will be no printed book available, but a USB drive can be picked up in the Exhibition Area at the Sanofi Genzyme booth. You will receive a voucher together with your bag.

You can create your personal abstract book by using the Interactive Programme Planner (IPP).

The abstracts can also be found online on

www.ean.org/Lisbon2018

www.europeanjournalofneurology.com.

App

The congress app "EAN Congress" is available for download free of charge on Google Play and iTunes.

It includes the interactive programme planner (IPP), all session evaluations as well as the voting system for the Interactive sessions. Please download the app and login with your EAN user information. You can then go ahead and create your personal congress programme. You will also be able to access the favourites you made on the EAN Congress website.

Seize all benefits of the EAN Congress app to connect and meet with colleagues, prepare your meeting schedule, be able to actively participate in the Interactive Sessions and have additional and up-to-date information on the congress.

The congress app is supported by



ATM/Cash Machine

An ATM/cash machine is located in the registration area.

Attendance tracking report

See page 13

Badges

Access to all scientific and networking events will only be possible with your personal badge. All participants are requested to wear their name badge throughout the congress.

If you forget your badge, we can reprint it for a deposit of

Information from A to Z

30€. The deposit will be returned once you show that you still have both badges, of which we will keep one. If you lost your badge or do not show both badges anymore, 30€ will be charged.

Scanning of badges

Participants are not obliged to allow exhibitors to scan their badge in the exhibition area or when entering an industry symposium. Participants must show their badge for proof of access rights, but do not need to let someone scan it. With allowing a company to scan, you acknowledge that your registration details will be forwarded to the exhibitor.

Caring for the environment

Bag recycling – You can leave your congress bag at the registration desk when leaving the congress.

Green print - The print materials of this congress have been printed on paper that is PEFC approved. PEFC is an organisation that certifies paper manufacturers who keep to sustainable forest management criteria.

Reducing print - The printed programme is available only for participants who order it in advance at registration. The complete programme can also be found online in the Interactive Programme Planner (IPP) and on our congress app and you can create your individual schedule & abstract book.

Recycling - As part of our efforts we try to produce less waste, and recycle plastic, glass, cans and paper.

Offset your Carbon Footprint - You can contribute to our ecological efforts by offsetting the Carbon Footprint of your travels to Lisbon. A Carbon Offset represents a reduction in emissions somewhere else. You can learn more and offset your carbon foot print at: www.carbonfund.org.

We are doing our best and there is still much to learn. We will be happy to hear your ideas; please do not hesitate to write to us at headoffice@ean.org.

Certificates including CME Accreditation:

If you wish to receive individual reports of your attendance in sessions, please use the EAN website and congress app and evaluate all sessions that you have attended. You can also find a designated “evaluation station” in the congress entrance area in Foyer B.



CME Certificates will only be provided to participants who have evaluated the sessions attended during the congress.

Evaluation is possible until Wednesday, 20 June 2018, 23:59 CET. From Thursday, 21 June, onwards, you can download your CME certificate including a report of all sessions you have attended and evaluated. The certificate lists all sessions that were evaluated and includes all CME points.

The 4th Congress of the European Academy of Neurology (EAN) has been accredited by EACCME and is designated for a maximum of, or up to 24 European CME credits (ECMEC). Please find a list of countries that accept EACCME accreditation on the UEMS Website. The UEMS-EACCME® has mutual recognition agreements with the American Medical Association (AMA) and with the Royal College of Physicians and Surgeons of Canada for live Events.

Children at EAN Congress 2018

There is no childcare facility available at the congress. Accompanying children over the age of 1 year are not allowed to access the exhibition area due to the pharma codex. Thank you for your understanding.

Cloakroom

A cloakroom is located in front of the CCL in a separate tent and is open during the secretariat opening hours. The cloakroom service is free of charge.

Congress secretariat and registration helpdesk

The registration helpdesk, located in the entrance area of the congress venue is open during the following hours:

Friday,	15.06.2018: 16.00 – 19.00 h (badge/congress bag pick-up for pre-registered delegates only)
Saturday,	16.06.2018: 7.30 – 20.00 h
Sunday,	17.06.2018: 7.30 – 19.00 h
Monday,	18.06.2018: 7.30 – 19.00 h
Tuesday,	19.06.2018: 7.30 – 16.45 h

All documents included in the registration package (congress bag, personal name badge) will be handed over to the registered participants. Onsite registration will be accepted, but receipt of all congress documents cannot be guaranteed.

The registration helpdesk can be reached at +351 96 2799370

Information from A to Z

CONGRESS VENUE

Lisbon Congress Centre CCL
Praça das Indústrias
1300-307 Lisbon
Portugal
www.lisboacc.pt

The 4th Congress of the European Academy of Neurology takes place at the Lisbon Congress Centre (CCL) which is located only a few minutes away from the city centre and only 20 minutes away from the airport.

Best way to go from the airport to the congress centre is by taxi - the average cost is around 10 to 15 €. By public transportation, you need to take the bus: the fast way is take bus n° 783 and then change at Campo Pequeno to bus n° 756 (no direct connection)

- For bus & tram, please check:
<http://carris.transporteslisboa.pt/en/home/>
- For train connection, please check:
<https://www.cp.pt/passageiros/en>
- Local cab-companies:
AUTOCOOP Tel. (+351) 217 932 756;
RETALIS Tel. (+351) 218 119 000;
TELETAXIS Tel. (+351) 218 111 100

Currency

The official currency of the 4th EAN Congress in Lisbon is Euro (€). The easiest way to get Euros is to withdraw cash from a Multibanco ATM (“Caixa automático”), which are everywhere in Lisbon. Most ATMs work with credit cards of the Visa and MasterCard type, and debit cards that use the Maestro or Cirrus systems.

Most banks and post offices are open from Monday to Friday between 8.30h and 15.00h. Exchange bureaus are usually open from 9.00-13.00h and from 14.00-19.00h.

EAN Booth – Your Home of neurology

“700.000.000 brains - 45.000 members - 47 countries - one community!”

Location: first floor, between Auditorium I and II.

Opening hours:

Saturday, 16.06.2018: 08.00 – 18.00 h
Sunday, 17.06.2018: 07.30 – 18.00 h
Monday, 18.06.2018: 07.30 – 18.00 h
Tuesday, 19.06.2018: 07.30 – 15.00 h

Visit the EAN Booth and its different areas (HOME, MEET, LEARN and RESEARCH) and find out more about the European Academy of Neurology, your home of neurology, and its aims and missions:

HOME & MEET area

Visit this area already in the morning for a cup of coffee and a chat among colleagues from all over Europe and the world and seize the opportunity for quick casual business meetings. Relax on our sofas and feel at HOME. Learn everything about EAN and the benefits of being a valuable part of Europe’s largest community of neurologists. Get all information on our different membership programmes, meet the people behind EAN, the EAN Board as well as the EAN Head Office. Get information on MyEAN and our activities in social networks.

Latest information on the 2019 EAN Congress in Oslo will also be made available.

EAN Congress Postcards can be mailed - just drop them in the EAN mailbox, EAN will provide the stamp and mail it for you!

Join us and become a member of our community!

LEARN


When visiting the LEARN area, you can find all educational aspects that underpin the EAN vision to promote excellence in Neurology in Europe. From study programmes outside the EAN congress or grants to support projects in other European Neurological Departments or online learning possibilities.

During coffee and lunch breaks, challenge yourself with the tricky EAN “hot wire” game – special prizes will be offered for the lucky winners.

Need one-of-a-kind memorabilia? Come by and purchase one of the unique EAN bags – strictly limited to only 150 pieces maximum per congress year, made of the poster background tarps of the 2015, 2016 and 2017 EAN congresses in Berlin, Copenhagen and Amsterdam. EAN decided to re-use nearly all printed tarps and cloths of the poster booths and design its very own limited collector item. Be sure to get your one-of-a-kind limited bag for only €20 (discount possibilities: 2 for €35 and 3 for €45 only)

Information from A to Z

The EAN bags are produced locally in Vienna, Austria by WienWork, an organisation that enables people with disabilities, chronic illnesses or long-term unemployed people to participate in economic and social life. With every purchase of a bag you support this project.



The EAN Photo-wall is also located here... come by and have your photo taken – while waiting for your turn, just solve one of the funny brain puzzles.

RESEARCH

Get all the information on Scientific Panels - not only on panel membership but also what these panels do. Grab your copy of the *European Journal of Neurology* and make yourself familiar with other great publications.

Learn more about EAN Guideline Production, related crossword puzzles are available.

Come by and pick a paper printout of your #ean2018 picture posted on social media.

SCIENTIFIC THEATRE

In Lisbon, the scientific theatre is an extension of the EAN booth, where EAN committees, working-groups and task forces as well as partner organisations and related sub-specialties societies can use short timeslots to talk about their work, inform about their missions and encourage people to have a seat and listen-in.


The Programme overview can be found on page 20.

During lunch and coffee breaks, the scientific theater is made available for forum talks by our industry partners.

The detailed programme can be found on page 157.

Capacity is for 40 people, please bring your earphones (available at the Poster help desk)

EAN Booth



MEMBER'S LOUNGE

Information from A to Z

Evaluation/Quality control

In order to guarantee the quality of the upcoming congresses, we are carrying out congress evaluations.

General Evaluation

The general evaluation of the congress will be sent to all congress participants after the congress.

Session Evaluation/CME Certificate

If you wish to receive individual reports of your attendance in sessions, please use the EAN website and congress app and evaluate all sessions that you have attended. You can also find a designated “evaluation station” in the congress entrance area in Foyer B. Evaluation is possible until Wednesday, 20 June 2018, 23:59 CET.



CME Certificates will only be provided to participants who have evaluated the sessions attended during the congress.

From Thursday, 21 June, onwards you can download your CME certificate including a report of all sessions you have attended and evaluated. The certificate lists all sessions that were evaluated and includes all CME points.

Please take time to complete the electronic evaluation forms provided for each session you attend. Your input is essential for planning future EAN congresses and for receiving your certificate.

Exhibition

An extensive exhibition will be held concurrently with the congress.

Exhibition opening hours are:

Saturday,	16 June 2018: 09.30 – 17.00h
Sunday,	17 June 2018: 09.30 – 17.00h
Monday,	18 June 2018: 09.30 – 17.00h
Tuesday,	19 June 2018: 09.30 – 13.30h

Accompanying children over the age of 1 year are not allowed to access the exhibition area due to the Pharma Codex. Thank you for your understanding.

The exhibition floor plan can be found on page 121.

Film and photos

Please be advised that photographs and video recordings may be taken at the 4th EAN Congress. By participating in the congress, you consent to the publication, release, exhibition and/or reproduction of such photos to be used for the EAN website, EAN newsblog “EAN pages”, and on social media.

Hotel and travel

Official Housing Agency
 Congrex Switzerland Ltd.,
 Email: hotel.ean@congrex.com
 Congrex Switzerland is present at the Congress registration help desk. Staff can assist you with your hotel bookings.

Insurance & Liability

The Congress organisers and PCO cannot accept liability for personal accidents or loss of or damage to private property of participants, either during or indirectly arising from the 4th Congress of the European Academy of Neurology.

You can choose your individual cancellation and travel insurance package when registering to the congress at extra costs.

It is recommended that all participants take advantage of this.

Internet Corner

An Internet Corner is located in the exhibition area (Hall 3) and is available to all congress participants during the opening hours of the exhibition.
 Wi-Fi information on page 22.

Interactive Programme Planner (IPP)

Please use the IPP in order to create your personal programme and abstract book.

All invited lectures, oral sessions and poster presentations will be available in the IPP. By logging in with your EAN user information, you will be able to save and edit your personal programme. It is available for desktop, laptop and in our congress app.

Contents are sorted by topic and can be searched through standard web search functions. Once you have created your personal programme, you can export it to different calendar formats, or download it as a book of abstracts.

The IPP will be available before and during the congress.

Information from A to Z

Language

The official language of the congress is English. No simultaneous translation will be provided.

Lost & Found

Please apply to the congress registration helpdesk.

Lunch and Coffee breaks

Light lunch and coffee is included in the registration fee and will be served in the exhibition area as per the times indicated in the timetable. Coffee will be served in Halls 1, 2 and 3. Lunch will only be served in Hall 2.

Mail/Messages

ePoster and ePresentation presenters can be contacted via the online poster system.

If you wish to leave a message for somebody, please apply to the information desk.

Media Contact

B&K
 Dr Birgit Kofler
 Phone: +43-1-319 43 78
 Mobile: +43-676-63 68 930
 E-Mail: kofler@bkkommunikation.com
 Skype: bkk_Birgit.Kofler
 PRESS OFFICE

Medical assistance

Please apply to the congress registration helpdesk.

Members' lounge

EAN Full and Corresponding individual members, FEANs and Faculty Members have the possibility to network and enjoy their lunch in a separated Members' Lounge. The Members' Lounge is located next to the EAN Booth area and is open during the exhibition opening hours. A separate "Members working Lounge" can be found above the staircase to Hall 4 (ePoster area).

A photographer, to take a portrait picture of you for your EAN profile, is located in Foyer E during on-site announced hours.

Mini-Programme

The mini-programme gives you an overview of the scientific programme at a glance.

Mobile charging stations

Mobile charging stations will be placed all over the venue available to all congress participants. The mobile charging stations are supported by



Mobile phones

Please note that mobile phones must be switched off during all sessions.

Networking

Opening and Welcome Reception (See page 37)
 Challenges for women in neurology (see page 38)
 Musical Recital (see page 39)
 History of Neuroscience visit (see page 40)
 Networking event "Meet your Neurology Network" (see page 40)
 Resident and Research Fellow Section Activities (see page 9)
 Members' Lounge (see page 19)
 EAN booth (see page 16)

Poster Sessions /Poster Overview

Please see page 14 and 31

Press room

A media room with wireless internet access is available to registered journalists. The Press Room is located in Foyer A on the ground floor.

Information from A to Z

Scientific Replay lounge

The Scientific Replay Lounge is located in the exhibition area (Hall 3) and will be available for the comfort of participants, providing a place to see webcasts of selected previous sessions, relax and meet with colleagues.

Scientific Theatre

Located on the ground floor, in Exhibition Hall 2, the Scientific Theatre is a forum for EAN committees, working groups, task forces and other EAN partner organisations to inform the audience in short about their latest achievements and future ambitions.

Set-up for 40 participants with their own ear phones.

Scientific Theatre Programme

Saturday, June 16

10:00-10:30

Forum talks by industry (page 157)

10:30-11:00

How political action can improve the lives of neuropathic pain patients? An introduction to the Societal Impact of Pain campaign

Marc Marlion – EFIC

11:30-12:00

EAN grants and other possibilities

G. di Liberto, L. Klingelhofer, V. Papp

12:30-13:00

Presentation: eBook on neurological examination

Klaus V. Tokya

14:00-14:30

EAN Guideline Production

Maurizio Leone – EAN

15:30-16:00

How to prepare a scientific paper for publication

Pertti Saloheimo - European Journal of Neurology

16:15-16:45

Forum talks by industry (page 157)

Sunday, June 17

9:30-10:00

Forum talks by industry (page 157)

10:00-10:30

News from European Union of Medical Specialists – European Board of Neurology

Patrick Cras – UEMS – SN

10:30-11:00

European Board Exam for Neurology

Jan Kuks – UEMS

11:30-12:00

IFCN European Chapter – Training and education in Europe in Clinical Neurophysiology

Johnathan Cole – IFCN

12:00-12:30

Mind the Treatment Gap!

Wolfgang Oertel – EAN

Joke Jaarsma – EFNA

12:30-13:00

How to build a successful health policy campaign? Lesson learnt from the Societal Impact of Pain campaign

Sam Kynman – EFIC

14:00-14:30

EBC – VoT Project – Improved patient journey in neurology

Joke Jaarsma – EFNA

Maura Pugliatti – EAN

15:00-15:30

EAN Guideline task force – Palliative Care in MS

Allesandra Solari

16:15-16:45

Forum talks by industry (page 157)

Monday, June 18

9:30-10:00

Forum talks by industry (page 157)

10:00-10:30

Palliative Care and Neurology

David Oliver – EAPC

10:30-11:00

News from the International Neuro-Urology Society

Jalesh Panicker – INUS

Information from A to Z

11:30-12:00

EAN grants and other possibilities

G. di Liberto, L. Klingelhoef, V. Papp

12:30-13:00

EAN Scientific Panels – how to get involved

Celia Oreja-Guevara – EAN

13:30-14:00

Health, wealth and workability: young people with MS

Helen Chandler – EMSP

14:00-14:30

Presentation: eBook on neurological examination

Klaus V. Tokya

15:30-16:00

Action Plan for Stroke in Europe in Cooperation with SAFE – Stroke Alliance for Europe

Valeria Caso – ESO

Tuesday, June 19

12:00-12:30

EAN grants and other possibilities

G. di Liberto, L. Klingelhoef, V. Papp

Session descriptions and Buttons

Please make sure to be in session halls on time as all sessions will begin as per schedule.

If you wish to receive individual reports of your attendance in sessions, please use the EAN website and congress app and evaluate all sessions that you have attended. You can also find a designated “evaluation station” in the congress entrance area in Foyer B.



CME Certificates will only be provided to participants who have evaluated the sessions attended during the congress.

Scientific Sessions:

Symposia:

Symposia are scheduled on each congress day and will last 2 hours each. Lecturers will give general information on the main topics of the congress.

Focused Workshops:

Focused workshops (FWs) will be held in the morning and last for 1.5 hours. They cover narrow topics and aim to promote discussion around new ideas, evidence or theories. Ample time for discussion will be provided.

Special Sessions:

Special Sessions (SPS) cover topics of special interest.

Educational Sessions:

Teaching Courses:

If you wish to participate, tickets can still be purchased at the Registration for a fee of € 50/ €30, availability permitting.

TCs are held on each congress day in the afternoon and last for 3 hours (plus 1/2 hour coffee break). They are interactive with ample opportunity for participants to ask questions. All TCs are aimed primarily at a post-graduate audience.

There are 3 levels of TCs:

Level 1 (Introductory): Aimed primarily at neurologists in training, or those wishing to refresh/update their basic knowledge in the field. Level 1 can also be suitable for undergraduates or general trainees with a particular interest.

Level 2 (standard): Assumes familiarity with basic clinical knowledge and practice, aimed at specialist trainees or practitioners wishing to update and further develop their knowledge in the field.

Level 3 (advanced): Aimed at specialist trainees or practitioners with a particular interest in that field, covering the latest advances of particular interest to a specialist audience.

Participation is not included in the registration fee. Participants will receive a manuscript of the lectures.

Hands-on Courses:

If you wish to participate, tickets can still be purchased at the Registration for a fee of € 50/ €30, availability permitting.

These Hands-on Courses (HoC) are for a small number of participants only, with some built-in work in smaller groups who attend parallel by rotating to each presenter of the course. Live demonstrations with screening machines are the core of these courses.

Participation is not included in the registration fee. For a limited number of participants only (first come-first-served basis). Participants will receive a manuscript of the presentations.

Case-based Workshops:

If you wish to participate, tickets can still be purchased at the Secretariat for a fee of € 50/ €30, availability permitting.

The case-based workshops are to support knowledge and practice in clinical diagnosis and management in a format, which requires the attendees to actively participate, with opportunities for direct discussion/contact with leading experts to discuss pre-prepared cases.

Information from A to Z

Participation is not included in the registration fee. For a limited number of participants only (first come-first-served basis).

Interactive Sessions:

These sessions are open for all participants. Through an interactive voting system via the congress app, the opinions of colleagues will be collected. Please download the congress app to actively participate in the Q&A.

Controversy Sessions:

Allow to give a critical overview of the current and most recent advances on key topics, share knowledge, stimulate debate and forge opinions on controversial issues of clinical care, research, educational practice and therapy.

Career development Sessions:

This format shall allow to share and improve knowledge on: “how to best write an academic paper”; “how to plan and organize a clinical or scientific study”; “how to apply for a grant”, “how to get a paper accepted” etc...

These sessions are open for all participants and primarily aim at a post-graduate audience.

Smoking policy

Smoking is prohibited at all times in the meeting halls, exhibit halls and restrooms. Your compliance is appreciated.

Speakers’ Service Centre (SSC)

See page 14.

WI-FI

Wi-Fi will be available free of charge in the registration and exhibition area as well as in the session rooms.

Network name: EAN-2018_supportedbyRoche

Username: ROCHEatEAN

Password: StartNOW

The Wi-Fi is supported by  .

Buttons @ scientific Programme



OVERARCHING
THEME

The Overarching Theme for the 2018 Congress is “Neurogenetics”. Sessions with this button are dedicated to the Overarching theme and were created by the Programme committee together with Local Organising committee.



PATIENTS’
CHOICE

EFNA (European Federation of Neurological Associations), the federation uniting European Patients’ Associations, has selected these sessions as high priority.



HIGHLIGHT

These are the highlights of the congress and/or innovative sessions.



RARE
DISEASES

These sessions were selected by the EAN Rare Neurological Disease Task Force.





Foto: Zdzislawski, Inna Pedersen, Vladimir Hodak/PhotoStock, Erik Bør, Thomas Starup, Utforming Wip Knudsen Studio AS




WELCOME TO OSLO

Norway has about one certified neurologist per 10.000 inhabitants, distributed among 18 Neurological departments. With more than 700 members, the Norwegian Neurological Association is looking forward to celebrate its 100th anniversary in 2020. Neurologists have been highly active in the development of the health care system in Norway, leading up to Norway being the first country in Europe to launch a National Brain Strategy Plan in 2018. We consider public education to be important, and during the annual Brain Awareness Week, Neurologists offer free lectures and other activities to the public.

The Norwegian Neurological Association and all our members are looking forward to seeing you in Oslo for the 5th EAN Congress 29 June - 2 July 2019!




Ground Floor




First Floor




FIRST FLOOR
1

- EAN Info Area
- ePoster Area
- Session Rooms
- Meeting Rooms
- Scientific Business Suite
- Toilets
- Lift






Second Floor




-  Meeting Rooms
-  Toilets
-  LIFT

ePoster Area



-  EAN Info Area
-  ePoster Area





Traditional Rabelo boats in river Douro, with Porto city in the background.

CONGRESS OF NEUROLOGY

14-17TH NOVEMBER 2018

**PORTO PALÁCIO HOTEL CONGRESS
CENTER | PORTO | PORTUGAL**

**MAIN THEME:
NEUROLOGY, ARTIFICIAL INTELIGENCE,
TECHNOLOGICAL INNOVATION**

Pre-congress courses:

Neuro-Otology
Neurosonology

Pre-congress Nurses Meeting

*The Portuguese Society of
Neurology (Sociedade Portuguesa
de Neurologia - SPN) was
founded in 1982.*

*The Society gathers all healthcare
professionals working in the care
of neurological patients including
Doctors, Nurses, Psychologists,
and Physiotherapists, as well as
researchers working in the field
of translational and clinical
neuroscience.*

*Join us in Porto
in November 2018!*



sec.spn@gmail.com

Overview of business meetings

(in chronological order, as per date of printing)

Additional meetings reserved after the date of printing will be announced on the Message screen in the registration area and can be found in the IPP (App).

Group/Committee	Day	Time	Room
European Affairs sub-Committee	Saturday, 16 June	08:30 – 10:00	Room 1.15
EBN/UEMS Board Meeting	Saturday, 16 June	09:00 – 17:00	Room 1.08
Assembly of Delegates	Saturday, 16 June	13:00 – 15:00	Auditorium II
RRFS National representatives	Saturday, 16 June	14:15 – 15:15	Room 1.17
Quality Assurance sub-Committee	Sunday, 17 June	08:30 – 10:00	Room 1.15
TF Neurology – SSA + Corresponding Societies	Sunday, 17 June	10:00 – 12:00	Room 1.17
European Journal of Neurology Editorial Board	Sunday, 17 June	13:30 – 14:30	Room 1.15
EAN / Wiley Meeting	Sunday, 17 June	15:00 – 16:00	Room 1.17
eCommunication Board	Sunday, 17 June	16:00 – 17:30	Room 1.15
Teaching Course sub-Committee	Monday, 18 June	08:00 – 09:30	Room 1.15
Scientific Panel Chairs Meeting	Monday, 18 June	12:00 – 14:00	Auditorium III
Communication Committee	Monday, 18 June	12:30 – 14:00	Room 1.17
Local Organising Committee Oslo	Monday, 18 June	12:30 – 14:00	Room 1.15
RRFS General Assembly	Monday, 18 June	14:15 – 15:15	Room 0.01
Scientific Committee	Monday, 18 June	14:30 – 16:30	Room 1.15
Industrial Relations Board (IRB)	Monday, 18 June	15:00 – 16:30	Auditorium III
Guideline Production Group	Monday, 18 June	17:00 – 18:30	Room 1.15
Education Committee	Tuesday, 19 June	08:30 – 10:00	Room 1.15
Programme Committee	Tuesday, 19 June	14:00 – 15:30	Room 1.15
Board debriefing	Tuesday, 19 June	16:00 – 17:00	Room 1.15
Rare disease Taskforce	please see IPP (App)		
eCommunication Board and Scientific Panel Website representatives	please see IPP (App)		

Overview of business meetings of Scientific Panels, Task Forces

(in chronological order, as per date of printing)

Additional meetings reserved after the date of printing will be announced on the Message seen in the registration area and can be found in the IPP (App).

Group/Committee	Day	Time	Room
Scientific Panel Autonomic nervous system disorders	Saturday, 16 June	13:00 – 14:30	Room 1.16
Scientific Panel Neuroepidemiology	Saturday, 16 June	14:30 – 16:00	Room 1.15
Scientific Panel Translational neurology	Saturday, 16 June	15:00 – 16:00	Room 1.11
Scientific Panel Multiple sclerosis	Saturday, 16 June	15:15 – 16:15	Room 1.13
Scientific Panel Neuroimaging	Saturday, 16 June	17:00 – 18:00	Room 1.15
Scientific Panel Muscle & NMJ disorders	Sunday, 17 June	09:00 – 10:30	Room 1.11
Scientific Panel Higher cortical functions	Sunday, 17 June	10:00 – 11:00	Room 1.13
Scientific Panel Neurorehabilitation	Sunday, 17 June	11:00 – 12:00	Room 1.12
Scientific Panel Neuro-oncology	Sunday, 17 June	12:00 – 13:00	Room 1.12
Scientific Panel Clinical neurophysiology	Sunday, 17 June	12:30 – 14:00	Room 1.16
Scientific Panel Neurotraumatology	Sunday, 17 June	13:00 – 14:00	Room 1.13
Task Force "Coma and chronic disorders of consciousness" Guideline	Sunday, 17 June	13:00 – 15:00	Room 1.11
Scientific Panel Pain	Sunday, 17 June	14:00 – 15:00	Room 1.12
Scientific Panel Neurosonology	Sunday, 17 June	14:00 – 15:00	Room 1.16
Scientific Panel Neurotoxicology	Sunday, 17 June	14:15 – 15:15	Room 1.13
Scientific Panel Neurocritical care	Sunday, 17 June	15:00 – 16:30	Room 1.16
Scientific Panel Sleep-wake disorders	Sunday, 17 June	16:00 – 17:00	Room 1.13
Scientific Panel Palliative care	Sunday, 17 June	16:00 – 17:00	Room 1.12
Task Force "Narcolepsy" Guideline	Sunday, 17 June	17:00 – 18:30	Room 1.13
Scientific Panel Neuro-ophthalmology and -otology	Sunday, 17 June	16:45 – 18:00	Room 1.17
Task Force "Palliative care in MS" Guideline	Sunday, 17 June	17:00 – 19:00	Room 1.12
Task Force "Parkinson's diseases" Guideline	Sunday, 17 June	17:00 – 18:00	Room 1.16

Overview of business meetings of Scientific Panels, Task Forces

(in chronological order, as per date of printing)

Additional meetings reserved after the date of printing will be announced on the Message screen in the registration area and can be found in the IPP (App).

Group/Committee	Day	Time	Room
Scientific Panel Epilepsy	Monday, 18 June	09:00 – 11:00	Room 1.16
Scientific Panel Headache	Monday, 18 June	09:30 – 10:30	Room 1.13
Scientific Panel Dementia and cognitive disorders	Monday, 18 June	10:00 – 11:00	Room 1.15
Scientific Panel Stroke	Monday, 18 June	11:00 – 12:00	Room 1.15
Scientific Panel Neuropathies	Monday, 18 June	14:15 – 15:45	Room 1.17
Scientific Panel Neurogenetics	Monday, 18 June	15:00 – 16:00	Room 1.16
Scientific Panel Infectious diseases	Monday, 18 June	17:00 – 18:00	Room 1.11
Scientific Panel Child neurology	Tuesday, 19 June	10:00 – 11:00	Room 1.12
Scientific Panel Coma and chronic disease of consciousness	Tuesday, 19 June	10:00 – 12:00	Room 1.13

ePoster overview

ePoster presenters are requested to be at their poster screen at the beginning of the session.
Pick up your audio equipment at the poster desk!

Saturday, 16 June 2018
12:30–13:15

Topic	Screen Nr	Poster Numbers	Chairs
Ageing and dementia	Screen A1	EPO1001 – EPO1011	Miguel Tábuas-Pereira, <i>Portugal</i>
Cerebrovascular diseases 1	Screen A3	EPO1012 – EPO1022	Diana Aguiar de Sousa, <i>Portugal</i>
Cognitive neurology/neuropsychology	Screen A6	EPO1023 – EPO1033	Alexandre Mendonça, <i>Portugal</i>
Epilepsy 1	Screen B1	EPO1034 – EPO1043	Ettore Beghi, <i>Italy</i>
Headache and pain 1	Screen B3	EPO1044 – EPO1052	Isabel Pavão, <i>Portugal</i>
Miscellaneous 1	Screen B9	EPO1053 – EPO1064	Bartosz Karaszewski, <i>Poland</i>
Movement disorders 1	Screen B6	EPO1065 – EPO1075	Aleksandra Herrera-Sokolowska, <i>Poland</i>
MS and related disorders 1	Screen B11	EPO1076 – EPO1089	Giovanni Di Liberto, <i>Switzerland</i>
MS and related disorders 2	Screen B7	EPO1090 – EPO1095	João Sá, <i>Portugal</i>
Muscle and neuromuscular junction disease 1	Screen C1	EPO1096 – EPO1105	Mamede de Carvalho, <i>Portugal</i>
Neurological manifestations of systemic diseases	Screen C4	EPO1106 – EPO1115	Irina Alexandra Orban, <i>Romania</i>

Sunday, 17 June 2018
12:30–13:15

Topic	Screen Nr	Poster Numbers	Chairs
Cerebrovascular diseases 2	Screen A3	EPO2001 – EPO2012	Natan Bornstein, <i>Israel</i>
Child neurology/developmental neurology	Screen A6	EPO2013 – EPO2020	Teresa Temudo, <i>Portugal</i>
Clinical neurophysiology	Screen B3	EPO2021 – EPO2027	Simon Podnar, <i>Slovenia</i>
Epilepsy 2	Screen B1	EPO2029 – EPO2037	Andrej Dubenko, <i>Ukraine</i>
Infectious diseases; Sleep disorders	Screen B9	EPO2038 – EPO2048	Stefan Golaszewski, <i>Austria</i>
Movement disorders 2	Screen B6	EPO2049 – EPO2059	Angelo Antonini, <i>Italy</i>
Movement disorders 3	Screen B11	EPO2060 – EPO2070	Panagiotis Zis, <i>United Kingdom</i>
MS and related disorders 3	Screen B7	EPO2071 – EPO2080	Patrick Vermersch, <i>France</i>
Neurogenetics 1	Screen C1	EPO2081 – EPO2091	Isabelle Le Ber, <i>France</i>
Neuro-oncology	Screen C4	EPO2092 – EPO2100	Francois Ducray, <i>France</i>
Neurorehabilitation	Screen C2	EPO2101 – EPO2111	Fior Dafin Muresanu, <i>Romania</i>
Peripheral nerve disorders	Screen A1	EPO2112 – EPO2124	Vitalie Lisnic, <i>Moldova</i>

All posters will be available throughout the congress on the poster screens and computer stations in the exhibition area.
You can contact ePoster and ePresentation presenters via the poster system. For this, please use one of the poster screens in the ePoster area and navigate to the poster you would like to contact the author of. You can find a contact link on the bottom of that page. You can do the same via the link on the congress website

ePoster overview

ePoster presenters are requested to be at their poster screen at the beginning of the session.
Pick up your audio equipment at the poster desk!

Monday, 18 June 2018
12:30–13:15

Topic	Screen Nr	Poster Numbers	Chairs
Cerebrovascular diseases 3	Screen A3	EPO3001 – EPO3012	Kristaps Jurjans, <i>Latvia</i>
Epilepsy 3	Screen B1	EPO3013 – EPO3022	Jera Kruja, <i>Albania</i>
Headache and pain 2	Screen B3	EPO3023 – EPO3031	Raquel Gil-Gouveia, <i>Portugal</i>
Miscellaneous 2	Screen A1	EPO3032 – EPO3043	Vida Demarin, <i>Croatia</i>
Motor neurone diseases; Cognitive neurology/ neuropsychology	Screen A6	EPO3044 – EPO3055	Riadh Gouider, <i>Tunisia</i>
Movement disorders 4	Screen B6	EPO3056 – EPO3066	K Ray Chaudhuri, <i>United Kingdom</i>
MS and related disorders 4	Screen B11	EPO3067 – EPO3076	Celia Oreja-Guevara, <i>Spain</i>
Muscle and neuromuscular junction disease 2	Screen C1	EPO3077 – EPO3086	Josef Finsterer, <i>Austria</i>
Neurogenetics 2	Screen C4	EPO3087 – EPO3097	Jean Marc Burgunder, <i>Switzerland</i>
Neuro-ophthalmology/ neuro-otology	Screen C2	EPO3098 – EPO3105	Neşe Celebisoy, <i>Turkey</i>
Sleep disorders	Screen B7	EPO3106 – EPO3116	Teresa Paiva, <i>Portugal</i>

All posters will be available throughout the congress on the poster screens and computer stations in the exhibition area.

You can contact ePoster and ePresentation presenters via the poster system. For this, please use one of the poster screens in the ePoster area and navigate to the poster you would like to contact the author of. You can find a contact link on the bottom of that page. You can do the same via the link on the congress website

ePresentation overview

ePresentation presenters are requested to be at their poster screen at the beginning of the session.
Pick up your audio equipment at the poster desk!

Saturday, 16 June 2018
13:30–14:15

Topic	Screen Nr	Presentation Numbers	Chairs
Ageing and dementia 1	Screen A1	EPR1001 – EPR1008	Federica Agosta, <i>Italy</i>
Cerebrovascular diseases 1	Screen A3	EPR1009 – EPR1017	Hugh Markus, <i>United Kingdom</i>
Cerebrovascular diseases 2	Screen A2	EPR1018 – EPR1026	Serefnur Öztürk, <i>Turkey</i>
Cognitive neurology/neuropsychology 1	Screen A6	EPR1027 – EPR1032	Elisa Canu, <i>Italy</i>
Epilepsy 1	Screen B1	EPR1033 – EPR1040	Kristl Vonck, <i>Belgium</i>
Headache and pain 1	Screen B3	EPR1041 – EPR1049	Radu Razvan, <i>Romania</i>
Motor neurone diseases 1	Screen A4	EPR1050 – EPR1057	Thomas M. Jenkins, <i>United Kingdom</i>
Movement disorders 1	Screen B6	EPR1058 – EPR1065	Miguel Coelho, <i>Portugal</i>
Movement disorders 2	Screen B8	EPR1066 – EPR1073	Jean-Philippe Azulay, <i>France</i>
Movement disorders 3	Screen B10	EPR1074 – EPR1081	Anna Czlonkowska, <i>Poland</i>
MS and related disorders 1	Screen B11	EPR1082 – EPR1090	Declan Chard, <i>United Kingdom</i>
MS and related disorders 2	Screen B7	EPR1091 – EPR1098	Maria José Sá, <i>Portugal</i>
MS and related disorders 3	Screen B5	EPR1099 – EPR1106	Gavin Giovannoni, <i>United Kingdom</i>
Muscle and neuromuscular junction disease 1	Screen C1	EPR1107 – EPR1114	Zohar Argov, <i>Israel</i>
Neurogenetics 1	Screen C3	EPR1115 – EPR1121	Corrado Angelini, <i>Italy</i>
Neuroimaging 1	Screen A5	EPR1122 – EPR1128	Sofia Reimão, <i>Portugal</i>
Neuroimmunology 1	Screen B9	EPR1129 – EPR1136	Alvaro Cobo-Calvo, <i>France</i>
Neurological manifestations of systemic diseases	Screen C4	EPR1137 – EPR1143	Markus Weber, <i>Switzerland</i>
Neuro-ophthalmology/neuro-otology; Spinal cord and root disorders	Screen B2	EPR1144 – EPR1151	Eleftherios Papathanasiou, <i>Cyprus</i>
Neurorehabilitation 1	Screen C2	EPR1152 – EPR1159	Anabela Pinto, <i>Portugal</i>
Peripheral nerve disorders 1	Screen B4	EPR1160 – EPR1168	Geir Julius Braathen, <i>Norway</i>
Peripheral nerve disorders 2	Screen B12	EPR1170 – EPR1177	Teresa Paiva, <i>Portugal</i>

All posters will be available throughout the congress on the poster screens and computer stations in the exhibition area.
You can contact ePoster and ePresentation presenters via the poster system. For this, please use one of the poster screens in the ePoster area and navigate to the poster you would like to contact the author of. You can find a contact link on the bottom of that page. You can do the same via the link on the congress website

ePresentation overview

ePresentation presenters are requested to be at their poster screen at the beginning of the session.
Pick up your audio equipment at the poster desk!

Sunday, 17 June 2018
13:30–14:15

Topic	Screen Nr	Presentation Numbers	Chairs
Ageing and dementia 2	Screen A1	EPR2001 – EPR2008	Alla Guekht, <i>Russia</i>
Autonomic nervous system; Sleep disorders	Screen C4	EPR2009 – EPR2017	Mario Habek, <i>Croatia</i>
Cerebrovascular diseases 3	Screen A3	EPR2018 – EPR2024	Patrik Michel, <i>Switzerland</i>
Cerebrovascular diseases 4	Screen A2	EPR2025 – EPR2033	Raquel Gutiérrez Zúñiga, <i>Portugal</i>
Child neurology/developmental neurology	Screen A6	EPR2034 – EPR2040	Urs Fisch, <i>Switzerland</i>
Clinical neurophysiology	Screen B3	EPR2041 – EPR2049	Letizia Leocani, <i>Italy</i>
Epilepsy 2	Screen B1	EPR2050 – EPR2057	Mar Carreño, <i>Spain</i>
Headache and pain 2	Screen B2	EPR2058 – EPR2065	Delphine Magis, <i>Belgium</i>
Infectious diseases	Screen B9	EPR2066 – EPR2072	Erich Schmutzhard, <i>Austria</i>
Movement disorders 4	Screen B6	EPR2073 – EPR2080	Carlo Colosimo, <i>Italy</i>
Movement disorders 5	Screen B11	EPR2081 – EPR2088	Philippe Damier, <i>France</i>
Movement disorders 6	Screen B8	EPR2089 – EPR2096	Olivier Rascol, <i>France</i>
MS and related disorders 4	Screen B7	EPR2097 – EPR2104	Ludwig Kappos, <i>Switzerland</i>
MS and related disorders 5	Screen B10	EPR2105 – EPR2112	Michael Khalil, <i>Austria</i>
MS and related disorders 6	Screen B5	EPR2113 – EPR2120	Abhijit Chaudhuri, <i>United Kingdom</i>
Neurogenetics 2	Screen C3	EPR2121 – EPR2127	Max Hilz, <i>Germany</i>
Neurogenetics 3	Screen C1	EPR2128 – EPR2133	Christine Van Broeckhoven, <i>Belgium</i>
Neuroimaging 2	Screen A5	EPR2134 – EPR2140	Laszlo Csiba, <i>Hungary</i>
Neurological manifestations of systemic diseases; Neuro-oncology	Screen B12	EPR2141 – EPR2146	Riccardo Soffietti, <i>Italy</i>
Neurorehabilitation 2	Screen C2	EPR2147 – EPR2154	Andreas Bender, <i>Germany</i>
Peripheral nerve disorders 3	Screen B4	EPR2155 – EPR2163	Ingemar SJ Merckies, <i>The Netherlands</i>
Peripheral nerve disorders; Muscle and neuromuscular junction diseases	Screen A4	EPR2164 – EPR2171	Yuri Alekseenko, <i>Belarus</i>

All posters will be available throughout the congress on the poster screens and computer stations in the exhibition area.

You can contact ePoster and ePresentation presenters via the poster system. For this, please use one of the poster screens in the ePoster area and navigate to the poster you would like to contact the author of. You can find a contact link on the bottom of that page. You can do the same via the link on the congress website

ePresentation overview

ePresentation presenters are requested to be at their poster screen at the beginning of the session.
Pick up your audio equipment at the poster desk!

Monday, 18 June 2018
13:30–14:15

Topic	Screen Nr	Presentation Numbers	Chairs
Ageing and dementia 3	Screen A1	EPR3001 – EPR3007	Pasquale Calabrese, <i>Switzerland</i>
Autonomic nervous system	Screen B2	EPR3008 – EPR3015	Walter Struhal, <i>Austria</i>
Cerebrovascular diseases 5	Screen A3	EPR3016 – EPR3023	Stefan Schwab, <i>Germany</i>
Cognitive neurology/neuropsychology 2	Screen A6	EPR3024 – EPR3030	Maria Assunta Rocca, <i>Italy</i>
Epilepsy 3	Screen B1	EPR3031 – EPR3039	Reetta Kälviäinen, <i>Finland</i>
Headache and pain 3	Screen B3	EPR3040 – EPR3048	Simona Sacco, <i>Italy</i>
Miscellaneous	Screen B9	EPR3049 – EPR3055	Patrick Cras, <i>Belgium</i>
Motor neurone diseases 2	Screen A4	EPR3056 – EPR3062	Christian Krarup, <i>Denmark</i>
Movement disorders 7	Screen B6	EPR3063 – EPR3070	Mário M. Rosa, <i>Portugal</i>
Movement disorders 8	Screen B8	EPR3071 – EPR3078	Leonor Correia Guedes, <i>Portugal</i>
Movement disorders 9	Screen A2	EPR3079 – EPR3086	Andreas Zwergal, <i>Germany</i>
MS and related disorders 7	Screen B11	EPR3087 – EPR3094	Per Soelberg Sörensen, <i>Denmark</i>
MS and related disorders 8	Screen B10	EPR3095 – EPR3102	Heinz Wiendl, <i>Germany</i>
MS and related disorders 9	Screen B5	EPR3103 – EPR3110	Tjalf Ziemssen, <i>Germany</i>
Muscle and neuromuscular junction disease 2	Screen C1	EPR3111 – EPR3117	Antonio Toscano, <i>Italy</i>
Neuroepidemiology	Screen B12	EPR3118 – EPR3126	Maura Pugliatti, <i>Italy</i>
Neurogenetics 4	Screen C4	EPR3127 – EPR3133	Michelangelo Mancuso, <i>Italy</i>
Neuroimmunology 2	Screen A5	EPR3134 – EPR3141	Luca Massacesi, <i>Italy</i>
Neuro-ophthalmology/ neuro-otology	Screen C2	EPR3142 – EPR3150	Michael Leo Strupp, <i>Germany</i>
Neurorehabilitation 3	Screen C3	EPR3151 – EPR3157	Volker Dietz, <i>Germany</i>
Peripheral nerve disorders 5	Screen B4	EPR3158 – EPR3164	Jean Marc Leger, <i>France</i>
Sleep disorders	Screen B7	EPR3165 – EPR3173	Luigi Ferini-Strambi, <i>Italy</i>

All posters will be available throughout the congress on the poster screens and computer stations in the exhibition area.
You can contact ePoster and ePresentation presenters via the poster system. For this, please use one of the poster screens in the ePoster area and navigate to the poster you would like to contact the author of. You can find a contact link on the bottom of that page. You can do the same via the link on the congress website

12:00 – 15:00h

Room 0.01 CCL - Lisbon Congress Centre

„Huntington’s Disease - Scientific Updates for the HD Community (EHA and APDH)“

12:00h

Opening Words



12:10h

EHDN past, present and future

Jean-Marc Burgunder (Bern, Switzerland)

“The European Huntington’s Disease Network has been created in 2004 with the aim to advance research, conduct clinical trials and improve clinical care for patients with the disease and their family. EHDN started as a small group with a core study, Registry, and constantly grew thanks to the strong involvement of members and the support by CHDI. After the globalisation of the observational study, now called Enroll-HD, EHDN has reshaped its activities still working on the same aims. EHDN tasks are still at hand and the network will continue its activities in close collaboration with the patients’ organisations.”

Jean-Marc Burgunder has graduated in Medicine at the Faculty of Medicine in Bern, Switzerland, and trained in internal medicine, neurology and neuroscience in Switzerland and in Bethesda, USA. He is a Professor of Experimental Neurology at the University in Bern. He is now, Chair of the EHDN Executive Committee, Co-Chair of the Scientific Panel on Neurogenetics of EAN, Chair of the European Reference Network on Rare Neurological disorders Advisory board. He is also director of the NeuroZentrum Siloah in Gümliigen (Bern).

12:50h

EHDN and Registry/Enroll-HD studies in Portugal

Leonor Correia Guedes (Lisbon, Portugal)

“How Portuguese patients and families collaborate in global HD research and how the European Huntington’s disease network collaborates in clinical care and research in HD in Portugal.”

Portuguese Coordinator of the European Huntington’s disease Network; Member of the EHDN Scientific and Bioethical advisory board; Neurologist at Hospital de Santa Maria, Lisbon, Portugal; Professor of Neurology, Medical School of the University of Lisbon, Portugal.

13:20h–13:40h

Coffee-Break

13:40h

Clinical Trials in Huntington’s Disease

G. Bernhard Landwehrmeyer (Ulm, Germany)

G. Bernhard Landwehrmeyer, MD, FRCP is Professor of Neurology at Ulm University Hospital, Dept. of Neurology where the Central Coordination of the European Huntington’s Disease Network (EHDN) is situated. In 2004 he was instrumental in founding EHDN and served as chairman of the Executive Committee until 2014. EHDN serves as a platform for professionals, people affected by Huntington’s disease (HD), and their relatives to facilitate working together throughout Europe and conducts large prospective natural history studies in HD. He received his Doctoral Degree from the Albert-Ludwigs-University, Freiburg. He was trained at the Royal Victoria Hospital, Queen’s University, Belfast, at the Kantonsspital, Basel and worked as post-Doc at MGH, Harvard Medical School, Boston.

14:20h

20 Years’ Experience with Genetic Testing and Counselling for Huntington Disease in Portugal

Jorge Sequeiros (Porto, Portugal)

“Genetic testing for HD began to be provided in 1998, at IBMC, following the IHA/WFN Guidelines and a genetic counselling protocol already in use for Machado-Joseph disease. As a reference lab for HD, we acquired some data on the number of patients/families in Portugal, as well as on population frequency of intermediate and low-penetrance alleles. The genetic counselling experience with HD helped building our research on psychosocial genetics, improving our protocol and clinical practice, as well as contributing to the revised international guidelines proposed by the EHDN. In the meantime, having begun as a research effort, our lab became fully licensed and accredited (ISO 15189).”

Jorge Sequeiros obtained his MD from the Fac. Medicine, Univ. Porto (1975) and a PhD in Genetics from ICBAS, Univ. Porto (1990). He was post-doctoral Fellow in Medical Genetics (1982-1985) at Johns Hopkins Hosp., Baltimore. He is Director of the MSc on Genetic Counselling, ICBAS, Univ. Porto and research group leader of UnIGENE and Director of the Centre for Predictive and Preventive Genetics (www.cgpp.eu) for clinical and laboratory genetic services at IBMC. He has held numerous positions including founder and first-President (1999-2009) of the College of Medical Genetics, at the Portuguese Medical Association. He has been a member of EHDN (then Euro-HD) since its beginning in 2003, and organised the 1st meeting of Portuguese-speaking study sites (Porto, 2004). He has been part of the EHDN working groups since their first meetings.

14:50h

Closing Words

Official Networking Programme & other activities

Saturday 16 June



CCL Auditorium I
18:30h

Opening & Welcome Reception

Welcoming addresses by
Joaquim Ferreira, *Local Chairperson*
Günther Deuschl, *EAN President*

Honorary Membership Awards
Mark Hallett, *Bethesda, USA*
Alistair Compston, *Cambridge, UK*

Announcement:
Paul Boon, *Chair EAN Programme Committee*

Opening Lecture:
“Should we concern about ethical limits in neurogenetics?”
Alexandre Quintanilha, *Porto, Portugal*

Musical performance:
Original Fado Guitar Performance by Marta Pereira da Costa

All participants and exhibitors are invited to the Opening and the Welcome reception afterwards. This year the reception will be outside on the plaza in front of the CCL. We are happy to serve food and cold drinks. Please wear your badge.



Official Networking Programme & other activities

13:00-14:30h
Room Copenhagen

Challenges for Women in Neurology

Chairperson:

Elena Moro (Grenoble, France)

The aim of the event is to help identify and overcome the challenges that women can find during their academic and hospital career development in neurology. This event is mainly directed to female neurology residents and female neurologists at the beginning of their career.

You are invited to bring your lunch to this session.



Catherine Lubetzki,
Paris, France

Catherine Lubetzki is Professor of Neurology at Pierre and Marie Curie University and head of the department of neurology in Salpêtrière Hospital, Paris, France. She is and/or has been involved in several committees and funding boards, including

ECTRIMS executive committee and the scientific committee of ARSEP (French multiple sclerosis association for research). Her clinical activity is mainly dedicated to the management of multiple sclerosis patients through the Salpêtrière multiple sclerosis clinic and clinical research center. She leads a research group in the Brain and Spinal cord Institute (ICM), located within the Salpêtrière campus. The research topic is focused on the cellular and molecular mechanisms involved in central nervous system myelination and remyelination, using different in vitro models as well as in vivo approaches and post-mortem analysis. The general aim of the research projects is to understand why some multiple sclerosis lesions remyelinate whereas others do not. This with the perspective of developing, through activation of promoting cues, or suppression of inhibitory pathways, strategies aimed at stimulating endogenous remyelination, hence preventing axonal damage and limiting disability progression in Multiple Sclerosis patients.



Jera Kruja,
Tirana, Albania

Dr Jera Kruja, Professor of Neurology, is head of the University Service of Neurology, Faculty of Medicine, University of Medicine and UHC Mother Teresa in Tirana, Albania. She has been president of the Albanian Society of Neurology and for more than

20 years the delegate of this chapter and an active member of scientific panels of the European Federation of Neurological Societies (EFNS) and afterward to the European Academy of Neurology. Prof. Kruja was also a member of the Scientific Committee of EAN. Since 2014 she is a member of Teaching Course Committee of the World Federation of Neurology (WFN). She is a Lancet Commissioner for LMIC. Furthermore, she was a trainer of European Academy of Epilepsy. From 2010-2013 she was the National Health Contact Point, European Commission, CORDIS Fp7 programme and she was the first Rector of the University of Medicine of Tirana, Albania. Prof. Kruja is a member of numerous national and international editing boards and speaker in many international meetings.



Claudia Trenkwalder,
Kassel, Germany

Claudia Trenkwalder, MD, started her clinical education in neurology and movement disorders at the University Hospital of the Ludwig-Maximilian-University in Munich in 1988 and was head of the "Movement Disorders and Sleep" research

group at the Max-Planck Institute of Psychiatry in Munich from 1993-2000, before moving to the Department of Clinical Neurophysiology at the University of Goettingen as Associate Professor. She is Medical Director of the Elena Klinik, in Kassel, the largest neurological hospital for Parkinson and Movement Disorders in Germany, since 2003. In 2012, she became Full Professor of Neurology as a Foundation Chair at University Medical Center in Goettingen. Her research interests are early symptoms and therapy in Parkinson disease, movement disorders in sleep such as Rem Sleep Behavior Disorder and Restless Legs Syndrome. She has published more than 365 peer reviewed papers and supports female careers in many ways including mentoring programs at the university site. She has been active in the International Parkinson and Movement Disorder society (IPMDS) for many years and is currently President-Elect of IPMDS, but was also Founding Member of the World Association of Sleep Medicine (WASM), and President of WASM from 2011-13 and active member of many national and international scientific societies

Sunday 17 June

20.15h

Music Recital at CCL, Auditorium II

A musical Journey from Hamburg to Paris, Vienna, New York and Petrograd with compositions by Georg Philipp Telemann (1681 – 1767), Frederic Chopin (1809 – 1849), Johannes Brahms (1833 – 1897), Gabriel Fauré (1845 – 1924), Antonin Dvorak (1841 – 1904), Dmitri Shostakovich (1906 – 1975).

This chamber music recital is the third one organised and scheduled at the time of an EAN congress by the neurologists Klaus V. Toyka, Würzburg, and Hannah Cock, London, and pianist Beate Toyka, co-organised by the Faculty Neurology Department of the Lisbon University Hospital.

Participants of the congress are cordially invited to spend an hour of relaxed listening.
The tickets are € 15 (€ 10 reduced fee).



Hannah Cock, Flute



Klaus V. Toyka, Violin



Beate Toyka, Piano



Advancing Research, Conducting Trials, Improving Care

What we do

- Advance knowledge of Huntington's disease
- Support the development of better therapeutic interventions
- Improve the quality of life of people affected by HD

What you can do

- Share your knowledge and ideas
- Become part of the HD research community
- Help us improve treatment and care for HD families

Come and meet us at

C37

Find out more at ehdn.org

Contact us at info@euro-hd.net

Join us for the EHDN2018 Plenary Meeting in Vienna, Austria, September 14-16



Networking Programme & other activities

Monday 18 June


13:00h

History of Neuroscience Visit to the Egas Moniz Museum

The participants of the History of Neuroscience Visit will be picked up by bus at 13.00 on Monday, June 18. All participants will arrive at the museum between 13.15 and 13.20. Between 14.45 and 15.00 the bus will take the participants back to the CCL.

The Museum Egas Moniz is located at the Department of Neurology - Hospital Santa Maria (6th floor) in Lisbon. The Hospital Santa Maria is the largest hospital in Portugal, inaugurated in 1953, it received the heritage of the Department of Neurology of the old School Hospital of Santa Marta where Egas Moniz developed his activity as investigator, Head of Department and Chair of Neurology until his retirement in 1945.

As a tribute to the founder of the first department of Neurology and Neurosurgery in Portugal and his pioneer work in angiography and psychosurgery, an area of the department was dedicated to preserve and display the original instruments created by him to perform the first angiograms and surgical interventions in psychiatric patients, together with a photo collection, books written by him, and diplomas from numerous international scientific societies.



A very important part of the exhibition is a sequence of x rays performed during the process to obtain the first angiograms in humans and another sequence displaying the use of angiography in various pathologies from different types of tumors to several vascular abnormalities.

The original furniture of his office was brought from the old hospital and is also displayed reconstructing its Spartan ambiance.

The visit is divided in two groups:

- A visit to the library of the Department (coffee will be served)
- A slide presentation about the life and work of Egas Moniz
- A visit to the Museum

20.00-22.30h

"Meet your Neurology Network" Museu Nacional de Arte Antiga, Lisbon

The meet and greet event will take place in the Museu Nacional de Arte Antiga. Created in 1884 and housed in the Palácio Alvor for almost 130 years, the MNAA-Museu Nacional de Arte Antiga has had its current title for more than a century. It is the home to the most important Portuguese public collection of art, ranging from paintings to sculpture, and gold and silverware, as well as decorative arts from Europe, Africa and the Far East.

Since its foundation, it has been housed at the palace built in the late 17th century at the behest of the first Count of Alvor, after his return from India, where he had served as Viceroy. The palace remained in the hands of the family until the mid-18th century, when it became the property of a brother of the Marquis of Pombal, Paulo de Carvalho, before becoming the residence of a rich diamond trader, Dutch consul in Portugal, Daniel Gildemeester, who sponsored major improvement work to the building's interior spaces.

Being a typical example of the Portuguese civil architecture of that period, the palace has a long façade running parallel to the street. The building has a highly simple design with the only decoration being its ornamental baroque doorways.

The entrance fee is € 25 (reduced fee € 20) and includes free snacks and drinks, the entrance to the museum and free guiding through selected areas.

Between 20.00-21.00h, 6 guided tours will be made available.

It is easy to reach from the Congress center by trams number 714 or 727 (station Rua da Junqueira next to the CCL to Rua Presidente Arriaga) or within a 25-minute walk along the river.

Location: R. das Janelas Verdes, 1249-017 Lisboa, Portugal
website: <http://www.museudearteantiga.pt/>





Jetzt online
anmelden!

neurowoche 2018

30. Oktober – 3. November 2018
Berlin (Messe Berlin, Eingang Süd)

- 91. Kongress der Deutschen Gesellschaft für Neurologie
- 44. Jahrestagung der Gesellschaft für Neuropädiatrie
- 63. Jahrestagung der Deutschen Gesellschaft für Neuropathologie und Neuroanatomie



www.neurowoche.org

14th Meeting of European
Neuro-Ophthalmological Society

EUNOS

PORTO
16 - 19
JUNE
2019

Alfândega
Congress Centre
Porto, Portugal

Scientific Sessions, Hot Topics, Interactive Clinical Challenges & Educational Sessions.

- Main Topics:**
- Imaging in Neuro-ophthalmology - OCT and Functional MRI
 - Optic neuropathies (auto-immune, ischaemic and hereditary)
 - Ocular myasthenia gravis

Secretariat - Skyros Congressos
eunos2019@skyros-congressos.com
www.eunos2019.org



- 3DS** 3-Day Satellite Session
- CdS** Career Development Session
- CbW** Case-based Workshop
- CONT** Controversy

- FW** Focused Workshop
- HoC** Hands-on Course
- IoS** Interactive Session
- OS** Oral Session

- PLEN** Plenary Symposium
- SAT** Satellite Symposium
- SpS** Special Session
- SYMP** Symposium

- TC** Teaching Course
- T** Tournament
- NET** Networking

- €** Overarching Theme
- €** Chargeable

Sunday 17 June

Auditorium I	Auditorium VI	Room Berlin	Auditorium II	Auditorium V	Auditorium VIII	Room Amsterdam	Room Lisbon	Room Oslo	Auditorium III	Room Copenhagen	Room HoC	Room CbW	Room 0.01
IoS 3 08:00 - 09:30 EAN/ESO: Treatment decisions in some difficult scenarios of acute ischemic stroke	IoS 3 08:00 - 09:30 EAN/ESO: Treatment decisions in some difficult scenarios of acute ischemic stroke	FW 6 08:00 - 09:30 Management of Parkinson's disease in non-routine circumstances	FW 7 08:00 - 09:30 Epilepsy surgery in 2018: has anything changed in the last decades?	SpS 5 08:00 - 09:30 Neurological disorders of famous composers	FW 9 08:00 - 09:30 Novel genetic techniques in neurological practice - time for responsible clinical and research implementation	FW 8 08:00 - 09:30 Impact of technology in neuro-rehabilitation	FW 10 08:00 - 09:30 Lost in space - clinical and neurobiological aspects of topographical agnosia	SpS 6 08:00 - 09:30 Resident and Research Fellow Section learn about clinical work and research	SpS 7 08:00 - 09:30 EON Corresponding Members of the Mediterranean Area - Clinical Neuro-immunology	CdS 2 08:00 - 09:30 Abstract, poster and presentation tips for success at international meetings	HoC 3 08:00 - 09:30 TfL-table testing in neurology and clinical neurophysiology - Level 2	CbW 3 08:00 - 09:30 The process of multiple sclerosis diagnosis	
09:30-10:00 Coffee break @ exhibition Halls 1, 2, 3 and Foyer A													
09:30-10:00 Forum Talk ALNYLAM PHARMACEUTICALS - Acute Hepatic Porphyrias Scientific Theatre (Exhibition Hall 1)													
09:45-10:00 Forum Talks MERCK - Multiple Sclerosis Scientific Theatre (Exhibition Hall 1)													
09:30-17:00 Exhibition opening hours													
3-Day Satellite Session 09:30 - 10:00 Celegine: Brain volume loss: From healthy individuals to Multiple Sclerosis patients													
PS 10:00 - 12:00 Presidential Symposium	Overflow 10:00 - 12:00 Presidential Symposium	Overflow 10:00 - 12:00 Presidential Symposium	Overflow 10:00 - 12:00 Presidential Symposium	Overflow 10:00 - 12:00 Presidential Symposium	Overflow 10:00 - 12:00 Presidential Symposium	Overflow 10:00 - 12:00 Presidential Symposium	Overflow 10:00 - 12:00 Presidential Symposium	Overflow 10:00 - 12:00 Presidential Symposium	Overflow 10:00 - 12:00 Presidential Symposium	Overflow 10:00 - 12:00 Presidential Symposium	Overflow 10:00 - 12:00 Presidential Symposium	Overflow 10:00 - 12:00 Presidential Symposium	Overflow 10:00 - 12:00 Presidential Symposium
SAT 12:15 - 13:15 Abbvie: Optimising care in Advanced Parkinson's disease: Why, when, and how	SAT 12:15 - 13:15 Novartis: Our evolving understanding of the MS disease continuum: a decade of change	SAT 13:00 - 14:30 Novartis: Management of Seizures in Pediatric Patients with Tuberculous Sclerosis Complex	SAT 13:00 - 14:30 Novartis: Bringing hope for adults with Spinal Muscular Atrophy	SAT 13:00 - 14:30 Novartis: Bringing hope for adults with Spinal Muscular Atrophy	SAT 13:00 - 14:30 Novartis: Bringing hope for adults with Spinal Muscular Atrophy	SAT 13:00 - 14:30 Novartis: Bringing hope for adults with Spinal Muscular Atrophy	SAT 13:00 - 14:30 Novartis: Bringing hope for adults with Spinal Muscular Atrophy	SAT 13:00 - 14:30 Novartis: Bringing hope for adults with Spinal Muscular Atrophy	SAT 13:00 - 14:30 Novartis: Bringing hope for adults with Spinal Muscular Atrophy	SAT 13:00 - 14:30 Novartis: Bringing hope for adults with Spinal Muscular Atrophy	SAT 13:00 - 14:30 Novartis: Bringing hope for adults with Spinal Muscular Atrophy	SAT 13:00 - 14:30 Novartis: Bringing hope for adults with Spinal Muscular Atrophy	SAT 13:00 - 14:30 Novartis: Bringing hope for adults with Spinal Muscular Atrophy
SAT 13:45 - 14:45 Sanofi Genzyme: Demand more from life with Multiple Sclerosis #WomenMS	SAT 13:45 - 14:45 Bieline: Management of Parkinson's disease: from science to clinical wisdom	SAT 13:45 - 14:45 Bieline: Management of Parkinson's disease: from science to clinical wisdom	SAT 13:45 - 14:45 Bieline: Management of Parkinson's disease: from science to clinical wisdom	SAT 13:45 - 14:45 Bieline: Management of Parkinson's disease: from science to clinical wisdom	SAT 13:45 - 14:45 Bieline: Management of Parkinson's disease: from science to clinical wisdom	SAT 13:45 - 14:45 Bieline: Management of Parkinson's disease: from science to clinical wisdom	SAT 13:45 - 14:45 Bieline: Management of Parkinson's disease: from science to clinical wisdom	SAT 13:45 - 14:45 Bieline: Management of Parkinson's disease: from science to clinical wisdom	SAT 13:45 - 14:45 Bieline: Management of Parkinson's disease: from science to clinical wisdom	SAT 13:45 - 14:45 Bieline: Management of Parkinson's disease: from science to clinical wisdom	SAT 13:45 - 14:45 Bieline: Management of Parkinson's disease: from science to clinical wisdom	SAT 13:45 - 14:45 Bieline: Management of Parkinson's disease: from science to clinical wisdom	SAT 13:45 - 14:45 Bieline: Management of Parkinson's disease: from science to clinical wisdom
SpS 1 15:00 - 17:00 MDS-ES: European Basal Ganglia Club	IoS 4 15:00 - 16:30 How to diagnose acute vertigo and acute double-vision	TC 6 15:00 - 18:15 Update on MS treatment - Level 2	TC 8 15:00 - 18:15 Tips and tricks in diagnosing headache disorders - Level 1	SpS 10 15:00 - 16:30 Clinical Grand Rounds	TC 9 15:00 - 18:15 New insights in the management of patients with ischaemic stroke or TIA - Level 2	TC 7 15:00 - 18:15 Clinical neuro-physiology in neuro-rehabilitation - Level 2	OS 15:00 - 16:30 Cerebrovascular diseases 1	TC 19 15:00 - 18:15 The neurological bedside examination - the art of identifying pathology - Level 1	TC 10 15:00 - 18:15 Current treatments in neurology - Level 1	T 15:00 - 16:30 Tournament for neurologists in Training - basic	CbW 4 15:00 - 16:30 Difficult decisions in treatment of myasthenia gravis	CbW 4 15:00 - 16:30 Difficult decisions in treatment of myasthenia gravis	CbW 4 15:00 - 16:30 Difficult decisions in treatment of myasthenia gravis
16:15-16:45 Coffee break @ exhibition Halls 1, 2, 3 and Foyer A													
SAT 18:30 - 20:00 Novartis: It's time to Act on Migraine: How can we manage the unmet needs?	SAT 18:30 - 20:00 Merck: Foundation and Innovation in Multiple Sclerosis treatment - avoiding continuous immunosuppression	TC 6 cont.	TC 8 cont.	OS 17:15 - 18:15 Miscellaneous 1	TC 9 cont.	TC 7 cont.	OS 16:45 - 18:15 Epilepsy	TC 19 cont.	TC 10 cont.	OS 16:45 - 18:15 Neuro-oncology	HoC 5 16:45 - 18:45 Ultrasound in vascular diagnosis - Level 1	CbW 5 16:45 - 18:15 Neurogenetics goes therapy	CbW 5 16:45 - 18:15 Neurogenetics goes therapy
SAT 18:30 - 20:00 Novartis: It's time to Act on Migraine: How can we manage the unmet needs?	SAT 18:30 - 20:00 Merck: Foundation and Innovation in Multiple Sclerosis treatment - avoiding continuous immunosuppression	SAT 18:30 - 20:00 Alnylam: Connecting the Dots - Diagnosing hATTR Amyloidosis	SAT 18:30 - 20:00 Alnylam: Connecting the Dots - Diagnosing hATTR Amyloidosis	SAT 18:30 - 20:00 Alnylam: Connecting the Dots - Diagnosing hATTR Amyloidosis	SAT 18:30 - 20:00 Alnylam: Connecting the Dots - Diagnosing hATTR Amyloidosis	SAT 18:30 - 20:00 Alnylam: Connecting the Dots - Diagnosing hATTR Amyloidosis	SAT 18:30 - 20:00 Alnylam: Connecting the Dots - Diagnosing hATTR Amyloidosis	SAT 18:30 - 20:00 Alnylam: Connecting the Dots - Diagnosing hATTR Amyloidosis	SAT 18:30 - 20:00 Alnylam: Connecting the Dots - Diagnosing hATTR Amyloidosis	SAT 18:30 - 20:00 Alnylam: Connecting the Dots - Diagnosing hATTR Amyloidosis	SAT 18:30 - 20:00 Alnylam: Connecting the Dots - Diagnosing hATTR Amyloidosis	SAT 18:30 - 20:00 Alnylam: Connecting the Dots - Diagnosing hATTR Amyloidosis	SAT 18:30 - 20:00 Alnylam: Connecting the Dots - Diagnosing hATTR Amyloidosis
16:15-16:30 Forum Talks BIOGEN - Progressive supranuclear palsy Scientific Theatre (Exhibition Hall 1)													

3DS 3-Day Satellite Session
CdS Career development Session
CbW Case-based Workshop
CONT Controversy

FW Focused Workshop
HoC Hands-on Course
IaS Interactive Session
OS Oral Session

PLEN Plenary Symposium
SAT Satellite Symposium
SpS Special Session
SYMP Symposium

TC Teaching Course
T Tournament
NET Networking

Overarching Theme
€ Chargeable

Tuesday 19 June

Auditorium I	Auditorium VI	Room Berlin	Auditorium II	Auditorium VIII	Room Amsterdam	Room Lisbon	Room Oslo	Auditorium III	Room Copenhagen	Room CbW
SYMP7 08:00-10:00 A new look in neuropathogenesis of multiple sclerosis	SYMP8 08:00-10:00 Advances in molecular characterisation and personalised therapies in brain tumors	IaS8 08:30-10:00 Is it a vasculitis or not?	CdS3 08:30-10:00 Drug development and clinical trials in neurology	OS 08:30-10:00 Headache and pain	SpS11 08:30-10:00 Population, migration and neurological disorders	OS 08:30-09:45 Miscellaneous 2	OS 08:30-10:00 Muscle and neuromuscular junction diseases	OS 08:30-10:00 Movement disorders 2	CbW9 08:30-10:00 Imaging selection of stroke patients for specific treatment interventions	

09:30-13:30 Exhibition opening hours

10:00-10:30 Coffee break @ exhibition Halls 1, 2, 3 and Foyer A

PS 10:30-12:30 Highlights and Breaking News	Overflow 10:30-12:30 Highlights	Overflow 10:30-12:30 Highlights

12:30-13:30 Lunch break @ exhibition Hall 2 and Foyer A (lunch served from 12:30-13:30)

IaS7 13:00-14:30 Mixed movement disorders: what do we see and how do we approach?	TC15 13:00-16:30 The "difficult to treat" headache patient – Level 3	TC16 13:00-16:30 Autoantibodies in neurological disorders – Level 2	Controversy 2 13:00-14:30 Controversies in the diagnosis of Alzheimer's disease & in the treatment of Multiple Sclerosis	TC17 13:00-16:30 Advanced neuro-somology – Level 3	TC18 13:00-16:30 Basics of sleep medicine – Level 1	CbW8 13:00-14:30 Challenging cases of infections of the nervous system

14:30-15:00 Coffee break near Auditorium VI + ePoster Area

TC15 cont.	TC16 cont.	TC17 cont.	TC18 cont.

Separate registration fees apply for:

Teaching Courses = 50€ / 30€ reduced fee
 Hands-on Courses = 50€ / 30€ reduced fee
 Case-based Workshops = 50€ / 30€ reduced fee

ean congress **Lisbon**
congress **2018**

Neurogenetics
**Unravelling
hidden
diseases**



Scientific Programme

4th Congress of the
European Academy
of Neurology

June 16 – 19



**PRACTICAL ARTICLES
EXPERT INTERVIEWS
NEWS AND INSIGHTS**

**PEER REVIEWED | OPEN ACCESS
CONCISE | MULTIMEDIA**



**VIEW – DOWNLOAD – SUBSCRIBE
FREE**

touchNEUROLOGY.com

Saturday
16 June 2018

16

08:30 – 10:00
Room CbW

Case-based Workshop 1: EAN/ EAPC: End-of-life care for neurological patients

Chairperson:

David Oliver (Canterbury, UK)

- Ventilation and gastrostomy in ALS at the end of life
Idris Baker (Swansea, UK)
- Coping with patient/ family/ team distress at the end of life
Peter Zepper (Salzburg, Austria)
- Difficult discussions at the end of life
Orla Hardiman (Dublin, Ireland)

Educational content:

As a patient with progressive neurological disease deteriorates and comes to the end of life, there are increasing issues to be discussed:

- Awareness of the issues regarding the decisions as to continue or withdraw treatment, such as ventilation or gastrostomy feeding
- Awareness of the need for discussions with patient and family about the disease deterioration and helping them to plan ahead
- Awareness that the discussion within teams can be difficult, as members cope with the issues differently, potentially leading to conflict
- Awareness and ideas as to the possible ways of lead discussions about end of life, including the discussion of what to expect at the end of life, the fears that patients and families may have, preparations for the care at the end of life, consideration of hastened death

All these areas will be considered with opportunities for discussion of these difficult issues – practically and ethically.

Limited to 60 participants. Please register separately – additional fees will apply.

08:30 – 10:00
Room Oslo

Career development Session 1: Etiological investigation of disease: case-control studies

Chairperson:

Maura Pugliatti (Ferrara, Italy)

- Problems with the investigation of disease etiology
Pierre-Marie Preux (Limoges, France)
- Structure and pitfalls of the case-control studies
Maura Pugliatti (Ferrara, Italy)
- Statistical methods in case-control studies
Derrick Bennett (Oxford, UK)

Educational content:

Case-control studies represent the commonest study design for the investigation of the etiology of a disease. Although case-control studies can be easily run and are the only way to investigate rare diseases, they are affected by a number of confounders that must be controlled at the planning and analysis stage. The participation to this course will consent the participants to learn the indications, basic structure and pitfalls of this study design. Some basic statistical principles will be offered for the conduction and interpretation of case-control studies.

08:30 – 10:00
Auditorium VI

Interactive Session 1: EAN/ ILAE-CEA: Classification of the epilepsies: old wine in new skins?

Chairperson:

Tim J von Oertzen (Linz, Austria)

- Classifications of seizure types
Tim J von Oertzen (Linz, Austria)
- Terminology of seizure types
Philippe Ryvlin (Lausanne, Switzerland)
- Classification of epilepsies
Eugen Trinka (Salzburg, Austria)

Educational content:

A new concept of classification of epilepsies, seizure types and terminology were recently published by the ILAE. This session will discuss the transition of the new classification into clinical practice. The talks will summarise the main idea and structure of the new classification, the discussion will focus on the clinical applicability and its challenges.

Please download the app “EAN Congress” to actively participate in this Session and vote.

Saturday 16 June
08.30 – 10.00

16

08:30 – 10:00
Auditorium III

Focused Workshop 1: Brain health in Multiple Sclerosis: a catalyst for a new approach to management

Chairperson:

Gavin Giovannoni (London, UK)

- **Treating-2-target: the case for maximising brain health in MS**
Gavin Giovannoni (London, UK)
- **The economic cost of MS in Europe**
Gisela Kobelt (Mulhouse, France)
- **Translating recommendations for improving MS care into improved outcomes**
Jeremy Hobart (Plymouth, UK)

Scientific content:

Treating to target is an approach that has been successfully adopted in several therapeutic areas; owing to recent advances in treatment, this is now also a realistic goal for the clinical management of Multiple Sclerosis (MS). Early diagnosis and treatment of MS could improve outcomes for patients. MS Brain Health is thus promoting a strategy to maximise lifelong brain health by minimising delays in the care pathway. The focus of MS management is indeed shifting towards early diagnosis and intervention; this has been associated with changes in the drivers of the costs of care. We present the results of a large European study, which assesses differences in the burden of illness between countries. Understanding these between-country differences is crucial in order to evaluate the potential economic impact of future changes in MS care. To change existing practice, however, it is necessary to define measures relating to 'early' diagnosis and treatment, so as to provide a benchmark that MS service providers can use for comparison. A modified Delphi process that involved experts from over 20 countries was conducted to define standards for the timing of key steps in the MS care pathway. The results of the process and these new consensus standards will be presented at the workshop. Participants in the workshop will be invited to put forward and discuss suggestions for implementing and measuring these standards in clinical practice.

08:30 – 10:00
Auditorium V

Focused Workshop 2: Biomarkers of neuromuscular disorders



Chairperson:

Corrado Angelini (Venice, Italy)

- **Micro-RNA in muscular dystrophies**
Corrado Angelini (Venice, Italy)
- **Inflammatory neuropathies and antibodies**
Luis A Querol Gutierrez (Barcelona, Spain)
- **Mitochondrial disorders and biomarkers**
Rita Horváth (Newcastle, UK)

Scientific content:

The scientific content of the focused workshop is intended to highlight the biomarkers in neuromuscular disorders, neuropathies and mitochondrial diseases, since the follow-up of these disorders could be better performed by clinicians if they follow not only by clinical examination but also by specific molecular biomarkers in future clinical trials to treat these disorders.

08:30 – 10:00
Room Lisbon

Focused Workshop 3: The importance of brain network reorganisation in old age and for successful rehabilitation after stroke

Chairperson:

Paolo Maria Rossini (Rome, Italy)

- **Methods of directly interacting with brain function**
Walter Paulus (Göttingen, Germany)
- **The importance of shifting our models of the effects of NIBS from producing pure excitation or inhibition of target structures to considering the wider network effects**
John C. Rothwell (London, UK)
- **Connectivity disturbances in stroke as revealed by integrated multimodal neuroimaging by fMRI, EEG and TMS-EEG**
Paolo Maria Rossini (Rome, Italy)

Scientific content:

Non-invasive brain stimulation (NIBS) is available to many neurology and psychiatry departments nowadays but its use for interaction with brain circuitry in many neurological and psychiatric conditions is not much more than empirical. The course will focus on discussing the effects of brain stimulation and especially viewing these effects on a wide network, not just focusing on a single effect on a certain brain site or function. This will be specially focused on stroke and the information obtained by using electrophysiological and neuroimaging techniques together.

08:30 – 10:00
Room Copenhagen



Focused Workshop 4: Ability to drive in neurological disorders

Chairperson:

Johannes Mathis (Bern, Switzerland)

- Fitness to drive in sleepy patients
Johannes Mathis (Bern, Switzerland)
- Fitness to drive after the first epileptic seizure
Tony Marson (Liverpool, UK)
- Fitness to drive after stroke
Catarina Lundberg (Stockholm, Sweden)

Scientific content:

Permission to drive is of great importance in all patients, but because of accident risk due to disease this stands in conflict with public safety. Physicians will be more and more responsible, not only to diagnose and treat patients, but also to achieve driving rehabilitation, to consult patients on their individual driving risks including the legal situation and to decide if fitness to drive cannot be attested.

08:30 – 10:00
Room Berlin



Focused Workshop 5: Familial amyloid polyneuropathy: phenotype, genetics, treatment

Chairperson:

Teresa Coelho (Porto, Portugal)

- 60 years of transthyretin familial amyloid polyneuropathy in Europe: epidemiology, clinical presentation and genetic basics
Teresa Coelho (Porto, Portugal)
- The course and prognostic factors
Laura Obici (Pavia, Italy)
- Recent advances in therapy
Isabel Conceição (Lisbon, Portugal)

Scientific Content:

Familial Amyloid Polyneuropathy first described in Portugal by Andrade in 1952, is no longer just a rare neuropathy. Nowadays ATTR amyloidosis is recognised as a complex systemic disease, distributed worldwide. It can be related to the presence of TTR mutations or simply to the aging process. A large genotype and phenotype variability is increasingly recognised but it's always a severe, progressive and ultimately fatal disease. Misdiagnosis is a major problem. Several disease-modifying therapies are presently available, and others are under development. They have changed significantly the quality of life and survival of many patients.

The presenters of this focused workshop work in three European Reference Centres for ATTR amyloidosis and will present data on genetic aspects, epidemiology, clinical presentation, progression, prognostic factors and recent advances in therapy.

08:30 – 10:00
Room Amsterdam

Special Session 12: 25 Years of European Journal of Neurology – History, future and how to prepare your paper for publication

Chairperson:

Anthony Schapira (London, UK)

- History: the Editor-in-Chief's view
Anthony Schapira (London, UK)
- Future: the publisher's view
Silvana Losito
- "How to prepare a scientific paper for publication"
Pertti Saloheimo (Espoo, Finland)

Scientific Content:

In this session, special attention to 25 years of the European Journal of Neurology (EJN) will be given. The editor-in-chief will give an insight into how we review and handle papers, the publisher will outline how things have changed over 25 years and what the future of journal publishing holds. Particular knowledge on how to prepare your scientific paper for publication will be shared by one of the EJN's associate-editors.

Saturday 16 June
10.30 – 12.30

16

10:30 – 12:30
Auditorium I



Symposium 1: EAN/MDS-ES: Tauopathies: pathophysiology, clinical features and experimental therapies

Chairpersons:

Carlo Colosimo (Terni, Italy)
Isabelle Le Ber (Paris, France)

- **Tau protein in normal and pathological brain**
Tiago F. Outeiro (Goettingen, Germany)
- **The spectrum of frontotemporal dementias**
Isabelle Le Ber (Paris, France)
- **Progressive supranuclear palsy and corticobasal degeneration: one disease or two**
Carlo Colosimo (Terni, Italy)
- **Emerging disease-modifying treatments for tauopathies**
Guenther U. Hoeglinger (Munich, Germany)

Scientific content:

Clinical features and diagnosis strategy would be presented in the first part of each lecture (didactic) and potential therapeutic new strategies could be presented (including treatments that have been proposed and have no effects) in the second part.

10:30 – 12:30
Auditorium VI



Symposium 2: Diagnosing genetic epilepsies

Chairpersons:

Reetta K. Kälviäinen (Kuopio, Finland)
Hannah Cock (London, UK)

- **Is epilepsy a genetic disease?**
Simon D. Shorvon (London, UK)
- **Molecular diagnosis in genetic epilepsies: why we need to test**
Sarah Weckhuysen (Antwerpen, Belgium)
- **New therapeutic strategies in development for the genetic epilepsies**
José M. Serratosa (Madrid, Spain)
- **Whole exome sequencing (WES)**
Reetta K. Kälviäinen (Kuopio, Finland)

Scientific content:

Epilepsy is a common neurological disease, and there might be a genetic basis in almost half of the people with epilepsy. The diagnosis of genetic epilepsies makes the patient assured of the reasons of his/her seizures and avoids unnecessary, expensive, and invasive investigations. Last decade has shown tremendous growth in gene sequencing technologies, which have made genetic tests available at the bedside. Whole exome sequencing is now being routinely used in the clinical setting for making a genetic diagnosis. Genetic testing not only makes the diagnosis but also has an effect on the management of the patients, for example, the role of aggravating sodium channels blockers in SCN1A-Dravet syndrome patients and usefulness of ketogenic diet therapy in SLC2A1-generalised epilepsy patients. The purpose of this symposium is to give an overview in this direction and encourage the clinicians to start considering genetic testing as an important investigation along with EEG and magnetic resonance imaging for better understanding and management of epilepsy in their patients. However, we will also discuss the important potential social implications of the genetic findings, which should not be forgotten.

10:30 – 12:30
Auditorium V

Symposium 3: EAN/ESO: Cerebral small vessel disease - recent advances and clinical implications

Chairpersons:

José Ferro (Lisbon, Portugal)
Hugh Markus (London, UK)

- **"Occult" SVD on an MRI scan: what does it mean and what should I do?**
Stéphanie Debette (Paris, France)
- **New insights into what causes SVD- and treatment implications**
Hugh Markus (London, UK)
- **Cognitive impairment in SVD- mechanisms and management**
Frank-Erik de Leeuw (Nijmegen, The Netherlands)

Scientific content:

Cerebral Small Vessel Disease (SVD) causes a quarter of all strokes, being directly responsible for lacunar stroke and also contributing to intracerebral haemorrhage. It is also the most common cause of vascular cognitive impairment, and increasing evidence suggests it may increase the risk that someone with Alzheimer's pathology presents with clinical dementia during life. Despite its importance there is much we do not understand about it clinically and there are limited treatment options. This symposium will update attendees on a number of important advances in the field. It will start with new data on what incidental findings of SVD e.g. white matter hyperintensities and microbleeds, which are often found incidentally on MRI scans mean in terms of patient risk. This is followed by new insights into what causes SVD and what implications these may have for treatment. The symposium concludes with an update on what causes cognitive decline in this patient group.

Saturday 16 June
10.30 – 16.15

 10:30 – 12:30
 Room Berlin

**Symposium 9: EAN/ECTRIMS:
 Therapeutic challenges in
 progressive Multiple Sclerosis**
Chairpersons:

Per Soelberg Sørensen
 (Copenhagen, Denmark)
David Miller (London, UK)

- **Pathological concepts of progressive MS**
Christine Stadelmann
 (Göttingen, Germany)
- **Understanding progression: the contribution of clinical trials and natural history studies**
Jaume Sastre-Garriga (Barcelona, Spain)
- **Present and future treatment options in progressive MS**
Tobias Derfuss (Basel, Switzerland)
- **Who and how to treat progressive MS**
Giancarlo Comi (Milan, Italy)

Scientific content:

The pathological features of progressive MS and insight into the factors that drive progression of disability based on pathophysiological concepts (mitochondrial failure, ectopic expression of ion channels, virtual hypoxia, compartmentalized inflammation, microglial activation) will be summarised in the first talk.

In the second talk, the clinical definition of progressive MS, epidemiology of progressive MS, time course and quality of disability development in progressive MS, contributing factors for progression (small vessel disease, neurodegeneration, environmental factors, e.g. smoking, infections) will be described. Then clinical trials on progressive MS, concept of immunomodulation versus neuroprotection/remyelination will be presented.

In the last talk, the practical aspects of treatment of progressive MS will be highlighted: which patients might profit most, how to monitor treatment, when to stop treatment.

 10:30 – 12:30
 Auditorium VIII

**Symposium 4: EAN/EAPC:
 Palliative care and neurology**
Chairpersons:

Phil Larkin (Dublin, Ireland)
Paul Boon (Ghent, Belgium)

- **Palliative care from a neurologist's perspective: the evidence**
David Oliver (Canterbury, UK)
- **Guidelines in progress across Europe**
Raymond Voltz (Cologne, Germany)
- **What can a neurologist learn from palliative care specialists?**
Simone Veronese (Turin, Italy)

Scientific content:

Results of recent research on the effectiveness of palliative care in neurology/new evidence-based guidelines developed.

 14:15 – 16:15
 Room Berlin

**CME Topical Symposium:
 Digital outcome assessment**
Chairpersons:

Ludwig Kappos (Basel, Switzerland)
Jochen Klucken (Erlangen, Germany)

- **Digital outcome assessment in Multiple Sclerosis**
Ludwig Kappos (Basel, Switzerland)
- **Digital outcome assessment in epilepsy**
Sandor Beniczky (Dianalund, Denmark)
- **Digital outcome assessment in Parkinson's disease**
Jochen Klucken (Erlangen, Germany)

Scientific content:

Besides patient-reported outcomes objective outcome measures reflective of new diagnostic and therapeutic techniques are becoming increasingly important in neurological conditions. In this session digital outcome measures in MS, epilepsy and Parkinson's disease will be discussed in detail. This is particularly relevant to innovation driven clinical practice.

This symposium is supported by an educational grant from Roche.

ECTRIMS

EUROPEAN COMMITTEE FOR TREATMENT
AND RESEARCH IN MULTIPLE SCLEROSIS

WELCOME TO

ECTRIMS

10 – 12 OCTOBER

2018

BERLIN, GERMANY

34TH Congress of the
European Committee for
Treatment and Research
in Multiple Sclerosis




www.ectrims-congress.eu



ACCELERATING THE PACE OF CHANGE

دبي



DUBAI

WCN 2019

XXIV WORLD CONGRESS OF NEUROLOGY

DUBAI, UNITED ARAB EMIRATES, OCTOBER 26-31 2019



WWW.WCN-NEUROLOGY.COM

Saturday 16 June
14.15 – 16.15

16



14:15 – 16:15
Room HoC

Hands-on Course 1: Motor Unit Number Index (MUNIX) and phrenic nerve conduction studies - Level 3

Chairperson:

Markus Weber (St. Gallen, Switzerland)

- **Introduction: MUNIX - a progression marker of motor neuron loss**
Markus Weber (St. Gallen, Switzerland)
- **Introduction: Phrenic nerve conduction studies**
Mamede Alves de Carvalho (Lisbon, Portugal)
- **Device 1 – MUNIX – UL muscles – 20 minutes**
Markus Weber (St. Gallen, Switzerland)
- **Device 2 – MUNIX – Biceps – 20 minutes**
Christoph Neuwirth (St. Gallen, Switzerland)
- **Device 3 – MUNIX – LL muscles – 20 minutes**
Sanjeev Nandedkar (Hopewell Junction, USA)
- **Device 4 – phrenic nerve conduction – 20 minutes**
Mamede Alves de Carvalho (Lisbon, Portugal)

Educational content:

Objective markers of disease progression in ALS clinical trials are urgently needed. Weakness in ALS is mostly dependent on lower motor neuron loss. Force evaluation depends on patient cooperation and fatigue. This is also true for respiratory tests; in addition, bulbar patients do not perform well due to weak facial muscles. Quantification of motor unit loss by means of MUNIX has the great advantage that this measure directly reflects the underlying pathology. Likewise, phrenic nerve conduction studies will not only objectively reveal diaphragmatic function but also provides prognostic information. Both methods have gained a lot of sci-

entific attention over the past few years and are at the forefront of ALS research. Their potential application in future clinical trials fuel the interest about these techniques. This course will focus on practical issues. Participants will understand the applicability and limitations of these methods. Participants will apply the methods at each other. MUNIX will be performed on APB, ADM, FDI, Biceps, TA, EDB. After the course attendees will be able to make high quality and reliable MUNIX measurements and CMAP recordings of the diaphragm. Participants will be ready to apply these techniques in their centres, in particular in future clinical trials in ALS.

Limited to 60 participants. Please register separately – additional fees will apply.

This course is supported by NATUS Medical Inc.

14:45 – 16:15
Room CbW

Case-based Workshop 2: Cases of drophead, camptocormia and axial weakness and related treatment

Chairperson:

John Vissing (Copenhagen, Denmark)

- **Drophead syndrome**
Roberto Massa (Rome, Italy)
- **Camptocormia**
Heinz Reichmann (Dresden, Germany)
- **Axial weakness**
John Vissing (Copenhagen, Denmark)

Educational content:

The workshop is directed towards the diagnostic utility of recognising different causes and mechanisms of “drop head”, camptocormia and axial weakness related to a differential diagnosis in neuromuscular disorders and other neurological conditions. Treatment or management should be part of the presentation.

Limited to 60 participants. Please register separately – additional fees will apply.

14:45 – 16:15
Auditorium VI

Interactive Session 2: Update in chronic headache disorders

Chairperson:

Anish Bahra (London, UK)

- **Chronic migraine**
Julio Pascual (Santander, Spain)
- **Medication overuse headache**
Rigmor Jensen (Glostrup, Denmark)
- **Chronic daily headache**
Anish Bahra (London, UK)

Educational content:

Participants will learn how to diagnose chronic headache disorders according to the IHS classification and how to apply eventual further investigations and treatment strategies. Although chronic migraine is a common disorder that severely impacts patient functioning and quality of life, it is usually underdiagnosed, and treatment responses often remain poor even after diagnosis. In addition, effective treatment options are limited due to the rarity of randomised controlled trials involving such patients. In the present course pharmacological, non-pharmacological, treatment options for chronic migraine will be discussed.

Medication overuse headache is a common and disabling headache disorder. It has a prevalence of about 1-2 % in the general population. The International Classification of Headache Disorders 3rd edition (beta version) has defined MOH as a chronic headache disorder with clearcut diagnostic criteria. Chronic daily headache is a challenging condition to treat and it is often accompanied by significant comorbidities, such as chronic fatigue, depression, anxiety and insomnia, which further complicate treatment. Unrealistic expectations of treatment goals can lead to patient frustration and, as a result, decrease treatment adherence. Patients often desire headache-free status, but this outcome is not realistic for many patients. By contrast, an effective treatment goal starts

with establishing the correct diagnosis and creating a multimodal treatment plan to improve function and well-being. With proper comprehensive treatment, the condition improves in most patients.

The aim of the course is familiarising neurologists in training how to recognize chronic headache disorders one from another and to develop strategies to approach the problem.

Please download the app “EAN Congress” to actively participate in this Session and vote.

14:45 – 16:15
Room Oslo



Special Session 3: EAN/EFAS: Autonomic dysfunction as early markers in rare and neurodegenerative diseases

Chairperson:

Gregor Wenning (Innsbruck, Austria)

- **Preclinical target discovery in MSA: pitfalls and how can we avoid them**
Gregor Wenning (Innsbruck, Austria)
- **Biomarkers in MSA, a prerequisite for disease modification**
Alessandra Fanciulli (Innsbruck, Austria)
- **Can autonomic dysfunction differentiate early neurodegenerative diseases including dementia, Parkinson and MSA?**
Walter Struhal (Tulln, Austria)
- **Autonomic dysfunction in hereditary sensory and autonomic neuropathies and Fabry's disease**
Max Hilz (Erlangen, Germany)

Session Content:

Central and peripheral autonomic structures are compromised early in a number of neurodegenerative diseases. Autonomic dysfunction is of considerable interest to be employed as early biomarkers. Knowledge on the evaluation of autonomic nervous system however is not widely taught due to a lack of autonomic experts in Europe. This SPS discusses available early autonomic biomarkers on three manageable entities: dementia patients, Fabry's disease and synucleinopathies. Multiple system atrophy (MSA) is an adult-onset, fatal neurodegenerative disease presenting with progressive autonomic failure, parkinsonian, cerebellar and pyramidal features in various combinations. Up to date only symptomatic therapy is available. Several considerations may account for the therapeutic failure of many current trials: currently available MSA preclinical testbeds may not reflect the complexity of human MSA pathology; preclinical interventional

Saturday 16 June
14.45 – 18.15

16

protocols may be substantially different from human ones; a putative neuroprotective compound might be effective in early, or pre-clinical, disease stages only.

In the present session, the speakers will focus on the role of oligodendroglial dysfunction, synuclein aggregation and mitochondrial failure in the pathogenesis of MSA and their role in testbed modelling, as well as pre-clinical target discovery. Early clinical, autonomic, imaging and wet MSA-biomarkers and predictors of progression. Pitfalls of concluded RCTs and solutions how to overcome them in ongoing RCTs. The audience will learn on evaluation and interpretation of autonomic results and fitting those data into diagnosis and management of early neurodegenerative disease.

14:45 – 18:15
Auditorium I



Teaching Course 1: EAN/ MDS-ES: Dystonia - how to recognise and treat - Level 1

Chairperson:

Marie Vidailhet (Paris, France)

- **Inherited familial forms of dystonia**
Christine Klein (Lübeck, Germany)
- **Generalised dystonia**
Marie Vidailhet (Paris, France)
- **Focal dystoniae**
Alberto Albanese (Milan, Italy)
- **Functional dystonias and fixed dystonias**
Kailash Bhatia (London, UK)

Educational content:

The phenomenology and classification of dystonia will be presented. For each sub-type of dystonia, clinical features, diagnosis strategy and illustrative cases will be detailed. The value of genetic testing and the nomenclature of genetic forms will be discussed. A general overview of treatments, then a case-based discussion on each particular treatment and indication (limits and adverse effects) will be done (including special focus on specific forms such as the Dopa-responsive dystonia group. Differential diagnosis and look-alike will be discussed. Current concepts on pathophysiology will be briefly exposed. The sub-group of functional dystonias and fixed dystonia, diagnosis criteria, care and perspective will be specifically discussed.

14:45 – 18:15
Auditorium III



Teaching Course 2: How to proceed with a suspected myopathy? - Level 2

Chairperson:

Antonio Toscano (Messina, Italy)

- **How to proceed with elevation of serum CK**
Juan J Vilchez (Valencia, Spain)
- **Bioenergetic failure in muscle disorders**
Antonio Toscano (Messina, Italy)
- **Clinical relevance of autoantibodies in MDs clinical practice**
Benedikt Schoser (Munich, Germany)
- **How to deal with myotonic disorders**
Guillaume Bassez (Paris, France)

Educational content:

Myopathies are a heterogeneous group of rare disorders where skeletal muscle is primarily compromised. These disorders are relatively rare and may show a wide range of symptoms at infancy, childhood or adulthood. More recently, increased awareness, detailed characterisation of the clinical spectrum and improved diagnostic workup have made it easier to recognize these clinical entities although this is still challenging either in infantile or in adult cases. Innovative diagnostic techniques such as use of new released autoantibodies, biochemical approaches or molecular genetic methods as NGS (Next Generation Sequencing) or whole exome/genome sequencing have been considered to better evaluate either known or emerging clinical myopathic entities. This teaching course is aimed to update the evaluation of these disorders, taking into consideration the main pathogenic mechanisms of muscle dysfunction determined by genetic, bioenergetic and dis-immune causes, also to reach an early diagnosis, mainly in cases where a specific therapy is available.

14:45 – 18:15
Room Amsterdam



Teaching Course 3: The diagnoses of ALS – old and new approaches – Level 2

Chairperson:

Philip Van Damme (Leuven, Belgium)

- **How to diagnose ALS? Clinical aspects and staging of disease**
Philip Van Damme (Leuven, Belgium)
- **Neurophysiological measurements of ALS diagnosis and progression**
Susanne Petri (Hannover, Germany)
- **Neuroimaging biomarkers**
Martin R. Turner (Oxford, UK)
- **Blood and CSF biomarkers**
Vincenzo Silani (Milan, Italy)

Educational content:

In this teaching course, an overview of the clinical presentation and diagnosis of ALS will be given. The classification of ALS, which is based on clinical features and genetics will be explained, as well as the contribution of novel neurophysiological measurements to ALS diagnosis and progression. In addition, recent advances in neuroimaging and fluid biomarkers - reflecting various aspects of the disease - will be discussed.

a) The diagnosis of ALS largely remains a clinical diagnosis, relying on correct clinical judgement of the presenting symptoms and signs of the patients. The diagnostic algorithm of ALS will be discussed. ALS is a heterogeneous disorder and several clinical subtypes of ALS exist, which have different rates of progression. The first staging systems of ALS are emerging and will be discussed.

b) Neurophysiological measurements remain the most important test in the diagnostic algorithm of ALS, as they can confirm the presence of lower motor neuron involvement and allows for precise assessment of the extent of lower motor neuron degeneration. In addition, several novel neurophysiological

techniques can evaluate upper motor neuron involvement as well as disease progression.

Their value in the diagnosis and follow-up of patients will be explored.

c) In clinical routine, neuroimaging is mostly used to exclude other pathologies that could mimic specific symptoms and signs of patients with ALS. However, a growing body of evidence suggests that neuroimaging techniques can also contribute to the diagnosis of ALS by revealing specific and progressive changes in the brain and spinal cord. In addition, some imaging techniques can shed light on the underlying disease mechanisms, which may become important to track the effect of treatment interventions. A review of the value and prospects of neuroimaging biomarkers will be given.

d) A simple laboratory test for ALS is lacking, but over the last years a lot of progress has been made to identify and validate diagnostic biomarkers for ALS in blood and CSF. Such markers can not only aid in diagnosis, but may also contain prognostic information. Moreover, some of them reflect underlying disease mechanisms, important to follow in early phase clinical trials. An update on the current state of blood and CSF biomarkers for ALS will be given.

14:45 – 18:15
Auditorium V

Teaching Course 4: Neuroimaging and early detection of neurological diseases – Level 2

Chairperson:

Federica Agosta (Milan, Italy)

- **Radiologically isolated syndromes**
Nicola de Stefano (Siena, Italy)
- **Genetic motor neuron diseases**
Peter Bede (Dublin, Ireland)
- **Preclinical Alzheimer's disease and frontotemporal dementia**
Federica Agosta (Milan, Italy)
- **Preclinical stages of Parkinson's disease**
Klaus Seppi (Innsbruck, Austria)

Educational content:

Advanced neuroimaging techniques are of special interest for their potential to characterise the signature of demyelinating and neurodegenerative conditions and aid both the diagnostic process and the monitoring of disease progression. This TC will overview recent research on the study of the preclinical stages of demyelinating/neurodegenerative diseases as well as genotype-specific changes in asymptomatic gene mutation carriers. Characterising brain structural and functional abnormalities in these subjects using neuroimaging may help anticipating the diagnosis and perhaps prevent the devastating impact of these conditions. This aspect will become crucial when disease-modifying (personalised) therapies will be established.

Saturday 16 June
16.45 – 18.45

16

14:45 – 18:15
Auditorium VIII



Teaching Course 5: Acute emergencies in neuromuscular disease - Level 2

Chairperson:

Maxwell Damian (Cambridge, UK)

- Evaluation and differential diagnosis of acute neuromuscular weakness
Zohar Argov (Jerusalem, Israel)
- Vasculitis of the peripheral nervous system
Alexander Vrancken (Utrecht, The Netherlands)
- Emergencies in myasthenia, botulism and myasthenic syndromes
Maxwell Damian (Cambridge, UK)
- Emergencies in advanced genetic muscle disease
Marianne de Visser (Amsterdam, The Netherlands)

Educational content:

The diagnosis and management of Neuromuscular emergencies is difficult, and requires very significant specialist expertise. This session provides teaching from leading experts in the different facets of neuromuscular disorders that may present as emergencies, emphasising the rarer conditions that are often initially misdiagnosed.

16:45 – 18:15
Auditorium II



Special Session 4: EAN and European involvement in Rare Neurologic Diseases (European Reference Networks and other activities)

Chairperson:

Antonio Federico

- Introduction: EAN's activity on Rare Neurologic Diseases
Antonio Federico (Siena, Italy)
- Epicare: the European Reference Network for Rare Epilepsies
Reetta Kälviäinen (Kuopio, Finland)
- NMD-ERN: the European Reference Network for Neuromuscular Diseases
Teresinha Evangelista (Newcastle, UK)
- RND-ERN: the European Reference Network for Rare Neurologic Diseases
Holm Graessner (Tuebingen, Germany)
- General discussion

Scientific content:

The session will be focused on the presentation of the European Reference Networks (ERNs) on Rare Diseases, a recent organization by the European Union, that created 24 ERNs dedicated to the rare diseases related to different specific rare disorders. The ERNs, networking centres at least from 8 EU countries, will improve the care and the research for rare disorders. After 1 year of activity, we will discuss the activities of the ERNs related to the main neurologic rare diseases: Epilepsy, Rare Neurologic Diseases, and Neuromuscular disorders. We will also present the EAN activities in this field.

16:45 – 18:15
Auditorium VI



Interactive Session 9: EAN BrainChallenge – Quiz Show

Moderators:


Angelo Antonini (Padua, Italy)

Marie Vidailhet (Paris, France)

- Local Team
- International Team

The aim of the session is to promote a meaningful and interactive learning experience based on clinical study cases designed for both senior and junior neurologists from all over the world. The cases will not only show how prompt and accurate diagnosis can be achieved despite the complexity of neurology, but will also draw attention to rarely recognised conditions.

A team of local neurologists is competing with a team of international neurologists - each team consists of 4 senior and 2 junior neurologists.



Saturday 16 June
 14.45 – 18.45

16:45 – 18:45
 Room HoC

Hands-on Course 2: Nerve conduction studies and nerve echography - Level 1

Chairperson:

Simon Podnar (Ljubljana, Slovenia)

- Nerve conduction studies
Simon Podnar (Ljubljana, Slovenia)
- Nerve and muscle echography
Luca Padua (Rome, Italy)

Educational content:

Educational content: Nerve conduction studies are possibly the first and easiest approach of the neurologist intending to practice neurophysiology. In some countries, nerve conduction studies are performed by technicians. However, a few techniques require good technical skills and interpretation abilities according to the clinical context. This course is intended to revise all motor and sensory nerve conduction techniques utilised in human clinical neurophysiology, in order to avoid mistakes and errors in the interpretation of signals. Long latency responses such as the F-wave will also be part of this course.

Nerve and muscle echography is an important complement of the diagnosis of peripheral

nerve lesions. It is becoming increasingly used in many centers to assess nerve compression and entrapment syndromes. Where nerve conduction studies may fall short, echography can reach further and the other way around. The speaker will present the basis of testing, the ways to recognise the structures under the ultrasound probe and the methods of analysis, as well as clinical cases illustrating the increasing importance of ultrasound in the assessment of peripheral nerve lesions.

Limited to 60 participants. Please register separately – additional fees will apply.

This course is supported by NATUS Medical Inc.



A sponsored activity by The Adams Super Center for Brain Studies Tel Aviv University and the Joseph Sagol Neuroscience Center at the Chaim Sheba Medical Center, Tel Hashomer



Weill Cornell Medical College



15th Annual Update Conference Series on Neurology & Neurophysiology

Tel Aviv, Israel / February 17-19, 2019

www.neurophysiology-conference.com

Abstract
 submission
 Deadline
 November 16
 2018

Main Topics

- Neuro-Ophthalmology
- Movement Disorders
- Pain



PCO & Secretariat:
 ISAS International Seminars Ltd.
meetings@isas.co.il



EUROPEAN PAIN FEDERATION EFIC

As an organisation, the European Pain Federation EFIC® has been growing steadily over the last 25 years in its core domains of education, research, and advocacy. We have developed into Europe's most important multi-disciplinary and multi-professional organization in the field of pain medicine, representing 37 constituent national pain societies with over 20,000 scientists, physicians, nurses, psychologists, physiotherapists and other healthcare professionals.

OUR 11TH CONGRESS BRINGING THE FUTURE TO THE PRESENT

The 11th Congress of the European Pain Federation EFIC® will be held in Valencia, Spain from 4th to 7th September 2019. The congress will offer numerous lectures, workshops, refresher courses and networking initiatives on several aspects of pain. Along with the newest developments in basic science, we will discuss all aspects of multimodal interdisciplinary care for patients suffering from pain. This emphasis on the future of pain medicine leads up to the theme of our 2019 meeting: **"BRINGING THE FUTURE TO THE PRESENT"**. A comprehensive Industrial Exhibition, and sponsored Satellite Symposia, will complement the scientific content.

OUR ACTIVITIES IN THE FIELD OF EDUCATION, RESEARCH AND ADVOCACY

With regards to education, the European Pain Federation organises **'Pain Schools'**, bringing together leading educators to provide study programs across Europe. We have developed curricula for medical schools, and on pain medicine and pain physiotherapy, as well as accompanying examinations and qualifications. The **Examination for the European Diploma in Pain Medicine (EDPM)** was launched in 2017. The **Examination for the European Diploma in Pain Physiotherapy (EDPP)** has been launched for the first time in 2018. Concerning research, the European Pain Federation provides **grants and fellowships** for researchers and takes part in international research consortia.

On advocacy, we partner within the **Societal Impact of Pain platform**, along with the pharmaceutical company Grünenthal, the patients' organisation Pain Alliance Europe, and the citizens' rights organisation Active Citizenship Network. The European Pain Federation takes part in the Global Year Against Pain campaign, known as the **European Year Against Pain** in Europe.

Contact Information:

European Pain Federation (EFIC) • Grensstraat 7 4th Floor • B1831 Diegem • BELGIUM
Tel.: +32 2 251 55 10 • Fax: +32 2 251 48 10 • Email: secretary@efic.org

www.efic.org

Oral sessions

 14.45 – 16.15
 Room Lisbon

Neurological manifestations of systemic diseases

Chairpersons:

Theodor Landis (Lausanne, Switzerland)
Viktoria Papp (Aarhus, Denmark)

14.45 | O105

Phase 1/2, randomised, placebo controlled and open-label extension studies of givosiran an investigational RNAi therapeutic, in patients with acute intermittent porphyria

E. Sardh¹, J. Phillips², P. Harper³, M. Balwani⁴, P. Stein⁵, D. Rees⁵, J. Bloomer⁶, D. Bissell⁷, R.J. Desnick⁴, C. Parker², H. Bonkovsky⁸, N. Al-Tawil¹, S. Rock⁹, Q. Dinh⁹, C. Penz⁹, A. Chan⁹, W. Querbes⁹, A. Simon⁹, K. Anderson¹⁰

¹Solna, Sweden, ²Salt Lake City, USA, ³Solna, Sweden, ⁴New York, USA, ⁵London, UK,

⁶Birmingham, USA, ⁷San Francisco, USA,

⁸Winston-Salem, USA, ⁹Cambridge, USA,

¹⁰Galveston, USA

15.00 | O104

Impact of prior TTR stabilizer use in patients with hereditary transthyretin-mediated amyloidosis in the APOLLO phase-3 study of patisiran

T. Coelho¹, D. Adams², A. Gonzalez-Duarte³, W. O'riordan⁴, C.-C. Yang⁵, T. Yamashita⁶, A. Kristen⁷, I. Tournev⁸, H. Schmidt⁹, J. Berk¹⁰, K.-P. Lin⁵, P. Gandhi¹¹, M. Sweetser¹¹, J. Chen¹¹, S. Goyal¹¹, J. Gollob¹¹, O. Suhr¹²

¹Porto, Portugal, ²Le Kremlin-Bicêtre, France, ³Mexico D.F., Mexico, ⁴Lamesa, USA, ⁵Taipei, Taiwan, Chinese Taipei, ⁶Kumamoto, Japan, ⁷Heidelberg, Germany,

⁸Sofia, Bulgaria, ⁹Münster, Germany, ¹⁰Boston, USA,

¹¹Cambridge, USA, ¹²Umeå, Sweden

15.15 | O101

EXPLORE: a prospective, multinational natural history study of patients with acute hepatic porphyria with recurrent attacks

L. Gouya¹, J. Bloomer², M. Balwani³, D. Rees⁴, D. Bissell⁵, H. Bonkovsky⁶, P. Ventura⁷, E. Sardh⁸, P. Harper⁸, R. Desnick⁹, S. Rock¹⁰, Q. Dinh⁹, A. Chan⁹, W. Querbes⁹, C. Penz¹⁰, A. Simon⁹, K. Anderson¹⁰, J.-C. Deybach¹

¹Paris, France, ²Birmingham, USA, ³New York, USA,

⁴London, UK, ⁵San Francisco, USA, ⁶Winston-Salem, USA,

⁷Emilia-Romagna, Italy, ⁸Solna, Sweden, ⁹Cambridge, USA, ¹⁰Galveston, USA

15.30 | O103

Impact of Patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary Transthyretin-Mediated Amyloidosis (TMA)

L. Obici¹, T. Coelho², D. Adams³, A. Gonzalez-Duarte⁴, W. O'riordan⁵, C.-C. Yang⁶, T. Yamashita⁷, A. Kristen⁸, I. Tournev⁹, H. Schmidt¹⁰, J. Berk¹¹, K.-P. Lin⁶, P. Gandhi¹², M. Sweetser¹², J. Chen¹², S. Goyal¹², J. Gollob¹², O. Suhr¹³

¹Pavia, Italy, ²Porto, Portugal, ³Le Kremlin-Bicêtre, France, ⁴Mexico D.F., Mexico, ⁵Lamesa, USA, ⁶Taipei, Taiwan, Chinese Taipei, ⁷Kumamoto, Japan, ⁸Heidelberg, Germany, ⁹Sofia, Bulgaria, ¹⁰Münster, Germany,

¹¹Boston, USA, ¹²Cambridge, USA, ¹³Umeå, Sweden

15.45 | O102

Clinical characterisation of Wilson's disease patients: a retrospective study at a tertiary-care centre in Lisbon

J. Rosa, A. Sousa, P. Brás, M. Machado, M. Dias, M. Manita

Lisbon, Portugal

 14.45 – 16.15
 Room Copenhagen

Movement disorders 1

Chairperson:

Evzen Růžicka (Prague, Czech Republic)

14.45 | O109

Clinical predictors of screen-defined dementia in early Parkinson's disease

F. Baig¹, M. Lawton², M. Rolinski², C. Ruffmann¹, T. Barber¹, J.C. Klein¹, C. Lo¹, Y. Ben-Shlomo², M. Hu¹

¹Oxford, ²Bristol, UK

15.00 | O108

Skin nerve phosphorylated α -synuclein deposits in Parkinson's disease with orthostatic hypotension

V. Donadio¹, A. Incensi¹, F. Del Sorbo², G. Rizzo¹, R. Infante¹, C.L. Scaglione¹, N. Modugno³, E. Fileccia¹, A. Elia², F. Cencini¹, R. Liguori¹

¹Bologna, ²Milan, ³Isernia, Italy

15.15 | O111

Brain Lewy body density is associated with a lower prevalence of atherosclerotic cardiovascular disease risk factors in patients with Parkinson's disease

E. Driver-Dunckley¹, N. Zhang¹, C. Adler¹, G. Serrano², L. Sue², H. Shill³, S. Mehta¹, C. Belden², E. Zamrini², K. Davis⁴, T. Beach²

¹Scottsdale, ²Sun City, ³Phoenix, ⁴Sun city, USA

15.30 | O107

Glucose dysregulation in advanced Parkinson's disease: too much glucose or not enough insulin?

A. Marques, F. Duthel, E. Durand, I. Rieu, A. Mulliez, M.L. Fantini, Y. Boirie, F. Durif
 Clermont-Ferrand, France

Saturday 16 June
15.45 – 18.15

16

15.45 | O110

Temporal evolution of biomarkers in isolated REM sleep behavior disorder and early Parkinson's disease

M.-L. Muntean¹, B. Mollenhauer², J. Zimmermann³, N. Focke², T. Wicke¹, J. Ebentheuer¹, M. Schaumburg¹, E. Lang¹, W. Oertel⁴, C. Trenkwalder¹, F. Sixel-Döring¹

¹Kassel, ²Göttingen, ³Berlin, ⁴Marburg, Germany

16.00 | O112

Multimodal MRI markers modifications in Multiple System Atrophy (MSA): a longitudinal study

P. Péran¹, M. Galitzky¹, W. Meissner², O. Rascol¹, A. Pavy-Le Traon¹

¹Toulouse, France, ²Bordeaux, France

16.45 – 18.15

Room Berlin

MS and related disorders 1

Chairpersons:

Hans-Peter Hartung (Düsseldorf, Germany)

Bernard Uitdehaag

(Maarssen, The Netherlands)

16.45 | O116

Effects of Fingolimod on MRI outcomes in patients with paediatric-onset Multiple Sclerosis: results from the Phase-3 PARADIGMS study

D.L. Arnold¹, B. Banwell², A. Bar-Or², A. Ghezzi³, B. Greenberg⁴, E. Waubant⁵, G. Giovannoni⁶, J. Wolinsky⁷, J. Gärtner⁸, K. Rostasy⁹, L. Krupp¹⁰, M. Tardieu¹¹, W. Brück⁸, T. Stites¹², G.L. Pearce¹³, M. Merschhemke¹⁴, T. Chitnis¹⁵

¹Quebec, Canada, ²Philadelphia, USA, ³Gallarte, Italy,

⁴Dallas, USA, ⁵San Francisco, USA, ⁶London, UK,

⁷Houston, USA, ⁸Göttingen, Germany, ⁹Recklinghausen,

Germany, ¹⁰New York, USA, ¹¹Paris, France, ¹²East Ha-

nover, USA, ¹³Bloomington, USA, ¹⁴Basel, Switzerland,

¹⁵Boston, USA

17.00 | O117

Characterising the Slowly Evolving Lesions (SELs) in a cohort of secondary progressive Multiple Sclerosis patients

A. Calvi¹, F. Prados¹, C. Tur¹, F. de Angelis¹, N. John¹, A. Doshi¹, J. Stutters¹, D. Macmanus¹, S. Ourselin¹, O. Ciccarelli¹, J. Chataway¹, F. Barkhof¹

London, UK

17.15 | O113

Spinal cord area is a stronger predictor of physical disability than brain volume in secondary progressive Multiple Sclerosis

F. de Angelis¹, J. Stutters¹, A. Eshaghi¹, A. Garcia¹, F. Prados¹, D. Plantone¹, A. Doshi¹, N.A. John¹, A. Calvi¹, D. Macmanus¹, S. Ourselin¹, S. Pavitt², G. Giovannoni¹, R. Parker³, C.J. Weir³, N. Stallard⁴, C.P. Hawkins⁵, B. Sharrack⁶, P. Connick³, S. Chandran³, C.A. Gandini Wheeler-Kingshott¹, F. Barkhof¹, J. Chataway¹

¹London, ²Leeds, ³Edinburgh, ⁴Coventry, ⁵Keele,

⁶Sheffield, UK

17.30 | O118

Characterising dynamic functional network connectivity in the main clinical phenotypes of Multiple Sclerosis

M. Hidalgo de la Cruz, M.A. Rocca, P. Valsasina, B. Colombo, F. Esposito, G. Comi, M. Filippi

Milan, Italy

17.45 | O114

Long-term prognosis of disease evolution and evidence for sustained Fingolimod treatment effect by plasma neurofilament light in RRMS patients

J. Kuhle¹, J.A. Cohen², H. Kropshofer¹, R. Meinert³, C. Barro⁴, M. Merschhemke¹, D. Häring¹, D. Leppert¹, D. Tomic¹, L. Kappos¹

¹Basel, Switzerland, ²Cleveland, USA, ³Freiburg,

Germany

18.00 | O115

Alemtuzumab provides durable clinical efficacy in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS I (TOPAZ Study)

B. van Wijmeersch¹, P. Vermersch², A. Boyko³, J. de Seze⁴, H.-P. Hartung⁵, E. Kubala Havrdova⁶, J. Said Inshasi⁷, P. McCombe⁸, X. Montalban⁹, C. Pozzilli¹⁰, M. Melanson¹¹, N. Daizadeh¹¹, C. Rodriguez¹¹, K. Selmaj¹²,

O.B.O.T.C.-M.I.C. and Topaz Investigators¹¹

¹Hasselt, Belgium, ²Lille, France, ³Moscow, Russian Fe-

deration, ⁴Strasbourg, France, ⁵Düsseldorf, Germany,

⁶Prague, Czech Republic, ⁷Dubai, United Arab Emirates,

⁸Brisbane, Queensland, Australia, ⁹Barcelona, Spain,

¹⁰Rome, Italy, ¹¹Cambridge, USA, ¹²Lodz, Poland

Oral sessions

Saturday 16 June
16.45 – 18.15

16.45 – 18.00
Room Lisbon

Peripheral nerve disorders 1

Chairpersons:

Christian Krarup (Copenhagen, Denmark)
Peter van den Bergh (Brussels, Belgium)

16.45 | O120

Corneal confocal microscopy and skin biopsy in the evaluation of diabetic small fiber neuropathy

J. Bednarik, A. Rajdova, I. Kovalova, M. Horakova, S. Divisova, J. Raputová, E. Vlckova

Brno, Czech Republic

17.00 | O119

Axonal function predicts response to subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study

V. Bril¹, N. van Geloven², H.-P. Hartung³, G. Sobue⁴, J.-P. Lawo⁵, O. Mielke⁵, B.L. Durn⁶, I.S. Merkies⁷

¹Toronto, Canada, ²Leiden, Netherlands, ³Düsseldorf, Germany, ⁴Nagoya, Japan, ⁵Marburg, Germany, ⁶King of Prussia, USA, ⁷Maastricht, Netherlands

17.15 | O122

Cryoglobulinaemia-associated peripheral neuropathies: clinical characteristics and prognosis from 20 years experience of neuromuscular clinic

M. Mazzoli, A. Ariatti, M.T. Mascia, F. Valzania, P. Nichelli, G. Galassi

Modena, Italy

17.30 | O121

Charcot-Marie-Tooth disease type 4B with myelin outfoldings (CMT4B): a multicentre retrospective study

D. Pareyson¹, T. Stojkovic², S. Leonard-Louis², M.M. Reilly³, M. Laurà³, R. Horvath⁴, G. Ricci⁴, Y. Parman⁵, E. Battaloglu⁵, M. Tazir⁶, M. Bellatache⁶, N. Bonello-Palot⁷, S. Sacconi⁸, R. Guimarães-Costa², S. Attarian⁷, P. Latour⁹, A. Megarbane², A. Schenone¹⁰, G. Ursino¹⁰, M. Sabatelli¹¹, M. Luigetti¹¹, L. Santoro¹², F. Manganelli¹², A. Quattrone¹³, P. Valentino¹³, T. Murakami¹⁴, S.S. Scherer¹⁵, L. Dankwa¹⁵, M.E. Shy¹⁶, C.J. Bacon¹⁶, DN. Herrmann¹⁷, C. Pisciotta¹, S. Previtali¹, A. Bolino¹

¹Milan, ¹⁰Genoa, ¹¹Rome, ¹²Naples, ¹³Catanzaro, Italy; ²Paris, ⁷Marseille, ⁸Nice, ⁹Lyon, France; ³London, ⁴Newcastle, UK; ⁵Istanbul, Turkey; ⁶Algiers, Algeria; ¹⁴Kurashiki, Japan; ¹⁵Philadelphia, ¹⁶Iowa City, ¹⁷Rochester, USA.

17.45 | O123

Long-term efficacy and safety of Inotersen in patients with hereditary transthyretin (hATTR) amyloidosis treated in the open-label extension of the phase-3 study NEURO-TTR

V. Planté-Bordeneuve¹, T. Brannagan², A. Wang³, T. Coelho⁴, M. Waddington Cruz⁵, M. Polydefkis⁶, P. Dyck⁷, M. Scheinberg⁸, J. Berk⁹, F. Barroso¹⁰, D. Adams¹¹, C. Whelan¹², G. Merlini¹³, B. Drachman¹⁴, S. Heitner¹⁵, I. Conceicao¹⁶, H. Schmidt¹⁷, G. Vita¹⁸, J. Campistol¹⁹, J. Gamez¹⁹, P. Gorevic², B. Monia²⁰, M. Benson²¹, M. Gertz⁷

¹Creteil, France, ²New York, USA, ³Orange, USA, ⁴Porto, Portugal, ⁵Rio de Janeiro, Brazil, ⁶Baltimore, USA, ⁷Rochester, USA, ⁸Sao Paulo, Brazil, ⁹Boston, USA, ¹⁰Buenos Aires, Argentina, ¹¹Le Kremlin-Bicêtre, France, ¹²London, UK, ¹³Pavia, Italy, ¹⁴Philadelphia, USA, ¹⁵Portland, USA, ¹⁶Lisbon, Portugal, ¹⁷Münster, Germany, ¹⁸Messina, Italy, ¹⁹Barcelona, Spain, ²⁰Carlsbad, USA, ²¹Indianapolis, USA

16.45 – 18.15
Room Oslo



Neurogenetics

Chairpersons:

Thomas Klopstock (Munich, Germany)
Jean-Mark Burgunder (Bern, Switzerland)

16.45 | O124

Estimated lifetime prevalences of autosomal mitochondrial disorders based on allele frequencies of pathogenic variants in exome databases

J. Tan, M. Wagner, S. Stenton, T.-M. Strom, H. Prokisch, T. Klopstock

Munich, Germany

17.00 | O126

Phenotypic and neuroimaging expression of NKX6-2 mutations lead to a new distinct disease with spastic ataxia and hypomyelination

V. Chelban¹, M. Alsagob², K. Kloth³, A. Chirita-Emandi⁴, J. Vandrovцова⁴, S. Efthymiou¹, T. Bierhals³, N. Kaya², N.W. Wood¹, H. Houlden¹

¹London, UK, ²Riyadh, Saudi Arabia, ³Hamburg, Germany, ⁴Timisoara, Romania

17.15 | O125

UFM1 founder mutation in the Roma population causes severe variant of Hypomyelination with Atrophy of the Basal ganglia and Cerebellum (H-ABC)

E.M. Hamilton¹, E. Bertini², L. Kalaydjieva³, B. Morar³, D. Dojčáková⁴, D. Diodato², N. Wolf⁵, Q. Waisfisz¹, T.E. Abbink¹, M.S. van der Knaap¹

¹Amsterdam, Netherlands, ²Rome, Italy, ³Perth, Australia, ⁴Presov, Slovakia

Saturday 16 June
16.45 – 18.15

16

17.30 | O129

A randomised trial of deferiprone for pantothenate Kinase-associated Neurodegeneration (PKAN)
T. Klopstock¹, F. Tricta², C. Fradette², M. Spino², B. Büchner¹, I. Karin¹, L. Neumayr³, C. Aguilar³, F. Zhao², T. Kmiec⁴, N. Nardocci⁵, G. Zorzi⁵, H. Steele⁶, R. Horváth⁶, P. Chinnery⁷, P. Hogarth⁸, S.J. Hayflick⁸, A. Blamire⁶, E. Vichinsky³
¹Munich, Germany, ²Toronto, Canada, ³Oakland, USA, ⁴Warsaw, Poland, ⁵Milan, Italy, ⁶Newcastle upon Tyne, ⁷Cambridge, UK, ⁸Portland, USA

17.45 | O128

Next Generation Sequencing results in an Italian cohort of hereditary optic neuropathy patients
C. La Morgia¹, F. Tagliavini¹, L. Caporali¹, M. Carbonelli¹, L. Di Vito¹, P. Barboni¹, M.L. Cascavilla², A. Carta³, A. Rifa⁴, S. Bianchi Marzoli², F. Mari⁵, M. Mancuso⁶, M.A. Donati⁵, A.M. de Negri⁷, F. Sadun⁷, M.L. Valentino⁴, R. Liguori¹, V. Carelli¹
¹Bologna, ²Milan, ³Parma, ⁴Sienna, ⁵Florence, ⁶Pisa, ⁷Rome, Italy

18.00 | O127

The natural history of mitochondrial stroke-like episodes: observational cohort study from the UK
Y.S. Ng¹, A. Schaefer¹, R. Pitceathly², V. Nesbitt³, J. Hall¹, M. Farrugia⁴, M. Roberts⁵, J. Poulton³, M. Hanna², R.W. Taylor¹, D. Turnbull¹, R. McFarland¹, G. Gorman¹
¹Newcastle, ²London, ³Oxford, ⁴Glasgow, ⁵Salford, UK

16.45 – 18.15
Room Copenhagen

Neuroimmunology

Chairpersons:
Maarten Titulaer
(Rotterdam, The Netherlands)
Radu Tanasescu, (Nottingham, UK)

16.45 | O134

Aquaporin-4 autoantibodies from Neuromyelitis Optica Spectrum Disorder: patients cause complement-independent spinal cord pathologies and motor deficits in mice
K.H. Chan, L.W. Yick
Hong Kong, Hong Kong (SAR of China)

17.00 | O132

Evaluation of treatment response in adults with relapsing MOG-Ab associated
A. Cobo-Calvo¹, M. Sepulveda², T. Armangué², A. Ruiz¹, E. Maillard³, B. Audoin⁴, H. Zephir⁵, D. Biotti⁶, J. Ciron⁶, F. Durand Dubief⁷, N. Collongues⁷, X. Ayrygnac⁸, E. Thouvenot⁹, A. Montcuquet¹⁰, F. Rollot¹, N. Solà Valls², S. Llufriu², Y. Blanco², S. Vukusic¹, A. Saiz², R. Marignier¹

¹Lyons, France, ²Barcelona, Spain, ³Paris, ⁴Marseilles, ⁵Lille, ⁶Toulouse, ⁷Strasbourg, ⁸Montpellier, ⁹Nîmes, ¹⁰Limoges, France

17.15 | O135

Thrombotic and non-thrombotic neurological manifestations in Primary Antiphospholipid Syndrome
C. Cunha¹, J. Serodio², I. Moreira¹, A. Bettencourt¹, E. Santos¹, R. Samões¹, G. Carvalheiras¹, S. Cavaco¹, A. Martins Silva¹

¹Porto, ²Viana do Castelo, Portugal

17.30 | O131

Mimics of Autoimmune Encephalitis
J. de Vries, R. Neuteboom, M.W. Vernooij, R. Verdijk, P.A. Sillevis Smitt, M.J. Titulaer
Rotterdam, The Netherlands

17.45 | O133

Syndrome and outcome of antibody-negative limbic encephalitis
F. Graus¹, D. Escudero¹, L. Oleaga¹, J. Bruna¹, A. Villarejo-Galende², J. Ballabriga³, M.I. Barceló³, F. Giló², S. Popkiron⁴, P. Stourac⁵, J. Dalmau¹
¹Barcelona, ²Madrid, ³Palma de Mallorca, Spain, ⁴Bochum, Germany, ⁵Brno, Czech Republic

18.00 | O130

Neurofilament Light chain (NFL) serum concentration reflects disease severity in patients with MOG-Ab associated disorders
S. Mariotto¹, A. Gajofatto¹, E. Sechi², R. Capra³, C.R. Mancinelli³, K. Schanda⁴, D. Alberti¹, R. Bombardi⁵, L. Zuliani⁶, M. Zoccarato⁷, M.D. Benedetti¹, R. Tanel⁸, F. Rossi⁹, A. Pavone¹⁰, L. Grazian⁶, G. Sechi², R. Delogu², D. Urso², F. Janes¹¹, V. Fetoni¹², V. Manfioli¹³, G. Cantalupo¹, M. Reindl¹⁴, S. Monaco¹, S. Ferrari¹
¹Verona, ²Sassari, ³Montichiari, Italy, ⁴Innsbruck, Austria, ⁵Vicenza, ⁶Treviso, ⁷Padua, ⁸Trent, ⁹Legnago, ¹⁰Catania, ¹¹Udine, ¹²Milan, ¹³Rovigo, Italy

PROGRAM 2018

INTERNATIONAL MEETING OF THE SFN
IN PARTNERSHIP WITH THE SOFMA
Movement Disorders and Parkinson's disease
ICM, Paris

> 8 & 9
NOVEMBER

SFN PRESIDENT DAY – Pr Bruno Dubois
From gene to behavior: the model of frontotemporal
Dementia
ICM, Paris

> 7
DECEMBER

PROGRAM 2019

3RD MEETING FOR YOUNG NEUROLOGISTS
AND CLINICAL RESEARCH “J2N”
In partnership with the College of Teachers in Neurology
Paris

> 1st & 2
FEBRUARY

INTERNATIONAL MEETING OF THE SFN
Neurology and Infectious diseases
Paris

> 10 & 11
OCTOBER

SFN PRESIDENT DAY – Pr Christine Tranchant
Cerebellar Ataxia
Strasbourg

> 6
DECEMBER

French Society of Neurology

Contact : Sfneurologie.org@gmail.com
Website : www.sfn.org



Sunday
17 June 2018

17

Sessions

Sunday 17 June
08.00 – 09.30

08:00 – 09:30
Room Copenhagen

Career Development Session 2: Abstract, poster and presentation tips for success at international meetings

Chairperson:
Claudia Sommer (Würzburg, Germany)

- How to prepare & submit your abstract
Marianne Dieterich (Munich, Germany)
- Preparing your poster or slides
Aksel Siva (Istanbul, Turkey)
- Delivering your poster or oral presentation
Claudia Sommer (Würzburg, Germany)

Educational content:

Practical advice on every step from abstract preparation to delivering your poster or oral platform presentation will be provided by experts from the Education and Program committees of the EAN, with ample opportunity to ask questions and seek advice.

Target audience:

Neurologists at any level who are relatively inexperienced in submitting work for presentation at international congresses, or experienced in their native country, but may be less competitive/successful on an international stage.

08:00 – 09:30
Room CbW

Case-based Workshop 3: The process of MS diagnosis

Chairperson:
Maria José Sá (Porto, Portugal)

- New diagnostic criteria
Wallace Brownlee (London, UK)
- Most frequent misdiagnosis
Franz Fazekas (Graz, Austria)
- Patterns of decision making in demyelinating diseases
Maria José Sá (Porto, Portugal)

Educational content:

Wallace Brownlee will inform on participants the knowledge provided by the international consensus groups of MS experts with a critical analysis of the evolution of MS diagnostic criteria, discussing the main pitfalls in the 2010's criteria and measures to improve MS diagnostic accuracy.

Franz Fazekas will get the audience acquainted with particular imaging aspects that may be atypical for MS and lead to diagnostic errors (vascular and non-vascular diseases), showing examples of most frequent misdiagnosis prior to MS, and also aspects that may be of help to overcome diagnostic delay in MS.

Maria José Sá will inform how on the need of a structured and disciplined clinical reasoning that must be followed since the suspect of MS, in a step by step way: identify the classical clinical features (typical neurological syndrome, relapsing-remitting pattern of complaints), perform a neurological examination and request complementary exams looking for evidence of MS and exclusion of MS mimickers (MRI, CSF, VEP, OCT, analytic workup) and when to suspect MS misdiagnosis (non-responders to MS therapies, superimposed atypical symptoms, unusual MRI findings).

It will be proposed a step by step approach to overcome MS misdiagnosis: awareness that misdiagnosis do exist also in highly

specialised MS Clinics, that patients must be closely monitored and often re-studied and that request for a second opinion may be important.

Limited to 60 participants. This course is sold out.

08:00 – 09:30
Room HoC

Hands-on Course 3: Tilt-table testing in neurology and clinical neurophysiology - Level 2

Chairperson:
Gert van Dijk (Leiden, The Netherlands)

- Cardiovascular autonomic nervous system: basic concepts
Isabel Rocha (Lisbon, Portugal)
- Autonomic function testing in neurogenic orthostatic hypotension
Alessandra Fanciulli (Innsbruck, Austria)
- Tilt-table patterns in transient loss of consciousness (TLOC): reflex syncope, orthostatic hypotension and psychogenic TLOC
Gert van Dijk (Leiden, The Netherlands)

Endorsed by European Federation of Autonomic Societies (EFAS)

Educational content:

Syncope is responsible for 3% of hospital admissions; its economic burden of syncope is huge. A considerable part of these high costs is spent on tests that are not indicated. Till now few neurologists have taken an interest in syncope and tilt-table testing (TTT). However, reflex syncope and epilepsy often feature in one another's differential diagnosis; they require a similar emphasis on history taking and deductive reasoning. A TTT is useful for diagnosis and treatment, not just for reflex syncope but also for various other syndromes including orthostatic hypotension, postural orthostatic tachycardia syndrome and psychogenic pseudo-syncope. Autonomic function testing can provide

Sunday 17 June
08.00 – 09.30

17

additional detail in the differentiation of various autonomic neuropathies. In this course, we will review the basic concepts of cardiovascular physiology.

Limited to 60 participants. Please register separately – additional fees will apply.

08:00 – 09:30
Auditorium VI

Interactive Session 3: EAN/ESO: Treatment decisions in some difficult scenarios of acute ischaemic stroke

Chairperson:

Patrik Michel (Lausanne, Switzerland)

- Ischaemic stroke in a patient with high bleeding risk
Patrik Michel (Lausanne, Switzerland)
- Ischaemic stroke upon awakening
Carla Ferreira (Braga, Portugal)
- Ischaemic stroke in a disabled person
Janika Kõrv (Tartu, Estonia)

Educational content:

In this course participants learn the considerations, options and management steps for using i.v. thrombolysis, mechanical thrombectomy and other treatments in some difficult settings of acute ischaemic stroke.

Please download the app “EAN Congress” to actively participate in this Session and vote.

08:00 – 09:30
Room Berlin



Focused Workshop 6: EAN/MDS-ES: Management of Parkinson's disease in non-routine circumstances

Chairperson:

Philippe G. Damier (Nantes, France)

- Fasting during Ramadan
Philippe G. Damier (Nantes, France)
- Travelling abroad
Evžen Růžička (Prague, Czech Republic)
- Undergoing a surgical procedure
Heinz Reichmann (Dresden, Germany)
- Can people with PD drive?
Joaquim Ferreira (Lisbon, Portugal)

Scientific content:

Dopamine replacement therapy is highly effective to reduce Parkinson's disease symptoms and helps many patients to have a fair quality of life. Patients may have to face some non-routine circumstances for which the treatment needs to be adjusted. The workshop aims to provide practical advice to manage such circumstances: Ramadan fasting, travelling abroad, undergoing a surgical procedure or driving. How to adapt a transient treatment reduction or withdrawal, how to change drug administration schedule, how to take into consideration treatment or treatment decrease side effects? What is adjustable? What is not? Clinicians should gain some hints and knowledge helping them in their daily practice.

08:00 – 09:30
Auditorium II

Focused Workshop 7: Epilepsy surgery in 2018: Has anything changed in the last decades?

Chairperson:

Mar Carreño (Barcelona, Spain)

- Update on the concept of drug resistance. When should paediatric and adult patients be referred for epilepsy surgery?
Edouard Hirsch (Strasbourg, France)
- Common and not so common surgically remediable syndromes
Christoph Baumgartner (Vienna, Austria)
- Epilepsy surgery in patients without obvious MRI lesions: are we overusing intracranial electrodes?
José Serratosa (Madrid, Spain)

Scientific content:

To review the current indications to perform epilepsy surgery in children and adults; review the clinical features and clinical outcomes of common and not so common surgically treatable epilepsy syndromes, to review the role of amplex resections to treat epilepsy and to review the current approach using invasive electrodes to patients with drug resistant epilepsy and no obvious lesion on the MRI.

Sessions

Sunday 17 June
08.00 – 09.30

08:00 – 09:30
Room Amsterdam



Focused Workshop 8: Impact of technology in neuro-rehabilitation

Chairperson:

Volker Dietz (Zurich, Switzerland)

- Rehabilitation of hand function post-stroke: application of research based technology
Volker Dietz (Zurich, Switzerland)
- Robotic support for cognitive therapy of hand function
Olivier Lambercy (Zurich, Switzerland)
- Robotic technology in the rehabilitation of gait after a stroke and spinal cord injury
Klaus Jahn (Munich, Germany)

Scientific content:

The FW aims to present the actual advantages and the limitations of technology to improve performance of locomotor and hand function after a stroke or spinal cord injury. A specific goal will be to discuss the devices that are based on research achievements and are shown to be effective in the application in neurorehabilitation centres. Especially aspects of individually adapted rehabilitation of limb function by technology will be presented. Another goal will be to discuss the actual activities to strengthen home training using simple technology with a focus on functional requirements of daily life activities. A special focus will be to discuss the present weaknesses/limitations of robot-supported neurorehabilitation.

08:00 – 09:30
Auditorium VIII



Focused Workshop 9: Novel genetic techniques in neurological practice - time for responsible clinical and research implementation

Chairperson:

Thomas Gasser (Tübingen, Germany)

- What should the general neurologist know about Next Generation Sequencing (NGS)?
Henry Houlden (London, UK)
- Interpretation of NGS test: neurological disease and beyond
Thomas Gasser (Tübingen, Germany)
- The use of genetic information in the context of clinical trials
Cristina Sampaio (Lisbon, Portugal)

Scientific Content:

The development of genetic research, made possible mainly by unprecedented technological advances over the past few years, has transformed many areas of neurology. New classification systems based on genetic defects have in many cases replaced the old clinico-pathologic order. Clinical genetic testing has become a routine procedure in clinical neurology, and the first studies are designed that use genetic variants to stratify disease groups.

In this workshop, we will give an overview of existing and emerging technologies and their applications in clinical practice and research.

08:00 – 09:30
Room Lisbon

Focused Workshop 10: Lost in space - clinical and neurobiological aspects of topographagnosia

Chairperson:

Wolfgang Heide (Celle, Germany)

- The map cannot be explored - disorders of spatial exploration in neglect (perceptive topographagnosia)
Masud Husain (Oxford, UK)
- The map is distorted - disorders of the perceptual analysis of space (apperceptive topographagnosia)
Wolfgang Heide (Celle, Germany)
- The map is lost - disorders of spatial memory (associative topographagnosia and topographical amnesia)
Jan Laczó (Prague, Czech Republic)

Scientific content:

Topographagnosia is a form of agnosia involving an inability to find one's way around ("lost in space"), read maps, draw plans, or perform similar functions, often associated with damage to the right parietal or temporal lobe. The term stands for different clinical disorders of spatial orientation that according to De Renzi (1982) and Landis (1991) can be divided into 3 groups: 1. disorders of spatial exploration (perceptive topographagnosia), 2. disorders of perceptual analysis of space (apperceptive topographagnosia) and 3. disorders of spatial memory and spatial navigation (associative topographagnosia & topographical amnesia). They are the basis of the 3 lectures of this workshop, where experts in each of these fields will demonstrate the significance of these old clinical terms in the light of recent findings of modern cognitive neurology, neuroimaging and neurorehabilitation in patients with focal or neurodegenerative cortical damage.

Sunday 17 June
08.00 – 09.30

17

08:00 – 09:30
Auditorium V

Special Session 5: Neurological disorders of famous composers

Chairperson:

Tomislav Breitenfeld (Zagreb, Croatia)

- Maurice Ravel's fatal neurological illness
Vida Demarin (Zagreb, Croatia)
- Joseph Haydn – a case of subcortical vascular encephalopathy
Hansjörg Bänzner (Stuttgart, Germany)
- Stroke in famous composers
Tomislav Breitenfeld (Zagreb, Croatia)
- Breaking barriers in neuro-musicology: Beethoven's deafness, Schumann's madness, Porter's pain, Gershwin's uncinat seizures
Phillip L. Pearl (Boston, USA)

Session content:

This Special session will present a series of biopathographies and short portraits of famous composers describing their biography, talent, creation and medical history. All presented famous composers suffered from different neurological disorders. The presentations will explain influence of those disorders on composer's creativity and try to interpret historical materials in terms of modern medicine. Audience will be allowed (and animated) to comment and discuss the interaction between neurological disorders and composer's ability to create art. While trying to explain the complex relationship between neurological disorders and creativity through pathographies of famous composers, organisers intend to present a new, really interesting and "something else from other topics" session. We believe that it will turn into a memorable gathering of people who share the same passion, genuine love and enthusiasm for both, neurology and music. After all, Lisbon with its glorious cultural, musical and medical history seems to be an ideal site for a special session "Neurological disorders of famous composers".

08:00 – 09:30
Room Oslo

Special Session 6: Resident and Research Fellow Section round table discussion: learn about clinical work and research (clinical and labora- tory) around Europe

Chairperson:

RRFS Representatives

- Table 1
José M Ferro (Lisbon, Portugal)
- Table 2
Klaus Toyka (Würzburg, Germany)
- Table 3
Hannah Cock (London, UK)
- Table 4
Eva Havrdova (Prague, Czech Republic)

Session Content:

Main aims:

- Learn about academic career and research opportunities around Europe
- Get expert advices on laboratory and clinical research
- Meet experts from different parts of Europe and improve the professional European network
- Get to know opinion leaders' careers and how they got there

The participants will directly sit down with each Professor from different parts of Europe (North, West, Central and East) and with different fields of interest (such as stroke, epilepsy, Multiple Sclerosis). The participants will circulate and have the unique opportunity to discuss questions such as career or research projects in detail. This will offer the opportunity to ask more detailed and individualised questions. We aim to give interested residents an overview of different ways of developing a research or clinical career.

08:00 – 09:30
Auditorium III

Special Session 7: EAN Corresponding Members of the Mediterranean Area – Clinical Neuro-immunology

Chairperson:

Jean-Michel Vallat (Limoger, France)

- NMO Devic's disease
Adnan Awada (Beirut, Lebanon)
- Neurological complications of Behçet's disease
Maria Benabdelljlil (Rabat, Morocco)
- Auto-immune encephalitis
Maarten Titulaer (Rotterdam, The Netherlands)
- Neurological complications of Lupus and anti-phospholipid antibodies
Jean-Michel Vallat (Limoges, France)

Session Content:

The wide spectrum of auto-immune Central Nervous System diseases (CNS) is more and more well recognised but is still underestimated for several reasons. Clinical symptoms and signs are diverse and can be observed in non-dysimmune CNS disorders. These last years, numerous and various antibodies associated to some of these diseases have been discovered; nevertheless, the laboratory work-up for such antibodies is currently only available in a few laboratories, so that it may be difficult to confirm the diagnosis. For most of these diseases, the treatment should not be delayed as the dysimmune process needs to be arrested at an early stage to avoid severe sequellae. Some of these dysimmune entities are encountered worldwide and a few others, like Behçet's syndrome, are more frequent in Mediterranean countries. The objective of this session is to stress the main CNS clinical and imaging characteristics of such patients and to discuss the role of associated antibodies in auto-immune encephalitis, Behçet's disease, neuromyelitis optica (Devic's syndrome) and systemic lupus erythematosus. Clinical phenotypes together with their typical paraclinical measures, putative disease mechanisms, and therapeutic options in this emerging class of inflammatory CNS disorders will be presented.

IN OUR WORLD, A STEADY FLOW KEEPS PATIENTS ALIVE.

LET'S TAKE CARE OF IT.
TOGETHER.

Driving Excellence in Neurology.

Be part of one of humankind's most ambitious projects to help uncover the workings of the nervous system. EAN connects 45,000 specialists in neurology in 47 countries across Europe. Promoting excellence, cutting-edge science and innovative therapies for a better life for more than 430 million patients in Europe alone. Read more on ean.org

Great Minds.



Sunday 17 June
10.00 – 12.00
17

 10:00 – 12:00
 Auditorium I


Plenary Symposium 2: Presidential Symposium: Named Lectures

Chairpersons:

Günther Deuschl (Kiel, Germany)
Manuel Correia (Porto, Portugal)

- **Camillo Golgi Lecture –**
The Immune Pathogenesis of Multiple Sclerosis: Degeneration, inflammation and gut microbiota – an unholy alliance
Hartmut Wekerle (Munich, Germany)
- **Edouard Brown-Séquard Lecture –**
The evolution of Alzheimer's disease and dementia
Philip Scheltens (Amsterdam, The Netherlands)
- **Moritz Romberg Lecture –**
Migraine mechanisms and new drug targets
Jes Olesen (Glostrup, Denmark)



Prof. Hartmut Wekerle

Hartmut Wekerle was director and member of the Max Planck Institute of Neurobiology. In 2012 he was awarded a Hertie Senior Professorship, and he leads an Extended Emeritus Group. Hartmut Wekerle's scientific research focuses on the mechanisms initiating and driving Multiple Sclerosis and its experimental models, which imply autoimmune attack against the nervous

system. Wekerle's work led to the identification of brain reactive autoimmune T lymphocytes in the immune system. Most recently, he identified the commensal bacterial gut flora as a factor triggering the pathogenic potential of immune cells. He develops and uses new imaging approaches to detail the mechanisms of autoimmune T-cell migration into the brain. Wekerle has received numerous awards, including the Jung Prize, Zülch Prize, Koetsier Prize, Charcot Award (MS International Federation), Grand Prix Louis D. (Institut de France), and a Koselleck Award (DFG), Jacob-Henle-Medal (University Medical Center, Goettingen). He holds an Honorary Professorship of the University of Munich and Honorary Doctorates of the Universities of Hamburg and Wuerzburg. He is a member of the German Academy of Science (Leopoldina), Honorary Member of the Société Française de Neurologie and Honorary Member of the Cuban Neuroscience Society.



Prof. Philip Scheltens

Prof. Dr. Philip Scheltens studied at the VU University Amsterdam, Netherlands, gaining his MD in 1984, and PhD (Magnetic Resonance Imaging in Alzheimer's disease) in 1993. Since 2000 he is Professor of Cognitive Neurology and Director of the Alzheimer Center at the VU University Medical Center in Amsterdam. His main clinical and research interests are

Alzheimer's disease, vascular dementia, frontotemporal dementia, magnetic resonance imaging, PET imaging and fluid biomarkers. He is active in the field of biomarkers and clinical trials and has been the national PI for many studies, including phase 1-3 multicenter clinical trials. He founded and directs the Alzheimer Center since 2000, from which over 55 PhD theses have appeared since then. In 2013, he co-founded the Dutch national plan against dementia (Deltaplan Dementie) and serves as vice-chair of the board since then. He has authored over 850 peer reviewed publications and his H-factor is currently 103. In 2011, he was elected as member of the Royal Dutch Academy of Arts and Sciences (KNAW) and serves as Secretary General since 2015. In 2016 he was awarded the European Grand Prix for Alzheimer's Research.



Prof. Jes Olesen

is Professor of Neurology, dr.med. (Copenhagen, Denmark), dr. hon.c. (Rome, Italy), dr. hon.c. (Yekaterinburg, Russia), and fellow of the Royal College of Physicians (FRCP). Born on 9.9.1941 in Hobro, Denmark, Jes Olesen received his MD at the University of Copenhagen 1967. Further specialist education in neurology at major teaching hospitals

in Copenhagen, the National Hospital, Queen Square, London, and the Cornell Medical Center, New York. Consultant neurologist at Gentofte Hospital 1985-1993, Glostrup Hospital 1993-. He is the founder Danish Headache Center 2001-Previous Associate Editor of Cephalalgia and Pain. He was Editorial board member of several journals and President of several Organisations, such as the Danish Headache Society, Scandinavian Migraine Society, International Headache Society, Danish Stroke Association, Year of the Brain 1997 campaign, European Federation of Neurological Societies (EFNS) and European Brain Council (EBC). Honorary member Australian, German, Austrian and International headache societies and of the Austrian, French, British, German and Polish Neurological Societies and of European Federation of Neurological Associations (EFNA) and EAN (as former EFNS President). He received the Great Nordic Research Prize of the Lundbeck Foundation and many other national and international prizes. Citations: Google Scholar 50673 H-Factor: Google Scholar 113, i/10-index: Google Scholar 539. 525 articles in refereed journals, 235 book chapters, 33 books. Has supervised 16 doctoral and 25 Ph.D. dissertations.

15:00 – 16:30
Room CbW



Case-based Workshop 4: Difficult decisions in treatment of myasthenia gravis

Chairperson:

*Jan J.G.M. Verschuuren
(Leiden, The Netherlands)*

- **Refractory MG treatment**
Nils Erik Gilhus (Bergen, Norway)
- **Thymectomy in MG**
*Jan J.G.M. Verschuuren
(Leiden, The Netherlands)*
- **Treatment in pregnancy**
Jacqueline A. Palace (Oxford, UK)

Educational content:

In this case-based workshop the participants will learn in small working groups how to diagnose and treat myasthenia gravis in different stages of their condition.

Limited to 60 participants.
This course is sold out!

15:00 – 16:30
Auditorium VI

Interactive Session 4: How to diagnose acute vertigo and acute double vision

Chairperson:

Michael Leo Strupp (Munich, Germany)

- **Acute vertigo**
Michael Leo Strupp (Munich, Germany)
- **Acute diplopia**
Konrad P. Weber (Zurich, Switzerland)
- **Acute vertigo and diplopia**
Caroline Tilkete (Lyon, France)

Educational content:

- **Acute vertigo.** The first question to be answered is whether this is central, i.e., brainstem or cerebellar infarction, or peripheral, i.e., acute unilateral vestibulopathy/ vestibular neuritis. This has major diagnostic and therapeutic consequences. By means of a careful patient history and a systematic clinical examination one can make a correct diagnosis with a sensitivity and specificity of more than 90%. Key clinical signs of a central lesion (“the big five”) are: skew deviation/vertical divergence, central fixation nystagmus (versus peripheral vestibular spontaneous nystagmus), gaze-evoked nystagmus, saccadic smooth pursuit and normal head-impulse test. Typical signs and symptoms and their interpretation in terms of a topographic anatomical diagnosis are presented by the cases and discussed with the audience.

- **Acute diplopia.** The goal of the session is to provide practicing neurologists with a framework for examining patients with acute diplopia. Based on a targeted history, the participants will be introduced to bedside examination skills with objective methods (e.g. cover test) and subjective methods (e.g. Maddox rod). Simple instrument-based methods, such as the Hess screen test, will be demonstrated to document strabismus. The examination skills will be presented in a case-based manner and discussed with the audience.

- **Diplopia accompanied by vertigo.** The aim is to explore those common brainstem syndromes which present with simultaneous diplopia and vertigo. Typical presentations of lower brainstem ischemia and demyelination will be discussed. The speaker will expand on the above two presenters’ material to explore the specific scenarios in which simultaneous diplopia and vertigo offer particular localisation value.

Please download the app “EAN Congress” to actively participate in this Session and vote.

15:00 – 17:00
Auditorium I



Special Session 1: EAN/MDS-ES: European Basal Ganglia Club

Chairperson:

Evzen Růžička (Prague, Czech Republic)

- **David Marsden Award Lecture – Functional (psychogenic) Dystonia**
Mark Hallett (Bethesda, USA)
- **Video case presentations**

Session Content:

Every year the European Basal Ganglia Club features a prominent speaker to present a C. David Marsden Award lecture. In addition, selected video case studies will be featured. Presenters of the video case studies will have been chosen through an application and selection process in collaboration with the International Parkinson and Movement Disorder Society – European Section’s Education Committee.

Sunday 17 June
15.00 – 18.15

17

15:00 – 16:30
Auditorium V



Special Session 10: Clinical Grand Rounds

Chairpersons:

José Ferro (Lisbon, Portugal)
Miguel Coelho (Lisbon, Portugal)

- **Neuromuscular disorders**
Mamede Carvalho (Lisbon, Portugal)
- **Movement disorders**
Werner Poewe (Innsbruck, Austria)
- **(Post) Stroke**
Didier Leys (Lille, France)

Patients will be examined during the session. The clinician will first inform on the patient's history, focus on neurological examination, work up a plan to confirm the diagnosis and etiology.

Session Content:

The practice of Neurology has been transformed and much improved by the use of a myriad of ancillary procedures, from neuroimaging to antibody and genetic testing. The current technology-based style of patient evaluation raises the question of the role of clinical skills in the diagnostic process.

In this session, highly experienced neurologists will interview and examine real patients with difficult or complex neurological conditions. They will discuss the clinical diagnosis, request and review all available diagnostic tests and will end by formulating a final diagnosis.

The session will highlight how clinical reasoning and skills are fundamental in guiding the neurological patient clinical pathway.

Target audience:

residents, practicing neurologists with interest in general neurology, movement disorders, stroke and neuromuscular disorders.

15:00 – 18:15
Room Berlin

Teaching Course 6: Update on MS treatment - Level 2

Chairperson:

Giancarlo Comi (Milan, Italy)

- **Treating relapsing remitting MS: what we have learned and what we still need to know**
Per Soelberg Sørensen (Copenhagen, Denmark)
- **Is there an option to treat progressive MS?**
Giancarlo Comi (Milan, Italy)
- **What is new on symptomatic treatment**
Alan Thompson (London, UK)
- **Strategies to enhance remyelination**
Catherine Lubetzki (Paris, France)

Educational content:

This course is designed for neurologists wishing to update their knowledge in the treatment of Multiple Sclerosis. The recent availability of new treatments for relapsing Multiple Sclerosis and the growing evidences of the importance to personalise treatment requires a careful evaluation of the tools that may assist the neurologist in treatment choice and in monitoring the response to the intervention. The first treatment for progressive MS has been recently approved by EMA with some restrictions. In parallel some positive perspectives have also been opened for the treatment of secondary progressive MS - how to implement these new options in clinical practice will be discussed. New perspectives on remyelination have also quite recently appeared through some proof of concept studies. Success and failures in remyelination strategies and the future developments will be extensively explored. Relevant news are also available in symptomatic treatments and rehabilitation which are fundamental aspects in patient management.

15:00 – 18:15
Room Amsterdam

Teaching Course 7: Clinical neurophysiology in neurorehabilitation - Level 2

Chairpersons:

Josep Valls-Solé (Barcelona, Spain)
Dafin Muresanu (Cluj Napoca, Romania)

- **Evoked potentials as biomarkers of neurologic dysfunction**
Peter Fuhr (Basel, Switzerland)
- **Non-invasive brain stimulation for the improvement of motor function after stroke**
Joseph Classen (Leipzig, Germany)
- **From immobility to spasticity. Neural and non-neural components of movement limitation**
Josep Valls-Solé (Barcelona, Spain)
- **Neurophysiological signals for brain computer interface**
Donatella Mattia (Rome, Italy)

Educational content:

Brain lesions involve changes in brain activity, either because of adaptation, compensation, plasticity or loss of function. Neurorehabilitation intends to make beneficial use of such changes by promoting those that are adequate to give better function or quality of live. Neurophysiology is the way to understand how the basic mechanisms of neurorehabilitation can work. In this course, the speakers will deal with several aspects of how neurophysiology contributes to assessment of clinical deficit, helps elucidating pathophysiological mechanisms and provides useful guidance to treatment. The attendants will be able to understand the value of biomarkers of central nervous system function, the bases for non-invasive stimulation treatment, the physiology of changes from immobility to spasticity and the role of remaining neurophysiological signals to assist in the use of computer-driven devices.

15:00 – 18:15
Auditorium II

Teaching Course 8: Tips and tricks in diagnosing headache disorders - Level 1

Chairperson:

*Rigmor Hojland Jensen
(Glostrup, Denmark)*

- Taking a proper headache diagnosis
*Rigmor Hojland Jensen
(Glostrup, Denmark)*
- Introduction into the IHS classification
Gisela Terwindt (Leiden, The Netherlands)
- Neuroimaging in headache:
why, when, how?
Gioacchino Tedeschi (Naples, Italy)
- Neurophysiology and laboratory
testing in headache
Delphine Magis (Liège, Belgium)

Educational content:

Participants will learn how to diagnose headache disorders according to the IHS classification and how to apply further imaging and other investigations.

15:00 – 18:15
Auditorium VIII

Teaching Course 9: New insights in the management of patients with ischaemic stroke or TIA - Level 2

Chairperson:

*L. Jaap Kappelle
(Utrecht, The Netherlands)*

- Mechanical thrombectomy for acute
ischaemic stroke
Jesper Petersson (Malmö, Sweden)
- Secondary prevention after stroke and
atrial fibrillation
Valeria Caso (Perugia, Italy)
- Moyamoya syndrome
*L. Jaap Kappelle
(Utrecht, The Netherlands)*
- TIA and mimics
Maria Tuna (Oxford, UK)

Educational content:

Without any doubt intra-arterial thrombectomy is the most spectacular breakthrough in the treatment of acute ischaemic stroke of the last decade. In this course both recent advances and chances for research with respect of this treatment will be discussed. Atrial fibrillation is one of the most common causes of TIA in elderly patients. New oral anticoagulants have been proven beneficial, but there are still some uncertainties how and when to use these new medications. Moyamoya disease should nowadays be considered as an uncommon cause of TIA or ischaemic stroke in young patients. Clinical features, diagnosis and management of this intracranial vasculopathy will be the topic of the third presentation in this course. Finally, stroke neurologists know that a TIA can be a difficult diagnosis and that one of the most common causes of a TIA that does not respond to proper treatment is a wrong diagnosis. Therefore, mimics of TIA are important to recognise and will be discussed from a clinical point of view.

15:00 – 18:15
Auditorium III

Teaching Course 10: Current treatments in neurology – Level 1

Chairperson:

*Nadine Attal
(Boulogne-Billancourt, France)*

- Current treatment possibilities in
dementia
Ana Verdelho (Lisbon, Portugal)
- Update on diagnosis and therapy of
metabolic myopathies
Pascal Laforêt (Paris, France)
- Current treatment in Guillain-Barré
Syndrome and myasthenia gravis
*Pieter A van Doorn
(Rotterdam, The Netherlands)*
- Pain in neurology: what to treat
and how
*Nadine Attal
(Boulogne-Billancourt, France)*

Educational content:

This Teaching Course on current treatments in various neurological disorders/diseases will give an update of current treatment and management strategies in dementias, muscle disorders, two major autoimmune neuromuscular diseases, i.e. GBS and myasthenia gravis. Furthermore, not only neuropathic pain, but pain associated with different types of neurological diseases will be covered. The lectures will not only refer to current state of the art therapies but also address secondary and tertiary therapies and allow a glimpse into potential future therapeutic options and developments.

Sunday 17 June
15.00 – 18.45

17

15:00 – 18:15
Room Oslo

Teaching course 19: The neurological bedside examination – the art of identifying pathology - Level 1

Chairperson:

Klaus V. Toyka (Würzburg, Germany)

- **Cranial nerves**
Jean Schoenen (Liège, Belgium)
- **Motor system including functional motor disorders**
Klaus V. Toyka (Würzburg, Germany)
- **Reflexes & sensory system**
Claudio Bassetti (Bern, Switzerland)
- **Higher cortical functions and coma**
Joseph Classen (Leipzig, Germany)

Educational content:

The TC is in part a repetition of the 2015 TC in Berlin with a largely extended video demonstration of the examination techniques and its contextual interpretation, and the examination of comatose patient. Its content largely reflects the sections of the EAN-e-book co-authored by Profs. Toyka, Classen, Schneider and Saur (see the website of the EAN). The aim of the course is familiarising neurologists in training how to do the various tests at the bedside and in the emergency room and how to interpret findings in the context of other abnormalities ultimately identifying pathology and making a diagnosis. In addition, the course will briefly address the principles of diagnosing pseudo-neurological motor disorders by (1) analysing motor patterns and (2) identifying incongruences of abnormal findings and (3) understanding the role of psychiatric confounders.

In order to have access to the eBook and to download it directly from the website, you have to be an EAN member.

16:45 – 18:15
Room CbW



Case-based Workshop 5: Neurogenetics goes therapy

Chairperson:

Ettore Salsano (Milan, Italy)

- **A young female with sudden and recurrent abnormal movements**
Iris Unterberger (Innsbruck, Austria)
- **A young man with bilateral abnormalities of the basal ganglia**
Yann Nadjar (Paris, France)
- **A strange case of psychotic behaviour and intermittent ataxia**
Ettore Salsano (Milan, Italy)

Educational content:

Main goal of the workshop is to guide clinicians through the clinical reasoning process in diagnosing rare or very rare hereditary diseases (i.e., GLUT1 deficiency syndrome, biotin-responsive encephalopathy, and Hartnup disease) which are effectively treatable. We will stress that the change in the treatment (beyond genetic counselling) is possible also in very recently identified inherited neurologic diseases (Tarailo-Graovac et al., NEJM, 2016), thus justifying the need of deep phenotyping and prompt access to advanced genetic studies to obtain the precise diagnosis. Each case will allow to revise the causes of three uncommon neurologic/neuroimaging syndromes, i.e., paroxysmal dyskinesias, bilateral abnormalities of basal ganglia and thalamus, and episodic ataxias, and two of them will allow to briefly talk about the differential diagnosis (sometime difficult) of the functional/psychogenic disorders.

Limited to 60 participants. Please register separately – additional fees will apply.

16:45 – 18:45
Room HoC

Hands-on Course 5: Ultrasound in vascular diagnosis - Level 1

Chairpersons:

Elsa Azevedo (Porto, Portugal)
Natan Bornstein (Tel Aviv, Israel)

- **Basic principles in evaluation of carotid systems**
Natan Bornstein (Tel Aviv, Israel)
- **Evaluation of intracranial arteries by ultrasound**
Elsa Azevedo (Porto, Portugal)
- **Assessment of the venous system by ultrasound**
José Valdueza (Bad Segeberg, Germany)

Educational content:

This course will give an overview about the diagnostic abilities of extra and intracranial ultrasound with special emphasis on stroke and emergencies. Investigations with extra- and intracranial ultrasound will be demonstrated on healthy volunteers.

Limited to 60 participants. Please register separately – additional fees will apply.

Oral sessions

 15.00 – 16.30
 Room Lisbon

Cerebrovascular diseases 1

Chairpersons:

Jacques De Reuck (Ghent, Belgium)
 Christian Enzinger (Graz, Austria)

15.00 | O204

Effect and safety of Tenecteplase in stroke patients with atrial fibrillation
A.H. Aamodt¹, E. Eriksen¹, M. Kurz², L. Altheheld¹, A. Fromm³, N. Logallo³, H. Naess³

¹Oslo, ²Stavanger, ³Bergen, Norway

15.15 | O202

Idarucizumab in cerebral ischemia or intracranial hemorrhage under Dabigatran therapy in Germany – a nationwide case collection
P. Kermer¹, C. Eschenfelder², H.-C. Diener³, M. Grond⁴

¹Sande, ²Ingelheim, ³Essen, ⁴Siegen, Germany

15.30 | O205

Characterisation of TRPM4-blocking antibody in ischaemic stroke
K.Y. Loh, R.Z. Lee, C.P. Poore, P. Liao

Singapore, Singapore

15.45 | O206

Mechanical thrombectomy for acute ischaemic stroke in the very old
A.S. Lopes de Sousa, M. Mariano, S. Galego, A. Fior, P. Ferreira, A. Paiva Nunes

Lisbon, Portugal

16.00 | O203

Cerebral thrombi are heterogeneous and their composition correlates with the density of the occluded vessel on CT scan
A. Semerano, M. Pozzato, G. Gullotta, D. Strambo, F. Simionato, F. Scmazzone, C. Righi, P. Panni, N. Anzalone, A. Falini, F. Sanvito, C. Doglioni, G. Martino, G. Comi, L. Roveri, M. Bacigaluppi

Milan, Italy

16.15 | O201

Short and long-term risks of stroke after orthodox-definition transient ischaemic attack versus disqualified monosymptomatic events: Oxford vascular study
M.A. Tuna, P.M. Rothwell

Oxford, UK

15.00 – 16.30

Room Room Copenhagen

Tournament Basic

Chairpersons:

Sofia Reimao (Lisbon, Portugal)
 Claudia Sommer (Würzburg, Germany)
 Pille Taba (Tartu, Estonia)

15.00 | TBASIC01

A missense mutation in the Low complexity domain of endogenous TDP43 induces gain of splicing function and neurodegeneration in the mouse
H. Oliveira¹, P. Fratta², T. Ricketts³, P. Sivakumar², K. Lo², J. Humphrey², S. Corrochano³, B. Kalmar², V. Plagnol², W. Emmet², A. Ule², E. Buratti⁴, F. Baralle⁴, E. Pauw², D. Housman⁵, E. Wang⁵, N. Fawzi⁶, A. Isaacs², P. Stanier², M. Lythgoe², Y. Gondo⁷, R. Fukumura⁷, L. Greensmith², E. Fisher², A. Acevedo-Arozena⁸

¹Newcastle, United Kingdom, ²London, United Kingdom, ³Oxfordshire, United Kingdom, ⁴Trieste, Italy, ⁵Massachusetts, USA, ⁶Providence, USA, ⁷Tsukuba, Japan, ⁸La Laguna, Spain

15.15 | TBASIC02

Parkinson's disease motor symptoms are linked to red nucleus volume and cerebellar metabolism

A. Bonnet¹, R. Sanford², A. Riou¹, S. Drapier¹, F. Le Jeune¹, M. Verin¹, D.L. Collins²

¹Rennes, France, ²Montreal, Canada

15.30 | TBASIC03

Salivary alpha-synuclein and tau in Parkinson's disease and progressive supranuclear palsy

G. Vivacqua, S. Antonio, R. Mancinelli, A. Fabbrini, D. Belvisi, E. Bianchini, E. Gaudio, A. Berardelli

Rome, Italy

15.45 | TBASIC04

A novel gene causing primary familial brain calcification: JAM2
L.V. Schottlaender¹, R. Abeti¹, Z. Jaunmuktane¹, M. Soutar¹, J. McKinley², O. Swayne¹, C. Bettencourt¹, R. Forbes³, P.J. Morrison², D. Hughes¹, A. Pittman¹, B. Kalmar¹, M. de Grandis⁴, G.V. McDonnell², S. Brandner¹, M. Aurrand Lyons⁴, P. Giunti¹, H. Houlden¹

¹London, United Kingdom, ²Belfast, United Kingdom, ³Portadown, United Kingdom, ⁴Marseilles, France

16.00 | TBASIC05

Subcortical anatomy of the default mode network: a functional and structural connectivity study
P. Nascimento Alves¹, C. Foulon², L. Cerliani², S. Karolis², M. Thiebaut de Schotten²

¹Lisbon, Portugal, ²Paris, France

16.15 | TBASIC06

A passive transfer animal model of CASPR2 antibodies
M.P. Giannoccaro¹, D.A. Menassa¹, L. Jacobson¹, E.P. Coutinho¹, B. Lang¹, R. Liguori², A. Vincent¹

¹Oxford, United Kingdom, ²Bologna, Italy

16.45 – 18.15

Room Lisbon

Epilepsy

Chairpersons:

Tim von Oertzen (Linz, Austria)
 Ivan Rektor (Brno, Czech Republic)

16.45 | O207

Will this child have epilepsy? Development and validation of a prediction model to assess the risk of epilepsy after (a) paroxysmal event(s)

E. van Diessen¹, H. Lamberink¹, W. Otte¹, N. Doornebal², O. Brouwer², F. Jansen¹, K. Braun¹

¹Utrecht, ²Groningen, Netherlands

17.00 | O212

National surveillance of mortality in children with Epilepsy in the UK and Ireland
O. Abdel-Mannan, A. Sutcliffe

London, UK

17.15 | O211

Laryngeal motor-evoked potentials as an indicator of vagus nerve activation
C. Bouckaert, R. Raedt, S. Gadeyne, E. Carrette, S. Proesmans, F. Dewaele, J. Delbeke, P. Boon, K. Vonck

Ghent, Belgium

17.30 | O209

Properties of epileptiform activity in the human hippocampus and temporal lobe intraoperatively recorded: preliminary results

F. Farias Serratos¹, C.V. Farias Serratos¹, B.M. Farias Serratos², K. Kawai³

¹León, ²Querétaro, Mexico, ³Tokyo, Japan

17.45 | O210

MiR-134 serum expression in Mesial Temporal Lobe Epilepsy (MTLE) patients
B. Leal, D. Rodrigues, C. Carvalho, R. Ferreira, J.M.M. Chaves, A. Bettencourt, J. Freitas, J.M.C.F. Lopes, J.E.D.P. Ramalheira, A. Martins Da Silva, P. P Costa, B. Martins Da Silva

Porto, Portugal

18.00 | O208

Late onset epilepsy of unknown origin and progression to dementia: two faces of beta amyloid pathology
M. Romoli¹, P. Eusebi¹, L. Farotti¹, C. Liguori², C. Bedetti¹, S. Siliquini¹, N.B. Mercuri², L. Parnetti¹, P. Calabresi¹, C. Costa¹

¹Perugia, ²Rome, Italy

16.45 – 18.15

Room Copenhagen

Neuro-oncology

Chairpersons:

Wolfgang Grisold (Vienna, Austria)

Anette Storstein (Bergen, Norway)

16.45 | O216

Stroke and „stroke-like“ events after brain radiotherapy: a large series with long-term follow-up

G. Berzero¹, A.L. Di Stefano², F. Ducray³, M. Eoli⁴, A. Pichiechio⁴, L.M. Farina⁴, V. Cuccarini⁴, M.C. Brunelli⁵, L. Diamanti¹, S. Condette Auliac², A. Salmaggi⁶, A. Silvani⁴, B. Giometto⁷, F. Bourdain², A. Pace⁸, A. Vidiri⁸, S. Bastianello¹, M. Ceroni¹, E. Marchioni¹

¹Pavia, Italy, ²Suresnes, ³Lyons, France, ⁴Milan, ⁵Treviso, ⁶Lecco, ⁷Padua, ⁸Rome, Italy

17.00 | O213

Increased efficacy of carboplatin after blood-brain barrier opening using low intensity pulsed ultrasound in preclinical models of glioblastoma

A. Dréan, N. Lemaire, G. Bouchoux, L. Goldwirt, L. Goli, A. Bouzidi, C. Schmitt, M. Canney, J. Guehennec, M. Verreault, M. Sanson, J.-Y. Delattre, K. Mokhtari, K. Beccaria, F. Sottolini, A. Carpentier, A. Idbah

Paris, France

17.15 | O214

Clinico-radiological, molecular, therapeutic and prognostic features of medulloblastoma of the adult: results from an institutional series

F. Franchino, F. Roveta, C. Chiavazza, A. Pellerino, F. Bruno, F. Mo, I. Morra, C. Mantovani, R. Rudà

Turin, Italy

17.30 | O215

Associations of anticoagulant use with outcome in newly diagnosed glioblastoma
E. Le Rhun¹, E. Genbrugge², R. Stupp³, O.L. Chinot⁴, L.B. Nabors⁵, T. Cloughesy⁶, D.A. Reardon⁷, W. Wick⁸, T. Gorlia², M. Weller⁹

¹Lille, France, ²Brussels, Belgium, ³Chicago, USA, ⁴Marseilles, France, ⁵Birmingham, ⁶Los Angeles, ⁷Boston, USA, ⁸Heidelberg, Germany, ⁹Zurich, Switzerland

17.45 | O218

Association between kynurenine metabolism in peripheral blood mononuclear cells and cognition in lung cancer patients undergoing chemotherapy

J. Rybacka-Mossakowska, D. Swiniuch, J. Gazdulska, R. Ramlau, W. Kozubski, S. Michalak

Poznan, Poland

18.00 | O217

Long-term follow-up of Optic Pathway Gliomas in children with neuro fibromatosis type-1: an oncology hospital experience

M. Valente Fernandes, J. Passos, D. Garcez, M. Mafrá, F. Campos, S. Nunes, D. Salgado

Lisbon, Portugal

Oral sessions

 17.15 – 18.15
 Auditorium V

Miscellaneous 1

Chairpersons:

Maxwell Damian (Cambridge, UK)
Gustave Moonen (Charneux-Herve, Belgium)

17.15 | O219

 Predicting long-term neurological
 outcome after cardiac arrest with serum
 Neurofilament Light chain

*M. Moseby Knappe¹, N. Mattsson¹,
 N. Nielsen¹, H. Zetterberg², K. Blennow³,
 J. Dankiewicz⁴, I. Dragancea⁴,
 M.P.H. Friberg⁴, G. Lilja⁴, P.S. Insel¹,
 C. Rylander², E. Westhall¹, J. Kjaergaard⁴,
 M.P. Wise⁵, C. Hassager⁶, M.A. Kuiper⁷,
 P. Stammet⁸, M.C. Jaeger Wanscher⁶,
 J. Wetterslev⁶, D. Erlinge¹, J. Horn⁹,
 T. Pellis¹⁰, T. Cronberg¹*
¹Lund, ²Gothenburg, ³Gothenburg/Mölnal, Sweden,

⁴Copenhagen, Denmark, ⁵Cardiff, UK, ⁶Copenhagen,

 Denmark, ⁷Leeuwarden, Netherlands, ⁸Luxembourg,

 Luxembourg, ⁹Amsterdam, Netherlands, ¹⁰Tricase, Italy

17.30 | O220

 Brain-computer interface technology for
 upper limb rehabilitation after stroke:
 a translational effort

*F. Pichiorri, E. Colamarino, F. Cincotti,
 D. Mattia*
Rome, Italy

17.45 | O221

 Clinical features and risk factors in
 Metronidazole-induced encephalopathy:
 a systematic review of 121 patients

*C.G. Sørensen, W. Karlsson, F.M. Amin,
 M. Lindelof*
Copenhagen, Denmark

18.00 | O222

 Predicting factors for quality of life
 following Traumatic Brain Injury:
 CROCFLAME catamnesis

*K. Rauen¹, L. Reichelt², P. Probst²,
 B. Schäpers³, F. Müller³, K. Jahn³, N. Plesnila²*
¹Zurich/Schlieren, Switzerland, ²Munich, Germany,

³Bad Aibling, Germany


Join us in Vienna

July 6 - 10, 2018 | Vienna, Austria


ICNMD
 2018

**15TH INTERNATIONAL CONGRESS
 ON NEUROMUSCULAR DISEASES**
www.icnmd2018.org

[icnmd2018](https://www.facebook.com/icnmd2018)
[#icnmd2018](https://twitter.com/icnmd2018)

 Ludwig Boltzmann Institute
 Experimental and Clinical Traumatology

EFAS Annual Meeting 2018 in conjunction with ICNMD2018

The European Federation of Autonomic Societies warmly welcomes you to the EFAS Meeting 2018

On behalf of the Scientific Committee, I am very pleased to invite you to our Annual Meeting 2018, to be held in conjunction with the 15th International Congress on Neuromuscular Diseases (ICNMD2018) in Vienna, Austria.

Our Annual Meeting will bring together autonomic scientists throughout Europe and the world to foster scientific research and knowledge exchange.

On Friday, July 6, 2018, the EFAS School trains autonomic skills on clinical evaluation and testing.

On Saturday, July 7, 2018 the EFAS Annual Meeting presents clinically relevant topics in autonomic nervous system research, such as peripheral autonomic neuropathies, neurodegeneration, cardiovascular autonomic failure, epilepsy, syncope, and fatigue in autonomic disorders. The meeting will provide clinical guides through autonomic conditions.

The meeting will offer plenty of networking opportunities with leading scientists and researchers, friends and colleagues.

Join us in Vienna on July 6 – 7, 2018!



Prof. Dr. Walter Struhal
EFAS 2018 Meeting President

JOIN US!
July 6 – 7, 2018
Vienna, Austria



ICNMD 2018 15TH INTERNATIONAL CONGRESS
ON NEUROMUSCULAR DISEASES
www.icnmd2018.org July 6 - 10, 2018 Vienna, Austria

www.icnmd2018.org/efas-2018 / www.efasweb.com / [#EFAS18](https://twitter.com/EFAS18)

The most authoritative voice in clinical neurological research



The *Lancet Neurology* is the trusted resource you need to stay informed of the important advances in your field. Our comprehensive coverage includes:

- **Articles:** original research that advocates change in neurological clinical practice
- **Reviews:** comprehensive overviews that are clinically focused and up-to-date on major neurological topics
- **Personal Views and Policy Views:** expert interpretation of recent evidence and its translation for decision makers
- **Commentary:** informative opinion on important recent advances in neurological practice and clinical research
- **In Context:** profiles, reviews of books and other media, lifelines, features on topical issues, and news on research advances

Discover more at www.thelancet.com/neurology

Monday
18 June 2018

18

08:00 – 09:30
Room CbW

Case-based Workshop 6: Antibodies causing epilepsy

Chairperson:

*Maarten J. Titulaer
(Rotterdam, The Netherlands)*

- **Faciobrachial dystonic seizures and other autoimmune seizure types**
Sarosh Irani (Oxford, UK)
- **What is the relevance of GAD65 antibodies in epilepsy?**
Helena Ariño (Barcelona, Spain)
- **Antibodies in status epilepticus**
*Maarten J. Titulaer
(Rotterdam, The Netherlands)*

Educational content:

There is an increasing of studies that link antibodies to epilepsy. However, it is currently unclear when to consider this cause for patients with epilepsy, and what pitfalls can be expected. Three neurologists with expertise in both antibodies and epilepsy will guide the attendants to this evolving new field of clinical neurology. The speakers will discuss the literature within this workshop using different cases. The antibodies most frequently related to epilepsy are LGI1, GAD and GABA_BR, and these will be all discussed from different perspectives, and common issues of debate during diagnosis and treatment will be covered within these case presentations.

Limited to 60 participants. Please register separately – additional fees will apply.

08:00 – 09:30
Room HoC

Hands-on Course 6: Interpreting MRI in practice - Level 2

Chairperson:

Maria Assunta Rocca (Milan, Italy)

- **White matter lesions**
Maria Assunta Rocca (Milan, Italy)
- **Grey matter lesions**
*Menno Schoonheim
(Amsterdam, The Netherlands)*
- **Brain atrophy**
Giocchino Tedeschi (Naples, Italy)

Educational content:

This 90-minute hands-on-course on MRI, one of the key elements of diagnosis and differential diagnosis in many neurological disease, is directed to specialist trainees and practitioners who already have a basic knowledge of neuroimaging. The course will have three stations with experts in the various aspects of imaging and the participants will rotate, to increase their possibility to actively discuss practical issues. The attendants will learn how to interpret imaging features of white matter (WM) lesions in the main WM diseases and will be trained in the recognition of imaging red flags, useful for the differential diagnosis of these conditions. They will become familiar with imaging strategies to identify lesions of the grey matter (GM) and will directly apply guidelines for the assessment of these lesions. Finally, they will have the chance to participate to a session of practical quantification of atrophy in healthy subjects and patients with different neurological conditions and will be guided in the interpretation of physiological and disease-related variations of brain atrophy measures.

Limited to 60 participants.
This course is soldout.

08:00 – 09:30
Auditorium VI



Interactive Session 5: Diagnostic pitfalls in neuromuscular disease

Chairperson:

Jochen Schäfer (Dresden, Germany)

- **Bilateral finger extension weakness – is it treatable?**
Jochen Schäfer (Dresden, Germany)
- **A typical phenotype of proximal muscle weakness with an unusual genetic result**
Kristl Claeys (Leuven, Belgium)
- **A diagnostic conundrum – various clinical manifestations, same genetic defect**
Gabriele Siciliano (Pisa, Italy)

Educational content:

In this interactive Session, differential diagnostic problems in neuromuscular medicine will be discussed with the audience using four cases to illustrate the diagnostic pathway and potential pitfalls in reaching a diagnosis. The cases will cover major fields of neuromuscular medicine: channelopathies, muscular dystrophies, metabolic myopathies, inflammatory myopathies. After presentation of the cases the audience will be invited to offer diagnostic options by means of a smartphone voting app; furthermore, questions will be asked and discussed regarding investigations and management of the patient. Emphasis will be laid upon demonstrating ways how to approach a neuromuscular patient with seemingly puzzling physical findings and how to consider and evaluate the neuromuscular differential diagnoses.

Please download the app “EAN Congress” to actively participate in this Session and vote.

Monday 18 June
08.00 – 09.30

18

08:00 – 09:30
Room Berlin

Focused Workshop 11: CGRP inhibition for migraine prevention – hype or hope?

Chairperson:

Michel Ferrari (Leiden, The Netherlands)

- Rationale of blocking CGRP
Messoud Ashina (Copenhagen, Denmark)
- Clinical results
Uwe Reuter (Berlin, Germany)
- Clinical interpretation
Michel Ferrari (Leiden, The Netherlands)

Scientific content:

Phase-2 trials have shown great promise of CGRP (Calcitonin gene-related peptide) and CGRP receptor antibodies and small molecule antagonist in the prevention and acute treatment of migraine and cluster headache attacks. By 2018 most phase-3 trials will have been completed. Efficacy and safety data will be presented and critically compared with those of existing migraine and cluster headache prophylactic (e.g. topiramate, propranolol, verapamil) and acute (e.g. triptans) treatments.

Target audience:

All clinical neurologists; basic science researcher with respect to pharmacology

08:00 – 09:30
Auditorium II



Focused Workshop 12: Neurogenetic avenues and new directions on risk factors in dementia?

Chairperson:

Ana Isabel Verdelho (Lisbon, Portugal)

- The penetrance continuum of genetic variants in common causal and risk genes in neurodegenerative dementia
Christine Van Broeckhoven (Antwerp, Belgium)
- Large data bases, big science?
Pieter Jelle Visser (Maastricht, The Netherlands)
- To exercise prevention
Ana Isabel Verdelho (Lisbon, Portugal)

Scientific content:

The objective of this session is to approach recent advances on the field of dementia and to make a critical appraisal of the real contribute of those advances in clinical practice.

08:00 – 09:30
Auditorium V

Focused Workshop 13: Autoimmune encephalitis in the Intensive Care Unit (ICU)

Chairperson:

Harald Prüss (Berlin, Germany)

- New concepts in etiology and disease mechanisms in autoimmune encephalitis
Harald Prüss (Berlin, Germany)
- “Established” and experimental treatments of refractory autoimmune encephalitis
Stephan Rüegg (Basel, Switzerland)
- Epileptic seizures and status in autoimmune encephalitis
Sophie Demeret (Paris, France)

Scientific content:

In this Focused Workshop we will give lectures about the issue of severe autoimmune encephalitis, requiring neurointensive care. New concepts of etiology and pathophysiology as well as special aspects of treatment, also alternative methods in refractory cases will be discussed. Prompt recognition of epileptic seizures or status epilepticus and adequate treatment are essential as this can prevent permanent neurological damage.

08:00 – 09:30
Auditorium VIII



Focused Workshop 14: EAN/MDS-ES: Evidence-based medicine and beyond in neuropsychiatric complications of Parkinson's diseases

Chairperson:

*David John Burn
(Newcastle upon Tyne, UK)*

- **Treatments of depression in Parkinson's disease**
Olivier Rascol (Toulouse, France)
- **Therapeutic approaches of cognitive decline and dementia**
*David John Burn
(Newcastle upon Tyne, UK)*
- **Therapeutic approaches of hallucinations and psychosis**
Murat Emre (Istanbul, Turkey)
- **Prevention, detection and therapeutic approaches of impulsivity disorders**
Angelo Antonini (Padua, Italy)

Scientific content:

This focused workshop will address several key non-motor symptoms that frequently complicate the course of Parkinson's or may even predate the motor features. In part, these symptoms may be precipitated or exacerbated by drugs used to treat motor impairments. But undoubtedly the genesis of depression, cognitive impairment, psychosis and impulse control disorder relates to underlying neuropathological and neurochemical changes in strategic brain areas. Treatments used to manage these challenging symptoms are generally inadequate, despite their de facto logical focus on neurotransmitter placement and/or receptor stimulation. Furthermore, despite the availability of several agents in class, such as antidepressants, the evidence basis to guide treatment of many of these symptoms is poor. Neuropsychiatric symptoms associated with Parkinson's are therefore an

area of major unmet need. This session will review current treatments for depression, cognitive impairment, psychosis and impulse control disorder and will also consider future possible therapeutic approaches.

08:00 – 09:30
Room Amsterdam

Focused Workshop 15: Guillain-Barré Syndrome: new developments in immunology, electrophysiology and treatment

Chairperson:

Peter Van den Bergh (Brussels, Belgium)

- **Understanding the auto-immune attack**
Hugh J. Willison (Glasgow, UK)
- **Unravelling the electrophysiological diagnostic challenges**
Peter Van den Bergh (Brussels, Belgium)
- **Novel treatment methods**
*Pieter A. van Doorn
(Rotterdam, The Netherlands)*

Scientific content:

This focused workshop aims at presenting recent advances in the understanding of the pathophysiology of Guillain-Barré syndrome. New insights in the immunopathology and electrophysiological abnormalities will be discussed. They are leading to novel treatment algorithms and to more specific treatments.

08:00 – 09:30
Room Oslo

Focused Workshop 16: Precision medicine in stroke

Chairperson:

José M Ferro (Lisbon, Portugal)

- **Do we need precision medicine in stroke?**
Daniel Berezcki (Budapest, Hungary)
- **Do we already have precision medicine in stroke?**
Catarina Fonseca (Lisbon, Portugal)
- **What to expect in the future?**
Joan Montaner (Barcelona, Spain)

Scientific content:

Precision medicine means a tailored approach to the diagnosis and management of the individual patient. Its ultimate goal is to provide individualised treatment for each patient, avoiding the uncertainty and side-effects of current treatment strategies. Personalised medicine is already a reality in current practice in oncology, both for establishing individual prognosis, and more importantly to select chemotherapy and immunotherapy for each patient, based on a number of genetic and biochemical biomarkers. For other fields of medicine the applications of precision medicine in daily practice, although promising, are still in its infancy. That is the case of stroke, whose current management only occasionally needs genetic information. However, this scenario is likely to be modified soon, due to developments in biology, imaging, and informatics. Prof. Berezcki will introduce the topic and will scrutinise if we need precision medicine beyond the clinical, biochemical and imaging parameters that we currently use to decide on treatments and to provide prognostic information. Dr. Fonseca will review recent progresses on the application of precision medicine to stroke, including a glimpse of ongoing studies. The last speaker, Prof. Montaner, will address the road to success of future developments in the field, including expected advances in genomics, serological biomarkers, novel biological data, imaging information and on the issues

Monday 18 June
08.00 – 09.30

18

raised by the analysis of large data collection of stroke patients both from clinical trials, registries and administrative sets.

08:00 – 09:30
Room Lisbon

Special Session 8: History of Neurology: Lessons from Portuguese clinical neurosciences

Chairperson:

Victor Oliveira (Lisbon, Portugal)

- **Functional neurosurgery: leucotomy revisited**
Alim Benabid (Grenoble, France)
- **Would whole-exome sequencing change the history of Machado Joseph disease?**
Patricia Maciel (Braga, Portugal)
- **From pioneers to interventional angiography**
Victor Oliveira (Lisbon, Portugal)

Scientific Content:

The field of Neurosciences deals nowadays with some challenges where one can track the connection with the early landmarks of Neurology. Some new discoveries or therapeutic applications revisit old attempts and, in some sense, pursue them. Surgical interventions in the brain were desperate attempts to help mental ill patients in the absence of any efficacious medication and without any foreseen way to entertain hope for a barely normal life. Deep brain stimulation for different therapeutic targets pursues the idea of surgical intervention in the brain to achieve therapeutic benefits. Well identified genetic diseases with precise abnormalities, allow us to entertain the hope of some sort of highly selective interventions to restore the normal sequence of amino-acids helping people to benefit from them. The broad use of angiography as it is performed at these early decades of the XXI century only hardly could be anticipated by Egas Moniz when he performed the first angiograms trying to identify intracranial tumours or even when, a few years later, he understood that the vessels, themselves,

presented abnormalities that could be of clinical significance. The bridging from diagnostic to therapeutic interventions was made in the last decades of the XX Century with the first devices able to perform intravascular interventions. Emergency intravascular procedures for clot removal, was the next step. These are only a few examples how human creativity can surpass imagination.

08:00 – 09:30
Room Copenhagen



Special Session 9: EAN/EBC/EFNA: The Value of Treatment (VoT) of brain disorders

Chairpersons:

Wolfgang Oertel (Marburg, Germany)

David Vodusek (Ljubljana, Slovenia)

Maura Pugliatti (Ferrara, Italy)

- **Brain disorders in Europe: unmet needs**
Wolfgang Oertel (Marburg, Germany)
- **The value of early diagnosis and treatment. A patient journey**
Joke Jaarsma (Amsterdam, The Netherlands)
- **The Value of Treatment: Using economic modelling to assess costs and outcomes associated with health care interventions.**
Michela Tinelli (London, UK)
- **The value of health: improving outcomes and care pathways**
Richard Dodel (Marburg, Germany)
- **The value of early treatment**
Maura Pugliatti (Ferrara, Italy)

Session Content:

Brain disorders (mental and neurological disorders) represent an enormous burden on both individuals and societies. The broad impact of brain disorders (BD) is threatening the quality of life of millions of European citizens with important implications on economic growth.

Most of the current healthcare systems do not adequately respond to the need of patients with brain disorders. They mainly respond when a person is sick and have many deficiencies in the management of patients with brain disorders who need long-term care and treatment.

We present the results from the Value of Treatment (VoT) Project providing evidence on the socio-economic impact of coordinated and patient-centered clinical interventions which has been launched within the European Brain Council. EAN was responsible for the neurological diseases and the scope of this project will be presented. EFNA will face the issue from the person with BD perspective through the description of a 'patient journey' from diagnosis to treatment, with special focus on patient reported outcomes, highlight on the main needs of people with BD, and ultimately providing elements for improving care pathways of people with BD.

10:00 – 12:00
Auditorium I



Plenary Symposium 3: Molecular and genetic therapies for neurogenetic disorders

Chairpersons:

Jorge Sequeiros (Porto, Portugal)

Jean-Marc Burgunder (Bern, Switzerland)

- **Molecular and genetic therapies for Friedreich ataxia**
Massimo Pandolfo (Brussels, Belgium)
- **Antisense oligonucleotide and gene replacement therapy in spinal muscular atrophy: a new therapeutic era for motor neuron diseases**
Kevin Talbot (Oxford, UK)
- **Anti-amyloid and gene therapy in the treatment of familial amyloid polyneuropathy**
Maria Joao Saraiva (Porto, Portugal)
- **Gene-based therapy in neurological disorders: what is in the pipeline?**
Jean-Marc Burgunder (Bern, Switzerland)

Scientific Content:

In recent years, novel therapeutical strategies and new approaches to old ones brought fresh hope for treatment of hereditary neurological diseases. We have been seeing the emergence of a variety of therapies, either aimed at a faulty (missing or toxic) protein function, targeted at RNA expression (gene silencing) or at DNA itself (gene therapy). Increased knowledge on disease progression, biomarkers and measurable outcomes, as well as on pathogenic pathways and networks, enabled more and better functional and preclinical studies (in cell and animal models). As a consequence, abundant clinical trials have been conducted or are now under way. New pharmaceutical molecules and novel genetic therapies have been developed for systemic or intrathecal delivery. Some, like (1) antisense oligonucleotides and (2) RNA interference compounds, interfere with messenger RNA, to reduce its expression, while (3) small molecules are designed to alter RNA splicing or for epige-

netic reactivation of endogenous genes. Others, as (4) zinc-finger transcriptional repressors and (5) CRISPR/Cas9 constructs (“gene editing”), interact directly with DNA. Fine examples of these therapeutical strategies, in recessive (spinal muscular atrophy and Friedreich ataxia) and dominant neurological diseases (familial amyloid neuropathy and Huntington disease), are being presented in this session.

15:00 – 17:00
Auditorium I



Symposium 5: The spectrum of dementias

Chairpersons:

Jonathan Schott (London, UK)

Evelien Lemstra

(Leiden, The Netherlands)

- **Alzheimer’s disease**
Reinhold Schmidt (Graz, Austria)
- **Vascular dementia**
José Ferro (Lisbon, Portugal)
- **Frontal lobe dementias**
Jonathan Schott (London, UK)
- **Lewy body dementia**
Evelien Lemstra
(Leiden, The Netherlands)

Scientific Content:

The dementias are at the heart of neurology: brain disorders with a significant impact on society and a huge challenge for neurologists in terms of diagnosis, treatment and care. Knowledge of the full spectrum of dementias is needed for each neurologist because of the high prevalence. The symposium covers all major diseases causing dementia and highlights all aspects of the diseases, given by the best specialists within the EU Neurology community

15:00 – 17:00
Room Berlin

Symposium 6: Coma: neuromodulation, imaging and neurobiology

Chairpersons:

Steven Laureys (Liège, Belgium)

Karin Diserens (Lausanne, Switzerland)

- **Mechanisms of impaired consciousness**
Daniel Kondziella (Copenhagen, Denmark)
- **Where structural changes predict outcome**
Louis Puybasset (Paris, France)
- **Cognitive-motor dissociation: cave!**
Karin Diserens (Lausanne, Switzerland)
- **Neuromodulation: outlook into the future**
Steven Laureys (Liège, Belgium)

Scientific Content:

Clinical and paraclinical evaluation of patients in coma and with chronic disorders of consciousness after brain injury has experienced an important development in these last years. This symposium aims at providing the audience with updated information on several domains, which will cover current understanding of mechanisms subtending disorders of consciousness, practice in post-cardiac arrest prognostication, newer neuroimaging data, an updated version of evaluation of chronic patients and an outlook into neurostimulation.

Target Audience:

Neurologists, neurointensivists, nurses in ICU, clinical neurophysiologists.

Monday 18 June
15.00 – 16.30

18

15:00 – 16:30
Room CbW



Case-based Workshop 7: Rare headache syndromes: idiopathic or symptomatic?

Chairperson:

Peter Sandor (Baden, Switzerland)

- **Exercise and sexual headache types**
Stefan Evers (Münster, Germany)
- **Thunderclap headache types**
Raquel Gil-Goweia (Lisbon, Portugal)
- **Chronic daily persistent headache**
Peter Sandor (Baden, Switzerland)

Educational content:

In this workshop, participants can learn to identify rare other idiopathic headache disorders (group 4 of IHS classification) and to differentiate from similar symptomatic headache disorders

Limited to 60 participants. Please register separately – additional fees will apply.

15:00 – 16:30
Room Amsterdam

Controversy 1: Steroids in neuroinfections & Seizures and epileptiform discharges

Chairpersons:

Israel Steiner (Petach Tikvah, Israel)

Iris Unterberger (Innsbruck, Austria)

- **Steroids in Acute and chronic Bacterial Meningitis – PRO**
Diederik van de Beek (Amsterdam, The Netherlands)
- **Steroids in Acute and chronic Bacterial Meningitis – CON**
Erich Schmutzhard (Innsbruck, Austria)
- **Seizures and epileptiform discharges worsen clinical outcome and should be aggressively treated**
Nicolas Gaspard (Brussels, Belgium)
- **Seizures and epileptiform discharges do not impact clinical outcome and should not be aggressively treated**
Vincent Alvarez (Lausanne, Switzerland)

Educational content:

Part 1:

Steroid therapy in neurological infections and seizures impact and management in comatose patients are a controversial topic. The debate will focus on its use in bacterial and viral infections of the nervous system

Part 2:

To know the consequences of seizures on brain and clinical outcome of acutely ill patients and to know how to approach subclinical seizures in the ICU and to understand the pros and cons of aggressive anti-seizures treatment

15:00 – 16:30
Room HoC

Hands-on Course 7: Neuro-otology - Level 2

Chairperson:

Eleftherios Papathanasiou

(Nicosia, Cyprus)

- **Benign paroxysmal positional vertigo: provocation and liberation maneuvers**
Michael Strupp (Munich Germany)
Thomas Brandt (Munich, Germany)
- **Vestibular evoked myogenic potentials**
Eleftherios Papathanasiou (Nicosia, Cyprus)
Dominik Straumann (Zurich, Switzerland)
- **Video impulse test**
Konrad P. Weber (Zurich, Switzerland)
- **Neuro-otological bedside tests**
Adolfo Bronstein (London, UK)
Marianne Dieterich (Munich, Germany)

Educational content:

This course encompasses the major bedside and auxiliary tests for evaluating patients with vestibular signs and symptoms. A room rotating scheme has been designed with four stations, spending twenty minutes at each, with practical demonstrations. The benign paroxysmal positional vertigo (BPPV) and neuro-otological bedside test stations will involve the neuro-otological clinical examination and the treatment of BPPV with the different manoeuvres for each separate canal BPPV. The vestibular evoked myogenic potential station will use a common evoked potential system available in all neurophysiological laboratories. The head impulse station will demonstrate head mounted video systems commercially available for eye movement documentation.

Limited to 60 participants. Please register separately – additional fees will apply.

15:00 – 16:30
Auditorium VI

Interactive Session 6: Not every twitch or movement is a seizure in the neurological ICU

Chairperson:

Raimund Helbok (Innsbruck, Austria)

- Not every twitch is a seizure - the view of an epileptologist
Andrea Rossetti (Lausanne, Switzerland)
- Movement disorders associated with hypoxic encephalopathy and brain death
Raimund Helbok (Innsbruck, Austria)
- Encephalitis and movement disorders
Pille Taba (Tartu, Estonia)

Educational content:

Seizures are commonly observed in the setting of acutely brain injured patients. Differentiation of epileptic seizures from non-epileptic seizures is challenging for the clinician and may be facilitated by the use of continuous EEG monitoring. Moreover, especially in patients with autoimmune encephalitis, hypoxic brain injury and brain death, typical and sometimes bizarre movement disorders are observed. Clinical cases will be presented with videos of patients and supported by additional monitoring tools (i.e. EEG). Each section will include a brief discussion of the underlying disease.

Please download the app “EAN Congress” to actively participate in this Session and vote.

15:00 – 18:15
Auditorium II



Teaching Course 11: EAN/MDS-ES: Evidence- based medicine in the treatment disabling motor and non-motor trouble in Parkinson’s disease - Level 2

Chairperson:

Maria Stamelou (Athens, Greece)

- Falls and gait disorders
Evžen Růžička (Prague, Czech Republic)
- Bladder disturbances and sexual disorders
Maria Stamelou (Athens, Greece)
- Hypotension and dysautonomia
.Gregor K. Wenning (Innsbruck, Austria)
- Nocturnal and sleep problems in PD
Claudia Trenkwalder (Kassel, Germany)

Educational content:

Parkinson’s disease is heterogeneous in clinical presentation and evolution of motor and non-motor symptoms. The pharmacological and non-pharmacological treatment of the individual patient is challenging in particular in advanced stages of the disease. This teaching course aims to provide the basis for independently and individually apply current evidence based treatments for disabling motor and non-motor features in patients with Parkinson’s disease, in clinical practice. More specifically, the first talk will focus on evidence-based pharmacological and rehabilitation approaches to deal with, probably the most important determinants of quality of life and prognosis in terms of motor symptoms, e.g., the falls and gait-disorders. The following talks will focus on evidence based treatments of important non-motor symptoms of PD, specifically urinary and sexual problems, as well as autonomic dysfunction, as expressed among other with orthostatic or post-prandial hypotension. Lastly, sleep related issues that may be prevalent in Parkinson’s disease and may influence the quality of sleep, and thus, quality of life in

PD patients, will be discussed, along with evidence on how best to approach treatment. After successfully completing this course the participants should be able to:

- 1) identify and approach clinically important motor and non-motor determinants of quality of life in a patient with PD from early to advanced disease
- 2) understand evidence-based treatments to approach gait problems and falls, as well as autonomic dysfunction and sleep problems in a patient with PD
- 3) make clinical decisions that take into account the scientific evidence and patient preferences on an individualised level.

Monday 18 June
15.00 – 18.15

18



15:00 – 18:15
Auditorium V

Teaching Course 12: EAN/ILAE-CEA: How to approach EEG and avoid overreading in epilepsy - Level 1

Chairperson:

Soheyl Noachtar (Munich, Germany)

- Systematic approach to EEG abnormalities
Soheyl Noachtar (Munich, Germany)
- How to localise EEG potentials
Sándor Beniczky (Dianalund, Denmark)
- What are epileptiform discharges & what do they mean clinically?
Francisco Sales (Coimbra, Portugal)
- What is spiky but not epileptiform discharges?
Matthew C. Walker (London, UK)

Educational content:

EEG is a strong tool in the diagnosis of epilepsy. Yet, it is a subjective method with inherent short comings, when it is not approached systematically. This course will first give a systematic approach to reading the EEG and typical pitfalls. Then, the localisation of EEG discharges will be discussed with its use for differential diagnosis and typical pitfalls, when localisation is not done adequately. The last two lectures will give an overview of what constitutes an IED, how well EEG finds IEDs, what they mean clinically and lastly, which discharge differential diagnoses exist and how to identify them.

15:00 – 18:15
Auditorium VIII

Teaching Course 13: New concepts in critical care of stroke patients - Level 3

Chairperson:

Stefan Schwab (Erlangen, Germany)

- Ischemic stroke: periinterventional management for acute neurointerventions
Bart van der Worp (Utrecht, The Netherlands)
- Intracerebral hemorrhage (ICH) in patients with anticoagulation: New therapeutic options?
Stefan Schwab (Erlangen, Germany)
- Subarachnoid hemorrhage (SAH): How do we treat delayed ischemic neurological deficit (DIND)
Erich Schmutzhard (Innsbruck, Austria)
- Spontaneous intracerebral hemorrhage (ICH): The issue of perihemorrhagic edema
Dimitre Staykov (Eisenstadt, Austria)

Educational content:

Discussion of new therapeutic concepts in the management of patients with acute cerebrovascular disease treated on the NCCU. Especially the peri-interventional management of patients undergoing thrombectomy in ischemic stroke is debated and clear guidelines are missing. Another topic will be laid on the management of patients with intracerebral haemorrhage and brain oedema therapy as well as special therapy of ICH under anticoagulation. Patients with subarachnoid haemorrhage often develop further complications after aneurysm repair. However, neurocritical care therapy is often complicated by vasospasm which can cause further ischemic events, possible treatment interventions will be discussed.

15:00 – 18:15
Room Lisbon

Teaching Course 14: How to approach a patient with neuropathy: from symptoms to diagnosis - Level 2

Chairperson:

Eduardo Nobile-Orazio (Milan, Italy)

- Sensory Motor neuropathy
Michael Lunn (London, UK)
- Motor neuropathy
Eduardo Nobile-Orazio (Milan, Italy)
- Sensory Neuropathy
Claudia Sommer (Würzburg, Germany)
- Focal and asymmetric neuropathy
Jean-Marc Léger (Paris, France)

Endorsed by the Peripheral Nerve Society (PNS)

Educational content:

This introductory course is mainly directed at specialist trainees or practitioners wishing to update and further develop their knowledge in the diagnosis of neuropathy. The speakers will address how to approach a patient according to their clinical presentation and how to focus the diagnostic investigation according to them. We will also try to suggest a correct sequence of tests to be used to achieve a correct diagnosis starting from the less expensive and traumatic ones.

Monday 18 June
16.45 – 18.45

16:45 – 18:45
Room HoC

**Hands-on Course 4:
Basic EMG - needle EMG
and transcranial magnetic
stimulation as an
electrodiagnostic tool -
Level 2**

Chairperson:

Letizia Leocani (Milan, Italy)

- **Transcranial magnetic stimulation
as an electrodiagnostic tool**
Letizia Leocani (Milan, Italy)
- **Needle EMG**
*Christian Krarup
(Copenhagen, Denmark)*

Educational content:

Dysfunctions of the pyramidal tract may require assessment of central conduction time and other central motor functions to complete the diagnostic workout. This is accomplished nowadays thanks to the use of transcranial magnetic stimulation (TMS). Apart from the most common evaluation of central conduction time, TMS allows for the study of sensorimotor integration, cortical maps of representation of muscles, excitability threshold, intracortical inhibition and many other features of the motor system. The course is intended to familiarize the attendants with the magnetic stimulators and practice in themselves the evaluation of central motor functions.

Needle electromyography (EMG) is an essential part of electro-diagnosis. Several different criteria are recorded to diagnose neurogenic disorders or myopathy. These include recording of denervation potentials

and other spontaneous activity at rest, motor unit potentials (MUP) at weak effort, and the recruitment pattern at maximal voluntary effort. The examiner should be trained and skilful enough to combine sound and vision for the identification of subtle abnormalities. In this Hands-on-Course, the speaker will demonstrate how to perform a needle EMG exam, including positioning of the needle and searching for relevant information. There will also be demonstration of techniques to quantitate the shape, duration and amplitude of MUPs, which are useful in the assessment of degenerative neuromuscular disorders. The attendants will actively participate in discussing the exams and interpretation in volunteers

This course is supported by NATUS Medical Inc. and MagVentures.

Limited to 60 participants. Please register separately – additional fees will apply.

SAVE THE DATE

PNS PERIPHERAL NERVE SOCIETY

2018

PNS ANNUAL MEETING
BALTIMORE
MARYLAND
JULY 21-25

Renaissance Baltimore Harborplace Hotel
www.pnsociety.com

PNS PERIPHERAL NERVE SOCIETY

SAVE THE DATE

2019 PNS ANNUAL MEETING
GENOA, ITALY • 22-26 June
Centro Congressi - Porto Antico di Genova
www.pnsociety.com

International Congress of Parkinson's
Disease and Movement Disorders

October 5-9, 2018
HONG KONG



International Parkinson and
Movement Disorder Society

www.mdscongress.org

Oral sessions

15.00 – 16.15

Room Copenhagen

Ageing and dementia

Chairpersons:

*Patrik Cras (Edegem, Belgium)**Bruno Dubois (Paris, France)*

15.00 | O304

Added value of multimodal structural MRI to the clinical diagnosis of primary progressive aphasia variants

E. Canu¹, F. Agosta¹, F. Imperiale¹, F. Caso¹, A. Fontana², G. Magnani², A. Falini², G. Comi², M. Filippi²

¹Milan, ²San Giovanni Rotondo, Italy

15.15 | O305

Enrichment of clinical trials in prodromal AD using ventricular volume to identify individuals at increased risk of rapid disease progression

M. Marizzoni¹, C. Ferrari¹, L. Cavaliere¹, M. Didic², G.L. Forloni³, J. Jovicich⁴, J.L. Molinuevo Guix⁵, F. Nobili⁶, L. Parnetti⁷, P. Payoux⁸, F. Ribaldi¹, P.M. Rossini⁹, P. Schonknecht¹⁰, A. Soricelli¹¹, M. Tsolaki¹², P.J. Visser¹³, J. Wiltfang¹⁴, R. Bordet¹⁵, O. Blin², G. Frisoni¹⁶

¹Brescia, Italy, ²Marseilles, France, ³Milan, Italy, ⁴Trent, Italy, ⁵Barcelona, Spain, ⁶Genoa, Italy, ⁷Perugia, Italy, ⁸Toulouse, France, ⁹Rome, Italy, ¹⁰Leipzig, Germany, ¹¹Naples, Italy, ¹²Thessaloniki, Greece, ¹³Amsterdam, Netherlands, ¹⁴Essen, Germany, ¹⁵Lille, France, ¹⁶Geneva, Switzerland

15.30 | O302

ABBV-8E12, a humanised anti-Tau monoclonal antibody for the treatment of Early Alzheimer's disease and PSP: multiple dose, randomised, double-blind, placebo-controlled Phase-2 studies

N. Mendonca¹, H. Florian², D. Wang², W. Robieson², H. Soares², J.B. Braunstein³, D.M. Holtzman³, R.J. Bateman³, B. Rendenbach-Mueller⁴, K. Budur²

¹Ludwigshafen, Germany, ²North Chicago, USA, ³Saint Louis, USA

15.45 | O303

EEG microstates - association with cognitive impairment and Alzheimer's disease CSF biomarkers

U. Smailovic¹, T. Koenig², T. Andersson¹, E. Jonsson Laukka¹, G. Kalpouzos¹, B. Winblad¹, V. Jelic¹

¹Stockholm, Sweden, ²Berne, Switzerland

16.00 | O306

Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD)

M. Bauckneht¹, A. Chincarini¹, R. Piva¹, D. Arnaldi¹, N. Girtler¹, F. Massa¹, M. Pardini¹, H. Efturk¹, M. Pagani², G. Sambuceti¹, F. Nobili¹, S.D. Morbelli¹

¹Genoa, ²Rome, Italy

15.00 – 16.30

Room Oslo

Tournament Clinical

Chairpersons:

*Klaus V. Toyka (Würzburg, Germany)**Patricia Canhao (Lisbon, Portugal)**Hanna Cock (London, UK)*

15.00 | TCLIN01

Assessment of diabetic medication in ~8,000 dementia patients with diabetes mellitus. A study from the Swedish Dementia Registry

J. Secnik¹, E. Schwertner¹, K. Johnell², J. Fastbom², M. Alvarsson¹, B. Winblad¹, S. Garcia-Ptacek¹, M. Eriksdotter², D. Religa¹

¹Stockholm, Sweden, ²Stockholm, Sweden

15.15 | TCLIN02

Cerebrovascular events after surgery versus conservative therapy for moyamoya disease: a meta-analysis

I. Smets, A. Wouters, R. Lemmens

Leuven, Belgium

15.30 | TCLIN03

Pediatric and adults ms: a longitudinal multimodal MRI study to explore the substrates of the different clinical courses

E. de Meo¹, M.A. Rocca¹, A. Meani¹, L. Moiola¹, B. Colombo¹, M. Rodegher¹, A. Ghezzi², G. Comi¹, A. Falini¹, M. Filippi¹

¹Milan, Italy, ²Gallarate, Italy

15.45 | TCLIN04

Safety and efficacy of percutaneous pulsed radiofrequency at the C1-C2 level in chronic cluster headache: a retrospective analysis of 21 cases

T. Kelderman, G. Vanschoenbeek, E. Crombez, K. Paemeleire

Ghent, Belgium

Monday 18 June
17.15 – 18.15

18

16.00 | TCLIN05

Has deep brain stimulation changed the natural history of Parkinson's disease? A case control longitudinal study

P. Mahlknecht¹, M. Peball¹, M. Werkmann¹, K. Mair¹, M. Nocker¹, W. Eisner¹, C. Peralta², S. Eschlböck¹, G.K. Wenning¹, P. Willeit¹, K. Seppi¹, W. Poewe¹

¹Innsbruck, Austria, ²Buenos Aires, Argentina

16.15 | TCLIN06

Neuromyelitis optica spectrum disorder and rituximab: a multi-center analysis

G. Novi¹, M. Capobianco², F. Gallo¹, G. Mataluni³, A. Signori¹, A. Laroni¹, P. Annovazzi⁴, F. Buttarì⁵, S. Rossi⁶, L. Zuliani⁷, F. Sica⁵, E. Cocco⁸, L. Benedetti¹, J. Frau⁹, S. Malucchi¹⁰, F. Sperli², M.P. Sormani¹

¹Genoa, Italy, ²Orbassano, Italy, ³Rome, Italy, ⁴Gallarate (VA), Italy, ⁵Pozzilli, Italy, ⁶Milan, Italy, ⁷Treviso, Italy, ⁸CAGLIARI, Italy, ⁹Cagliari, Italy, ¹⁰Orbassano (TO), Italy

17.15 – 18.15
Auditorium I

Peripheral nerve disorders 2

Chairpersons:

*Davide Pareyson (Milan, Italy)
Judith Molnar (Budapest, Hungary)*

17.15 | O309

Validity and reliability of the Transthyretin Amyloidosis Neuropathy Score (TTR-ANS): a new outcome measure designed specifically for Familial Amyloid Polyneuropathy (TTR-FAP)

C. Monteiro¹, C. Rodrigues², J. Fernandes², M. Cardoso², C. Alves², A. Martins Da Silva², T. Coelho²

¹La Jolla, USA, ²Porto, Portugal

17.30 | O308

Mutations in MME cause autosomal recessive late-onset CMT type-2 disease

M. Frasquet Carrera¹, A. Sánchez-Monteagudo¹, A.L. Pelayo-Negro², T. Garcia-Sobrinho³, J. Pardo Fernandez³, M. Misiego⁴, J. Garcia-Garcia⁵, M.-J. Sobrido³, M.J. Chumillas¹, J. Vázquez-Costa¹, C. Espinos¹, V. Lupo¹, T. Sevilla¹

¹Valencia, ²Santander, ³Santiago de Compostela, ⁴Torrelavega, ⁵Albacete, Spain

17.45 | O307

Peripheral neuropathy in the context of systemic vasculitis and other autoimmune diseases: the importance of etiologic characterisation

R. Rodrigues¹, M. Branco¹, M. Lopes¹, L. Fontao¹, H. Scigliano¹, R. Taipa², M. Melo Pires², C. Santos¹

¹Feira, ²Porto, Portugal

18.00 | O310

Statins and cryptogenic axonal polyneuropathy: a literature review and case-control study

J. Warendorf¹, A. Vrancken¹, N. Visser¹, N.C. Notermans²

¹Utrecht, ²Huizen, Netherlands

16.45 – 18.15
Auditorium VI

Cerebrovascular diseases 2

Chairpersons:

*Valeria Caso (Perugia, Italy)
José Ferro (Lissabon, Portugal)*

16.45 | O312

Direct oral anticoagulants versus Vitamin K antagonists after a recent ischaemic stroke: a pooled individual patient data analysis

D.J. Seiffge¹, M. Paciaroni², D. Wilson³, M. Koga⁴, K. Macha⁵, M. Cappellari⁶, S. Schaedelin¹, C. Shakeshaft³, M. Takagi⁴, B. Bonetti⁶, B. Kallmünzer⁶, P. Bovi⁶, S. Schwab⁵, G. Tsiougoulis⁷, P. Lyrer¹, K. Toyoda⁴, D. Werring³, V. Caso⁸, S. Engelter¹, G.M. de Marchis¹

¹Basel, Switzerland, ²Perugia, Italy, ³London, UK, ⁴Osaka, Japan, ⁵Erlangen, Germany, ⁶Verona, Italy, ⁷Athens, Greece, ⁸Perugia, Italy

17.00 | O313

Cerebrovascular lesions during normal aging: a neuropathological study with 7.0-tesla magnetic resonance imaging

J.L. de Reuck¹, F. Auger¹, N. Durieux¹, V. Deramecourt¹, C. Cordonnier¹, C. Maurage¹, F. Pasquier¹, D. Leys¹, R. Bordet¹

Lille, France

17.15 | O314

Correlates of pontine small vessel disease: a post-mortem study

R. Geraldes¹, M. Esiri¹, J. Palace¹, G. Deluca¹

Oxford, UK

17.30 | O316

Integrity of the circle of Willis as an important predictor of early catastrophic outcome after endovascular thrombectomy in middle cerebral artery occlusion stroke

A. Karamyian¹, C. Ramesmayer¹, M. Killer-Oberpfalzer¹, J. Mutzenbach¹, K. Millesi¹, C. Hecker¹, S. Pikiija¹

Salzburg, Austria

Oral sessions

Monday 18 June
17.15 – 18.30

17.45 | O311

Predicting intracerebral hemorrhage expansion with non-contrast CT: the BAT Score

A. Morotti¹, D. Dowlatshahi², G. Boulouis³, F. Al-Ajlan², A. Demchuk⁴, R. Aviv⁵, L. Yu⁶, K. Schwab⁶, J. Romero⁶, E. Guro⁶, A. Viswanathan⁶, C. Anderson⁶, Y. Chang⁶, S. Greenberg⁶, A. Qureshi⁷, J. Rosand⁶, J. Goldstein⁶

¹Pavia, Italy, ²Ottawa, Canada, ³Lille, France, ⁴Calgary, Canada, ⁵Toronto, Canada, ⁶Boston, USA, ⁷Minneapolis, USA

18.00 | O315

Atrial fibrillation in cryptogenic stroke: the Nordic Atrial Fibrillation and Stroke Study (NOR-FIB)

A. Tancin Lambert¹, X.Y. Kong², B. Ratajczak-Tretel¹, B. Halvorsen², D. Russell³, V. Bjerkeli², M. Skjelland², H. Næss³, E.C. Sandset², H. Ihle-Hansen², S.B. Krogseth⁴, H. Ihle-Hansen⁵, G. Hagberg⁵, K. Arntzen⁶, T.C. Truelsen⁷, K.L. Ægidius⁸, C. Kruuse⁹, G. Eldøen¹⁰, S. Rafiq¹⁰, H. Lerstad², M. Kurz¹¹, J. Sømmark¹², E. Schordan¹³, D. Atar², A.H. Aamodt²

¹Fredrikstad, ²Oslo, ³Bergen, ⁴Tønsberg, ⁵Bærum, ⁶Bodø, Norway, ⁷Copenhagen, ⁸Bispebjerg, ⁹Herlev, Denmark, ¹⁰Molde, ¹¹Stavanger, ¹²Lillehammer, Norway, ¹³Hunin-gue, France

17.15 – 18.30
Room Berlin

Motor neurone diseases

Chairpersons:

*Alberth Ludolph (Ulm, Germany)
Vitalie Lisnic (Chisinau, Moldova)*

17.15 | O317

AVXS-101 Phase-1 gene replacement therapy clinical trial in SMA type-1: continued event free survival and achievement of developmental milestones

S. Al-Zaidy¹, R. Shell¹, W. Arnold¹, L. Rodino-Klapac¹, T. Prior¹, L. Lowes¹, L. Alfano¹, K. Berry¹, K. Church¹, J. Kissel¹, S. Nagendran², J. L'italien², D. Sproule², C. Wells², A. Burghes¹, K. Foust², K. Meyer¹, S. Likhite¹, B. Kaspar², J.R. Mendell¹

¹Columbus, ²Bannockburn, USA

17.30 | O319

RNA-sequencing and motif analysis of Human Motor Neurons implicates selective role of SMN/SYNERIP complex and Motif 7 in Spinal Muscular Atrophy

L. Faravelli¹, M. Nizzardo¹, F. Rizzo¹, M. Taiana¹, U. Pozzoli², R. Del Bo¹, N. Bresolin¹, G.P. Comi¹, S. Corti¹

¹Milan, ²Bosisio Parini, Italy

17.45 | O318

Integrated miRNAs analysis of ALS iPSCs and iPSCs-derived motor neurons towards the development of a molecular therapy for ALS

D. Gagliardi¹, M. Rizzuti¹, M. Nizzardo¹, V. Melzi¹, G. Filosa¹, L. Dioni¹, L. Calandriello¹, N. Bresolin¹, G.P. Comi¹, S. Barabino¹, S. Corti¹

Milan, Italy

18.00 | O320

Structural connectivity alterations in Amyotrophic Lateral Sclerosis are modulated by the topology of the anatomical brain connectome

E.G. Spinelli¹, F. Agosta¹, S. Basaia¹, N. Riva¹, Y. Falzone¹, A. Chiò², A. Falini¹, G. Comi¹, M. Filippi¹

¹Milan, ²Turin, Italy

18.15 | O321

Amyotrophic Lateral Sclerosis (ALS) spatial epidemiology in the Mount Etna region, Italy: further evidences for a pathogenetic role of volcanogenic metals

R. Vasta¹, C. Rascunà², S. Lo Fermo², P. Volanti³, F. Patti², M. Ferrante², M. Zappia², F. Boumédienne⁴, A. Nicoletti²

¹Turin, ²Catania, ³Mistretta, Italy, ⁴Limoges, France

Monday 18 June
16.45 – 18.15

18

16.45 – 18.15

Room Amsterdam

Cognitive neurology/ neuropsychology

Chairperson:

Walter Paulus (Göttingen, Germany)

16.45 | O326

Assessment of auditory localisation in patients with disorders of consciousness

M. Carrière, H. Cassol, S. Wannez, A. Thibaut, C. Chatelle, G. Martens, S. Laureys, O. Gosseries

Liege, Belgium

17.00 | O325

Transcranial Direct Current Stimulation (tDCS) over lateral parietal cortex facilitates object-location and face-word associative memory

J. Bjekić, M. Čolić, M. Živanović, S. Milanović, S. Filipović

Belgrade, Serbia

17.15 | O324

Association between neuropsychiatric symptoms, cognitive functioning and structural brain changes in Clinically Isolated Syndrome (CIS)

E. Hynčicová, M. Vyhnaček, A. Kalina, T. Nikolai, L. Martinković, J. Lisý, J. Hort, E. Meluzinová, J. Laczó

Prague, Czech Republic

17.30 | O322

Locus coeruleus atrophy assessed with 3T MRI in typical and atypical Alzheimer's disease and correlations to neuropsychological data

P. Olivier¹, J. Lagarde¹, R. Valabrègue¹, M. Bottlaender², S. Lehericy¹, M. Sarazin¹

¹Paris, ²Orsay, France

17.45 | O323

Reduced dynamism of functional connectivity is associated with cognitive impairment in Multiple Sclerosis patients: a dynamic functional connectivity study in a multi-center setting

M.A. Rocca¹, A. D'ambrosio¹, P. Valsasina¹, A. Gallo², N. de Stefano³, D. Pareto⁴, F. Barkhof⁵, O. Ciccarelli⁶, C. Enzinger⁷, G. Tedeschi², M.L. Stromillo³, M.J. Arévalo⁴, H. Hulst⁵, N. Muhlert⁸, M. Koini⁷, M. Filippi¹

¹Milan, ²Naples, ³Sienna, Italy, ⁴Barcelona, Spain,

⁵Amsterdam, Netherlands, ⁶London, UK, ⁷Graz, Austria,

⁸Manchester, UK

18.00 | O327

Persistent allocentric navigation deficits indicate hippocampal damage in Transient Global Amnesia

A. Zvergal¹, F. Schöberl¹, S. Irving¹, C. Pradhan¹, S. Bardins¹, C. Trapp¹, E. Schneider², P. Bartenstein¹, M. Dieterich¹, T. Brandt¹

¹Munich, Germany, ²Senftenberg, Germany

16.45 – 18.15

Room Oslo

MS and related disorders 2

Chairpersons:

Ludwig Kappos (Basel, Switzerland)

Antonella Macerollo (London, UK)

16.45 | O329

Multiple Sclerosis Impact Scale and brain volume are independent predictors of cognitive impairment in Secondary Progressive Multiple Sclerosis

A. Doshi¹, F. de Angelis¹, N. Muhlert², J. Stutters¹, A. Eshaghi¹, F. Prados¹, D. Plantone¹, N. John¹, A. Calvi³, D. Macmanus⁴, S. Ourselin¹, S. Pavitt⁴, G. Giovannoni¹, R. Parker⁵, C.J. Weir⁶, N. Stallard⁶, C.P. Hawkins⁷, B. Sharrack⁸, P. Connick⁵, S. Chandran⁵, C.A. Gandini Wheeler-Kingshott¹, O. Ciccarelli¹, F. Barkhof⁹, J. Chataway¹

¹London, ²Manchester, UK, ³Milan, Italy, ⁴Leeds, ⁵Edinburgh, ⁶Coventry, ⁷Keele, ⁸Sheffield, UK, ⁹Amsterdam, Netherlands

17.00 | O331

Phase-2 multicenter study results of Ublituximab, a novel glycoengineered AntiCD20 monoclonal Antibody (mAb), in patients with Relapsing Multiple Sclerosis (RMS)

E.J. Fox¹, A. Lovett-Racke², M. Inglese³, R. Shubin⁴, C. Twyman⁵, J. Eubanks³, K. Mok³, W. Su³

¹Round Rock, ²Columbus, ³New York, ⁴Pasadena,

⁵Lexington, USA

17.15 | O328

Efficacy of Ozanimod versus Interferon beta-1a by DMT treatment experience and EDSS categorisation from a multicenter, randomised, double-blind, phase-3 study of relapsing Multiple Sclerosis

H.-P. Hartung¹, J.A. Cohen², G. Comi³, A. Bar-Or⁴, K.W. Selmaj⁵, D.L. Arnold⁶, L. Steinman⁷, X. Montalban⁸, E.K. Havrdova⁹, J.K. Sheffield¹⁰, V. Huang¹⁰, B.A.C. Cree¹¹, L. Kappos¹²

¹Düsseldorf, Germany, ²Cleveland, USA, ³Milan, Italy,

⁴Philadelphia, USA, ⁵Lodz, Poland, ⁶Montreal, Canada,

⁷Stanford, USA, ⁸Toronto, Canada, ⁹Prague, Czech

Republic, ¹⁰San Diego, USA, ¹¹San Francisco, USA, ¹²Basel,

Switzerland

Oral sessions

17.30 | O333

A neurometabolic profile of SPMS: the relationship between brain metabolites and clinical disability

N. John¹, B. Solanky¹, F. Deangelis¹, J. Stutters¹, F. Prados¹, D. Plantone¹, C. Tur¹, A. Doshi¹, A. Monteverdi², D. Macmanus¹, S. Ourselin¹, S. Pavitt³, G. Giovannoni¹, R. Parker⁴, C.J. Weir⁴, N. Stallard⁵, C.P. Hawkins⁶, B. Sharrack⁷, P. Connick⁴, S. Chandran⁴, C. Wheeler-Kingshott¹, F. Barkhof¹, J. Chataway¹

¹London, UK, ²Pavia, Italy, ³Leeds, ⁴Edinburgh, ⁵Coventry, ⁶Keele, ⁷Sheffield, UK

17.45 | O330

Siponimod affects disability progression in SPMS patients independent of relapse activity: results from the phase III EXPAND study

B. Cree¹, R. Fox², G. Giovannoni³, P. Vermersch⁴, A. Bar-Or⁵, R. Gold⁶, D. Tomic⁷, B. Magnusson⁷, N. Rouyrre⁷, D. Piani Meier⁷, G. Karlsson⁷, F. Dahlke⁷, L. Kappos⁷

¹San Francisco, ²Cleveland, USA, ³London, UK, ⁴Lille, France, ⁵PA, USA, ⁶Bochum, Germany, ⁷Basel, Switzerland

18.00 | O332

Measuring disease activity in Multiple Sclerosis: do we need spinal cord MRI?

S. Ruggieri, A. Logoteta, E. Tinelli, L. de Giglio, L. Prosperini, C. Gasperini, C. Pozzilli

Rome, Italy

 16.45 – 18.15
 Room Copenhagen

Sleep disorders

Chairperson:
Ulf Kallweit (Hagen, Germany)

16.45 | O337

Actigraphy ultradian and circadian rhythmicity in disorders of consciousness

A. Camargo, S. Blandiaux, A. Piarulli, O. Gosseries, S. Laureys

Liege, Belgium

17.00 | O334

Sleep microstructure in Parkinson's disease: Cycling Alternating Pattern (CAP) as a sensitive marker of early NREM sleep instability.

R. Cremascoli¹, L. Priano², M. Bigoni³, G. Albani⁴, L. Sellitti⁵, E. Giacomotti³, R. Picconi³, A. Mauro⁵

¹Pavia, ²Turin, ³Verbania, ⁴Piancavallo, ⁵Piancavallo di Oggebbio, Italy

17.15 | O338

Autoreactive T-cells in narcolepsy patients target multiple antigens of hypocretin-producing neurons

D. Latorre¹, U. Kallweit², E. Armentani¹, J. Mathis³, A. Lanzavecchia¹, R. Khatami⁴, M. Manconi⁵, M. Tafti⁶, C. Bassetti³, F. Sallusto¹

¹Bellinzona, Switzerland, ²Hagen, Germany, ³Berne, ⁴Barmelweid, ⁵Lugano, ⁶Lausanne, Switzerland

17.30 | O335

Reliability of a standardised test to document cataplexy to identify hypocretin deficiency

F. Pizza, S. Vandi, E. Antelmi, G. Plazzi

Bologna, Italy

17.45 | O339

Differential diagnosis in excessive daytime sleepiness based on sleep- and vigilance tests: a preliminary analysis of the Bern sleep database

J. Mathis, A. Mathis, D. Andres, W. Schmitt, C. Bassetti, D. Schreier

Berne, Switzerland

18.00 | O336

Effects of acute exposure to high altitude on RLS symptoms and PLMS: a bilateral study

A. Stefani¹, H. Hackner¹, T. Wildt¹, N. Seelose¹, E. Holzknecht¹, H. Gatterer¹, M. Faulhaber¹, M. Burtscher¹, J. Ulfberg², B. Högl¹

¹Innsbruck, Austria, ²Hannplan, Örebro, Sweden

13th European Congress on Epileptology

ILAE International League
Against Epilepsy

ILAE-CEA


Vienna 

August 26-30

2018

www.epilepsyvienna2018.org

EMJ EUROPEAN MEDICAL JOURNAL



The free, open-access publication.


[Q EUROPEANMEDICAL-JOURNAL.COM](http://EUROPEANMEDICAL-JOURNAL.COM)

EMJ delivers quality, peer-reviewed, open-access eJournals covering a range of therapeutic areas. Perfect for healthcare professionals to read and share.

❖ **Visit stand C34 to subscribe for free!** ❖

Get all EMJ content straight to your inbox
and never miss an update again!





24th Meeting of the European Society of Neurosonology and Cerebral Hemodynamics

Joint Meeting with
Neurosonology Research Group

History Meets Future
Linz, Austria
5-7 April, 2019
www.esnch.org

**SAVE THE
DATE!**



We invite you to the 23rd annual congress of the World Muscle Society, the premier congress on neuromuscular disorders, attended by established and young physicians, researchers, therapists, and neuropathologists from all over the world

wms2018.com

**26th Annual Meeting
of the European
Charcot Foundation**

**The role of long-term
clinical studies in
defining DMTs' profile**

**15 - 17
November 2018**

**Grand Hotel Dino
Baveno, Italy**



**European
Charcot
Foundation**

www.charcot-ms.org



Attend the 26th Annual Meeting and...

- get up-to-date about the latest developments in the field of MS research and clinical practice
- actively participate in scientific debates
- get engaged in qualitative discussions with researchers, clinical practitioners and young investigators

To join the live stream or watch the live stream recordings of the 26th Annual Meeting, subscribe to ECF eLearning.

Early Bird Registration deadline: 31 July 2018

To register or for more information about the 26th Annual Meeting:
www.charcot-annual-meeting.org/26thannualmeeting

Tuesday
19 June 2018

19

08:00 – 10:00
Auditorium I

Symposium 7: A new look in neuropathogenesis of Multiple Sclerosis

Chairpersons:

Ralf Gold (Bochum, Germany)
Maria Troiano (Bari, Italy)

- Role of environmental factors for MS
Ralf Gold (Bochum, Germany)
- Role of B-cells in different types of MS
Xavier Montalban (Barcelona, Spain)
- Challenges for modern MS therapy on back-ground of pathogenesis
Luca Massacesi (Florence, Italy)
- The contribution of MRI for better understanding of MS
Declan Chard (London, UK)

Scientific content:

Progress in understanding the pathogenesis of MS includes epidemiological studies, influences of lifestyle and nutrition, development of novel MRI techniques and approval of new MS treatments. This is critically needed in view of the growing number of autoimmune diseases of the central nervous system in industrialised countries. Our proposed symposium aims at giving an integrated view of all these aspects. There is now solid scientific data on the influence of salt intake, dietary fatty acids and obesity, smoking, and UV light-exposure and their impact on the immune system. Novel immune players have entered the scenario: especially the function of B lymphocytes in relapsing and progressive MS, and in turn the therapeutic effects associated with B-cell depletion by monoclonal antibodies shed new light on this immune cell population. In view of the growing armamentarium of MS therapies we are better prepared to offer individualised treatment in relapsing MS. The point is whether we start early enough to avoid chronification of the immune response and still can recognise key factors. In addition, novel risks of highly active immunotherapies must be recognized. All this neces-

sitates non-invasive monitoring of treatment success, and new MRI approaches to detect cortical lesions, damage to myelin sheath and axonal integrity. Also, the contribution of high-Tesla field imaging to differentiation of MS lesions will be covered.

08:00 – 10:00
Auditorium VI

Symposium 8: Advances in molecular characterisation and personalised therapies in brain tumors

Chairpersons:

Riccardo Soffietti (Torino, Italy)
Stefan Oberndorfer (St. Pölten, Austria)

- Targeting the immune cells or the glial cells in glioblastoma: the new question
Michael Weller (Zurich, Switzerland)
- Subependymal giant cell astrocytoma (SEGA): a model of targeting tumor growth and seizures
François Ducray (Lyon, France)
- Specific inhibitors of molecular pathways in brain metastases: from improved response to improved survival
Riccardo Soffietti (Turin, Italy)
- New molecular subtypes of medulloblastomas and ependymomas: different outcome and treatment options
Stefan Pfister (Heidelberg, Germany)

Scientific content:

The Symposium will provide an overview and update about the recent advances in molecular biology of different types of brain tumors, that have led to innovative treatments either in clinical trials or daily clinical practice. M. Weller will present the new avenues of research in terms of immunotherapies and molecular treatments in glioblastoma. F. Ducray will discuss the possibility to target both seizures and tumor growth in SEGAs. R. Soffietti will report the improvement of prognosis following targeted therapies in

molecular subgroups of brain metastases from melanoma, breast and non-small cell lung cancer.

S. Pfister will describe the new molecular classifications of medulloblastomas and ependymomas, and the molecular pathways that are now druggable.

08:30 – 10:00
Room Berlin

Interactive Session 8: Is it a vasculitis or not?

Chairperson:

Peter Berlit (Essen, Germany)

- CNS- and PNS-manifestations of possible angiitis (case presentations)
Peter Berlit (Essen, Germany)

Educational content:

The clinical presentations include polyneuropathy, spinal cord disease, brain tumour, epilepsy and stroke. The necessary investigations (e.g. imaging, neurophysiology, CSF, biopsy), possible differential diagnoses and management will be discussed. In a step-to-step approach during each case presentation, several single best answer questions with up to 5 possible answers will be presented and answered by the audience. At the end of the session, attendees should know about the best approach to the diagnosis of vasculitis, important differential diagnoses, and the management of systemic vasculitides and primary CNS-angiitis.

Please download the app "EAN Congress" to actively participate in this Session and vote.

Tuesday 19 June
08.30 – 10.00

19

08:30 – 10:00
Room CbW

Case-based Workshop 9: Imaging selection of stroke patients for specific treatment interventions

Chairperson:

Christian Enzinger (Graz, Austria)

- **Concept: how to identify “salvageable” brain tissue**
Jean-Claude Baron (Cambridge, UK / Paris, France)
- **Morphologic criteria and perfusion**
Christian Enzinger (Graz, Austria)
- **Vessel occlusion and collaterals**
Marc Ribo (Barcelona, Spain)

Educational content:

Following the format of this interactive workshop, individual cases presented by experts will be used to demonstrate evidence-based approaches to select stroke patients faced in everyday care for specific treatment interventions, with a particular focus on imaging criteria. This workshop should allow attendants to appreciate the increasing knowledge-based concerning an extension of the time-window for interventions of selected patients fulfilling stringent criteria resting on information derived from neuroimaging, while also emphasizing to remain vigilant to deliver “standard” approaches to patients with stroke within accepted windows of treatment.

Limited to 60 participants. Please register separately – additional fees will apply.

08:30 – 10:00
Auditorium VIII

Career development Session 3: Drug development and clinical trials in neurology

Chairperson:

Marie Trad (Paris, France)

- **Introduction to drug development: Early stage development**
Isabelle Clavier (Paris, France)
- **Implementing pivotal clinical trials in Neurology**
Marie Trad (Paris, France)
- **Interpreting clinical trials results**
Kerry Gordon (Reading, UK)

Educational content:

This session will focus on the process of drug development in Neurology. Its objectives are: education for young neurologists' career development, train young clinical trial investigators on factors contributing to successful implementation and execution of clinical trials in neurology, as well as understanding study designs and clinical trials results interpretation.

08:30 – 10:00
Room Lisbon

Special Session 11: Population, migration and neurological disorders

Chairperson:

Antonio Federico (Siena, Italy)

- **Migration as a reality of today**
Antonio Federico (Siena, Italy)
- **Changing risk factor profile and migration. Health indicators – who cares?**
Serefnur Öztürk (Konya, Turkey)
- **Neurologic infections in immigrants**
Mostafa El Alaoui Faris (Rabat, Morocco)

Session content:

To increase awareness for effects of migration on neuroepidemiology, generalisation of regional special neurological diseases, negative effects on health care systems, specially effected groups (women, children, elderly)

10:30 – 12:30
Auditorium I



Plenary Symposium: Highlights and Breaking News

Chairpersons:

Joaquim Ferreira (Lisbon, Portugal)
Günther Deuschl (Kiel, Germany)
Paul Boon (Ghent, Belgium)

- Neuromuscular and neurophysiology
Mamede de Carvalho
- Stroke
Patricia Canhao
- Headache
Isabel Pavao Martins
- Multiple Sclerosis
João Cerqueira
- Dementia and cognition
Alexandre Mendonça
- Movement disorders
Miguel Coelho

Breaking News from Lancet Neurology

- Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled trial
Albert Ludolph (Ulm, Germany)
- Cognitive behavioural therapy with optional graded exercise therapy in severely fatigued patients with myotonic dystrophy type 1: a single-blind randomised trial
Baziel van Engelen (Nijmegen, The Netherlands)

After the presentation of the Congress Highlights, the winners of the Tournament for neurologists in training will be announced and receive their certificates.

Good-bye words & Presentation EAN 2019
Oslo

13:00 – 14:30
Room CbW

Case-based Workshop 8: Challenging cases of the infections of the nervous system

Chairperson:

Israel Steiner (Petach Tikvah, Israel)

- Chronic meningitis
Diederik van de Beek (Amsterdam, The Netherlands)
- Chronic encephalitis
Israel Steiner (Petach Tikvah, Israel)
- Space taking focal infection
Bettina Pfausler (Innsbruck, Austria)

Educational content:

Chronic meningoencephalitis is defined as an inflammation of the brain parenchyma and meninges of subacute onset and persisting evidence for an inflammatory process lasting more than one month. Chronic meningitis and encephalitis can be due to infectious and inflammatory causes. Diagnosis of the cause of this condition is of paramount importance in order to provide effective therapy that in many cases can lead to full recovery. The wide range of different etiologies renders the approach to patients with chronic encephalitis particularly difficult. Taking an in-depth history combined with a complete physical examination is mandatory in every patient. This should be followed by thorough analysis of the CSF, a systemic workup and in difficult and challenging cases also brain biopsy. This course aims to present the current knowledge on etiology, neurological course of disease, diagnostic and therapeutic management steps of patients presenting with clinical signs and symptoms of chronic meningoencephalitis.

Limited to 60 participants. Please register separately – additional fees will apply.

13:00 – 14:30
Auditorium VIII

Controversy 2: Controversies in the diagnosis of Alzheimer's disease & in the treatment of Multiple Sclerosis

Chairpersons:

Giancarlo Comi (Milan, Italy)
Jonathan M. Schott (London, UK)

- Induction is the key strategy in MS treatment
Eva Havrdova (Prague, Czech Republic)
- Induction is not the key strategy in MS treatment
Aksel Siva (Istanbul, Turkey)
- This house believes that all patients diagnosed with young onset dementia should be offered genetic testing – PRO
James Rowe (Cambridge, UK)
- This house believes that all patients diagnosed with young onset dementia should be offered genetic testing – AGAINST
Massimo Musicco (Milan, Italy)

Educational content:

Part 1:

The main objective of the topic for controversies in MS is how to decide which treatment should be started in naïve MS patients. The two opposing views on induction will be discussed by each speaker and the rationale for the initiation of more effective treatments.

Part 2:

Advances in genetics mean that it is now easy to screen for multiple mutations that can cause dementia. There is however marked variability in the uptake of genetic testing across different centres and between different countries, and opinion is divided as to when and to whom these tests should be offered. A robust debate will ensure that attendees are aware of the relevant issues including: which genetic tests are available, how genetic testing should be undertaken, the likelihood of

Tuesday 19 June
13.00 – 16.30

19

finding a genetic cause, and the potential benefits of establishing a definite diagnosis; as well as the potential disadvantages including the burden of knowledge on individuals and family members who may find themselves at risk, the costs, and the ethics of testing for conditions for which there are currently no disease modifying treatments.

13:00 – 14:30
Auditorium I



Interactive Session 7: EAN/ MDS-ES: Mixed movement disorders: what do we see and how do we approach

Chairperson:

*Marina de Koning-Tijssen
(Groningen, The Netherlands)*

- **Hypokinetic movement disorders; mixed movement disorders plus parkinsonism**
Dan Healy (Dublin, Ireland)
- **Mixed Hyperkinetic movement disorders: dystonia plus chorea, dystonia plus paroxysmal disorders, dystonia plus myoclonus**
Mark Edwards (London, UK)
- **Movement disorders plus ataxia**
*Marina de Koning-Tijssen
(Groningen, The Netherlands)*

Educational content:

This interactive session is focused on mixed movement disorders and how we do approach them in clinical practice. For clinicians encountering a patient with a movement disorder there are three main practical questions: what do we see (phenotype), what is the cause (etiology) and what is the optimal treatment? Assessing the phenotype is a crucial first step. Many disorders have a 'core' movement disorder such as parkinsonism, chorea, dystonia or ataxia. However, many patients in addition to their 'core' movement disorder also reveal pronounced comorbid features, such as other concurrent movement disorders, spasticity, myopathy, neuropathy, epilepsy, cognitive or

behavioral impairment. The often-complex heterogeneity of disease presentations and etiologies require clinical tools to recognise and categorise the disorder to subsequently focus on diagnostic and treatment strategies.

Three experts in the field will present cases with mixed movement disorders and discuss these patients interactively with the audience by using a digital (wireless) voting app. The first part will be focused on hypokinetic movement disorders; mixed movement disorders plus parkinsonism and presented by Dan Healy, from Dublin, Ireland. The second part focusses on mixed hyperkinetic movement disorders with a focus on dystonia: it will include cases with dystonia plus chorea, plus paroxysmal disorders, and plus myoclonus. The hyperkinetic cases will be discussed by Mark Edwards, London, UK. The final part is on movement disorders plus ataxia and cases will be presented by Marina de Koning-Tijssen, Groningen, the Netherlands. The focus of the sessions is on phenotyping and to improve clinical diagnosis and management in mixed movement disorders patients

Please download the app "EAN Congress" to actively participate in this Session and vote.

13:00 – 16:30
Auditorium VI

Teaching Course 15: The "difficult to treat" headache patient - Level 3

Chairperson:

Stefan Evers (Münster, Germany)

- **Migraine treatment beyond guidelines**
Stefan Evers (Münster, Germany)
- **Neuromodulation in clinical practice**
Jan Hoffmann (Hamburg, Germany)
- **Unconventional treatments of cluster headache**
Peter J. Goadsby (London, UK)
- **Refractory trigeminal neuralgia**
Giorgio Cruccu (Rome, Italy)

Educational content:

Participants will be learning how to treat patients not responding to treatment according to guidelines; including the use of unconventional treatments and not approved evidence-based treatment.

13:00 – 16:30
Auditorium II

Teaching Course 16: Autoantibodies in neurological disorders - Level 2

Chairperson:

Romana Höftberger (Vienna, Austria)

- What the neurologist needs to know in choosing the right assay for autoantibody testing
Romana Höftberger (Vienna, Austria)
- Demyelination: what is new in neuromyelitis spectrum disorder (NMOSD) and the value of myelin oligodendrocyte glycoprotein (MOG) antibodies
Jacqueline Palace (Oxford, UK)
- Autoimmune encephalitis
Maarten J. Titulaer (Rotterdam, The Netherlands)
- What's new in myasthenia gravis?
Amelia Evoli (Rome, Italy)

Educational content:

In this TC, the speakers will prove practical relevant knowledge on autoantibody testing in neurological disorders. They will discuss the clinical phenotypes, suggested treatments and discuss the newest developments in this rapidly advancing field of neurology. They will provide tricks to recognise these diseases and share pitfalls to avoid misdiagnosis. In addition, the attendant will learn how these diseases can be relevant to other disciplines within clinical neurology and basic neurosciences.

13:00 – 16:30
Room Amsterdam

Teaching Course 17: Advanced Neurosonology - Level 3

Chairperson:

Fabienne Perren (Geneva, Switzerland)

- Transcranial Doppler versus transoesophageal echocardiography for the detection of patent foramen ovale
Georgios Tsiygoulis (Athens, Greece)
- Application and benefits of transorbital sonography in neurological disorders
Christos Krogias (Bochum, Germany)
- High frequency versus low frequency transcranial ultrasound for sonothrombolysis
Fabienne Perren (Geneva, Switzerland)
- Brain parenchymal sonography in movement disorder: a practical clinical tool or theoretical research
João Sargento Freitas (Coimbra, Portugal)

Educational content:

Low cost, avoidance of irradiation, and high temporal resolution are inherent advantages of ultrasound imaging that translate into multiple clinical uses in many domains of neurology. This teaching course will aim to highlight clinical uses of ultrasound examination in cerebrovascular, neurodegenerative, and neuro-orbital diseases. In particular, modern treatment and prevention of ischemic stroke rely on prompt diagnosis. Ultrasonography has found a place as a noninvasive screening test and bedside technique that provides estimates of the degree of patent foramen ovale. Improvement in image quality permits novel uses of ultrasonography in neurodegenerative and transorbital system disorders, providing clinically important information that is complementary to the clinical examination and neuroimaging. Transcranial parenchymal sonography may assist in the differential diagnosis of movement disorders, while transorbital sonography ultrasound may

provide structural information regarding the underlying etiology of optic nerve and transorbital diseases. In conclusion, the proposed teaching course will highlight the rapidly expanding indications of neurosonology that increase its applicability on a wide spectrum of neurological disorders. This course is organised on behalf of the ESNCH.

13:00 – 16:30
Auditorium III

Teaching Course 18: Basics of sleep medicine - Level 1

Chairperson:

Rolf Fronczek (Leiden, The Netherlands)

- Normal sleep mechanisms & why do we sleep?
Rolf Fronczek (Leiden, The Netherlands)
- Diagnostics & methods – sleep investigations and pitfalls
Ulf Kallweit (Hagen, Germany)
- Primary sleep disorders – symptoms, diagnosis & treatment
Poul Jørgen Jennum (Copenhagen, Denmark)
- Sleep in neurological disorders
Guiseppe Plazzi (Bologna, Italy)

Educational content:

Neurological sleep disorders are common. More than 90% of these are either primary neurological disorders or secondary to other neurological disorders. Hence, pathology of the sleeping brain - sleep medicine - is a vital part of neurology training. This teaching course will cover the basics of sleep medicine and sleep-wake-disorders in neurology.

First, we will take a closer look at the sleep questions from the previous EAN exam.

- Dr. Fronczek will cover the basic mechanisms of physiological sleep with a focus on neuroanatomy and sleep staging, and give an update about our current knowledge about why we need to sleep.

Tuesday 19 June
13.00 – 16.30

19

- Dr. Kallweit will give an overview about the methods to diagnose sleep disorders (questionnaires, polysomnography, multiple sleep latency test (MSLT), maintenance of wakefulness test (MWT), actigraphy, vigilance tests and biomarkers). Furthermore, diagnostic pitfalls will be discussed, such as the most common mistakes, false-positive MSLT's and interpretation of the MWT. The evaluation of excessive daytime sleepiness versus fatigue and decreased vigilance will be covered.

- Dr. Jennum will give a broad overview of the different neurological primary sleep disorders (pathophysiology, clinical symptoms, diagnosis & treatment + video's), including REM parasomnias (primary REM-sleep behavior disorder, RBD), NREM parasomnias (pavor nocturnus, sleep walking), narcolepsy type 1 + 2, idiopathic hypersomnia, the Kleine Levin Syndrome, obstructive sleep apnea syndrome (OSAS)/central apneas, restless legs syndrome and periodic limb movements disorder.

- To conclude, Dr. Plazzi will discuss sleep and wake problems secondary to other neurological disorders (M. Parkinson, M. Alzheimer, M. Huntington, paraneoplastic disorders, Multiple Sclerosis/neuromyelitis optica and traumatic brain injury).

After this, the sleep questions from the EAN exam will be revisited, to hopefully observe a marked improvement in scores.



ISNI 2018
14th International Congress of Neuroimmunology
2nd GSNI Course - Global Schools of Neuroimmunology ESNI - ASNI - APSNI
AUGUST 27TH - 31ST, 2018 | BRISBANE - AUSTRALIA

TOURISM
& EVENTS
Queensland



Oral sessions

08.30 – 10.00
 Room Amsterdam

Headache and pain

Chairpersons:

Raquel Santos Gil Gouveia (Lisbon, Portugal)
Elena Lebedeva (Yekaterinburg, Russia)

08.30 | O405

Phase-3 study (SPARTAN) of Lasmiditan compared to placebo for acute treatment of migraine

L.A. Wietecha, B. Kuca, M.G. Case, K.J. Selzler, S.K. Aurora

Indianapolis, USA

08.45 | O406

Field testing the diagnostic criteria for headache attributed to Transient Ischaemic Attacks

E.R. Lebedeva¹, N.M. Gurary¹, J. Olesen²

¹Yekaterinburg, Russian Federation, ²Copenhagen, Denmark

09.00 | O403

Identifying natural subgroups of migraine-based on profiles of comorbidities and concomitant conditions: results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study

R. Lipton¹, K. Fanning², D. Buse¹, V.T. Martin³, M. Reed², A. Manack Adams⁴, P.J. Goadsby⁵

¹New York, ²Chapel Hill, ³Cincinnati, ⁴Irvine, USA,

⁵London, UK

09.15 | O402

Increased preictal beta-ERD-response of primary sensorimotor cortex during brief hand movements with sensory stimulation in migraine

M.S. Mykland¹, M.H. Bjørk², M. Stjern¹, T. Sand¹

¹Trondheim, ²Bergen, Norway

09.30 | O401

Cluster Headache is more than the extreme pain attack: a prospective diary study of 500 Cluster Headache attacks

A. Snoer¹, N. Lund¹, A. Hagedorn¹, R. Jensen², M. Barloese²

¹Glostrup, ²Copenhagen, Denmark

09.45 | O404

The long-term efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine in patients with medication overuse: results of the COMPEL study

S. Tepper¹, M.-C. Wilson², A. Orejudos³, A. Manack Adams³, A. Blumenfeld⁴

¹Hanover, ²Covington, ³Irvine, ⁴Carlsbad, USA

08.30 – 09.45
 Room Oslo

Miscellaneous 2

Chairpersons:

Erich Schmutzhard (Innsbruck, Austria)
Alexandre Bisdorff
(Esch-sur-Alzette, Luxembourg)

08.30 | O408

Early hemodynamic profile in tilt-induced vasovagal syncope

M. Gharig¹, D.P. Saal², F.I. Kerkhof¹, R.H. Reijntjes¹, R.D. Thijs¹, J.G. van Dijk¹

¹Leiden, ²Rotterdam, Netherlands

08.45 | O407

Reduced pupillary modulation in patients with relapsing-remitting Multiple Sclerosis is associated with longer disease duration and higher disease severity

R. Wang¹, S. Roy¹, C. de Rojas Leal¹, M. Liu¹, K. Hösl², D.-H. Lee¹, R.A. Linker¹, M.J. Hilz¹

¹Erlangen, ²Nuremberg, Germany

09.00 | O409

'JUMP', an innovative trans-pathology transitional care program for young adults with chronic neurological disease

E. Mc Govern, B. Marine, E. Manzato, F. Mochel, C. Guillonnet, B. Michel, E. Flamand-Roze, E. Maillart

Paris, France

09.15 | O410

Characterisation of a Listeria monocytogenes meningitis mouse model

M. Koopmans, J. Lee, M. Brouwer, W.K. Man, M. Valls Seron, D. van de Beek

Amsterdam, Netherlands

09.30 | O411

Cerebral lesion localisation in patients with acute pure vestibular and ocular motor strokes: results from the prospective EMVERT trial

A. Zwergal, K. Möhwald, E. Salazar-Lopez, H. Hadzhikolev, T. Brandt, M. Dieterich, K. Jahn

Munich, Germany

Tuesday 19 June
08.30 – 10.00

19

08.30 – 10.00
Auditorium III

Muscle and neuromuscular junction disease

Chairpersons:

Tiziana Mongini (Turin, Italy)

Theodoros Kyriakides (Nicosia, Cyprus)

08.30 | O412

Molecular mechanisms of mitochondrial DNA disease: pathological and genetic studies in patients with Mendelian disorders of mtDNA maintenance
D. Lehmann¹, A.E. Vincent², H. Rosa², M. Rocha², S. Zierz³, R.W. Taylor², D.M. Turnbull²

¹Ulm, Germany, ²Newcastle upon Tyne, UK, ³Halle, Germany

08.45 | O414

Quantifying muscle amyloid content in inclusion body myositis using [18F] florbetapir positron emission tomography
J. Lilleker¹, R. Hodgson², M.E. Roberts¹, K. Herholz², J. Howard², R. Hinz², H. Chinoy²

¹Salford, UK, ²Manchester, UK

09.00 | O415

Cardiorespiratory function in Duchenne Muscular Dystrophy in a UK large tertiary care centre: longitudinal progression and the role of steroid treatment

J. Domingos¹, C.G. Tay², K. Maresh¹, D. Ridout¹, P. Munot¹, A. Sarkozy¹, S. Robb¹, R. Quinlivan¹, M. Riley¹, M. Burch¹, M. Fenton¹, C. Wallis¹, E. Chan¹, F. Abel¹, A. Manzur¹, F. Muntoni¹

¹London, UK, ²Malaya, Malaysia

09.15 | O417

Statin-induced myopathies: beyond immuno-mediated necrotising myopathies
M.M.N. Muelas, Y. Pamblanco, I. Azorin, P. Marti, C. Gomis, F. Mayordomo, R. Vilchez, L. Gomez, J. Poyatos, J.J. Vilchez
Valencia, Spain

09.30 | O413

A phase 1/2 Golodirsén trial developed by the SKIP-NMD consortium to identify potential treatments for Duchenne Muscular Dystrophy: study design and patient characteristics

F. Muntoni¹, V. Straub², D. Frank³, A.M. Seferian⁴, G. Dickson⁵, M. Guglieri², J. Domingos¹, L. Servais⁴, E. Mercuri⁶, S.-N. Study Group³

¹London, ²Newcastle upon Tyne, UK, ³Cambridge, USA, ⁴Paris, France, ⁵Surrey, UK, ⁶Rome, Italy

09.45 | O416

Vacuolated PAS-positive lymphocytes as screening tool and a possible therapeutic biomarker in late-onset Pompe disease (LOPD)

O. Musumeci¹, D. Parisi¹, S. Mondello¹, T. Brizzi¹, V. Mosca¹, A. Migliorato¹, A. Ciranni¹, T. Mongini², C. Rodolico¹, G. Vita¹, A. Toscano¹

¹Messina, ²Turin, Italy

08.30 – 10.00
Room Copenhagen

Movement disorders 2

Chairpersons:

Pille Taba (Tartu, Estonia)

Joaquim Ferreira (Lisbon Portugal)

08.30 | O420

Generation and characterisation of iPSC-derived oligodendrocytes of patients with Multiple System Atrophy
E. Abati, G. Monzio Compagnoni, N. Bresolin, G.P. Comi, S. Corti, A. Di Fonzo
Milan, Italy

08.45 | O421

Spastic-ataxia in a Portuguese cohort of hereditary ataxias
J. Damásio, I. Alonso, C. Barbot, A.F. Brandão, A. Sardoeira, S. Pina, P. Coutinho, J. Barros, J. Sequeiros
Porto, Portugal

09.00 | O419

The Nocebo effect in Parkinson's disease
M. Leal Rato¹, G. Duarte², A. Ferreira², T. Teodoro², T. Mestre³, J. Costa², J. Ferreira²

¹Amadora, ²Lisbon, Portugal, ³Ottawa, Canada

09.15 | O418

Non-invasive intervention for motor signs of Parkinson's disease: the effect of vibratory stimuli

A. Macerollo¹, D. Cletheroe², J. Vega Hernandez³, J. Moody², G. Saul², N. Villar², P. Korlipara¹, T. Foltynie¹, P. Limousin¹, H. Zhang¹, J. Kilner¹

¹London, ²Cambridge, ³Manchester, UK

09.30 | O422

Evaluation of gait and posture in essential tremor before and after unilateral Gamma Knife Thalamotomy
E. Boutin, J.-P. Azulay, A. Eusebio, R. Carron, J. Regis, T. Witjas, M. Vaugoyeau
Marseilles, France

09.45 | O423

Functional brain connectome architecture in a large cohort of Parkinson's disease patients
S. Basaia¹, F. Agosta¹, H. Zahedmanesh¹, T. Stojkovic², V. Markovic², I. Stankovic², I. Petrovic², E. Stefanova², V.S. Kostic², M. Filippi¹

¹Milan, Italy, ²Belgrade, Serbia



Save the date!

CONSORTIUM OF MULTIPLE SCLEROSIS CENTERS 2019 Annual Meeting

Seattle, Washington
May 29 - June 1

WWW.MSCARE.ORG



Save the Date

Mechanisms, Clinical Strategies,
and Promising Treatments of
Neurodegenerative Diseases

AD/PD™ 2019

The 14th International Conference on
Alzheimer's & Parkinson's Diseases

March 26-31, 2019 | Lisbon, Portugal

ORGANIZING COMMITTEE



- Abraham Fisher, Israel, President
- Roger M. Nitsch, Switzerland, Executive Organizer
- Manfred Windisch, Austria, Executive Organizer



5 Highlights You Should Not Miss at AD/PD™

- Expert Plenary Speakers
- Junior Faculty Awards
- Forum Discussions
- Nobel Prize Laureates
- Beautiful Lisbon



  #ADPD2019

adpd.kenes.com



EUROPEAN STROKE
ORGANISATION

via the following social media platforms



...and through our **ESO Blog**



Stay connected through different channels be part of the online community to share information, ideas, personal messages and other content

- Join the discussion
- Receive the latest news
- Stay informed with all news and updates in stroke

www.eso-stroke.org



Journal of Neurology, Neurosurgery & Psychiatry

JNNP is a leader in the field, publishing ground-breaking and cutting-edge neurological sciences research from around the world.

Why read?

- **Access multidisciplinary content;** as a subscriber to **JNNP**, you will also have access to **Practical Neurology (PN)** and the **Journal of NeuroInterventional Surgery (JNIS)**
- **Keep up to speed** with cutting-edge international research that has a clinical focus
- **Save time and digest information in a way that suits you** with our multimedia content, including regular podcasts, blogs and social channels
- **Access an immense archive collection**
- **JNNP has the longest half-life** of any journal in clinical neuroscience



BMJ

Join our online communities:

 @JNNP_BMJ  /JNNP.BMJ

Find out more
jnnp.bmj.com

Industry Sponsored

Programme



Acknowledgements

We wish to express our gratitude to the following companies and organisations who contributed to the success at EAN 2018.

Premium Sponsors



Major Sponsors



Sponsors



Contributors



Exhibitors

NAME	Booth Number	NAME	Booth Number
AbbVie, Inc.	A18	European Society of Neurosonology and Cerebral Hemodynamics (ESNCH)	C46
Actelion Pharmaceuticals Ltd	B25	EVER Pharma	A15
Aequus Research	B30	F. Hoffmann-La Roche Ltd.	A06, A08
African Academy of Neurology	B09	French Society of Neurology - SFN	C05
Akcea Therapeutics	B21	Glut1 Deficiency Foundation	B07
Alexion	B15	ILAE-IBE Epilepsy Congress	B03
Alnylam Pharmaceuticals	A12	Impeto Medical	B24
American Academy of Neurology	C10	International Congress on Neuromuscular Diseases (ICNMD)	C36
Asper Biogene	C24	International Neuro-Urology Society (INUS)	C31
Bial	A11	International Parkinson and Movement Disorder Society (MDS)	B08
Biogen	A04	Journal of Medicine and Life	C07
BioMarin	B01	Karger Publishers	C04
Biomax Informatics	C09	Lilly	B20
Boston Scientific	C08	MedDay Pharmaceuticals	B16
British Medical Journal	B23	Merck	A07
Cefaly	B42	Natus Neuro	B19
CeGaT GmbH	B14	Neuro-Compass	A16
Celgene	A05	Norwegian Neurological Association	C32
CNS- Campus Neurológico	C40	Novartis Pharma AG	A01, A03
CSL Behring	A14	Pfizer Ltd	B40
DEYMED Diagnostic	B18	Pharnext	B10
Dystonia Europé	C02	Quanterix	C20
ECTRIMS	B06	Sanofi Genzyme	A02
EPILOG	C30	Teva Pharmaceuticals Industries Ltd.	A09
European Brain Council	C35	Wiley	B26
European Charcot Foundation	C01	Wilson Therapeutics	B11
European Federation of Autonomic Societies (EFAS)	C36	Wisepress Medical Bookshop	C21
European Federation of Neurological Associations (EFNA)	B12	Wolters Kluwer	C03
European Huntington's Disease Network	C37	World Federation of Neurology (WFN)	C06
European Medical Group	C34	Zambon SpA	A10
European Pain Federation (EFIC)	B04		

Exhibition Floorplan



- Exhibition
- Booth
- ☕ Coffee
- 🍴 Lunch
- @ Internet Corner



Redefining the management of relapsing multiple sclerosis and primary progressive multiple sclerosis

Satellite Symposium at the 4th EAN Congress

Saturday 16 June 2018

13:00–14:30

Auditorium VI, Lisbon Congress Centre

- 13:00–13:15 **Welcome and introduction**
Gavin Giovannoni (Chair)
- 13:15–13:30 **Suppressing disease activity and progression in relapsing multiple sclerosis and primary progressive multiple sclerosis**
Gavin Giovannoni
- 13:30–13:50 **Ocrelizumab safety across relapsing multiple sclerosis and primary progressive multiple sclerosis**
Ralf Gold
- 13:50–14:25 **Incorporating ocrelizumab into clinical practice**
Aaron Boster
- 14:25–14:30 **Q&A and close**
All faculty



MERCK EVENTS AT THE 4TH EAN CONGRESS

Lisbon, 16–19 June 2018

SATELLITE SYMPOSIUM

Auditorium VI, Lisboa Congress
Centre (CCL), Lisbon, Portugal

Foundation and innovation in MS treatment – avoiding continuous immunosuppression

18:30–20:00 • Sunday, 17 June 2018

Chair: **Jiwon Oh**

**João Cerqueira
Bassem Yamout
Raymond Hupperts**

SCIENTIFIC THEATRE FORUM PROGRAMME

Scientific Theatre, Hall 1, Lisboa
Congress Centre (CCL), Lisbon,
Portugal

Selective Immune Reconstitution Therapy in the MS treatment paradigm

10:15–10:30 • Saturday, 16 June 2018

By **Gavin Giovannoni**

Cladribine Tablets in clinical practice: switching from platform therapies

09:45–10:00 • Sunday, 17 June 2018

By **Klaus Schmierer**

Cladribine Tablets in clinical practice: initiating treatment in newly diagnosed patients

09:45–10:00 • Monday, 18 June 2018

By **Thomas Müller**



Visit us at
the Merck
booth A07



Novartis: committed to neuroscience for over 70 years

Join us on Sunday 17 June 2018

Novartis has **three Satellite Symposia** at the 4th EAN congress; join us to hear from prestigious speakers in the fields of multiple sclerosis, tuberous sclerosis complex and migraine.

Multiple Sclerosis

Our evolving understanding of the MS disease continuum: a decade of change

Sunday 17 June, 12:15–13:15

Auditorium VI

Tuberous Sclerosis Complex

Management of seizures in paediatric patients with TSC

Sunday 17 June, 13:00–14:30

Auditorium V

Migraine

It's time to act on Migraine: how can we manage the unmet needs?

Sunday 17 June, 18:30–20:00

Auditorium I

Novartis looks forward to welcoming you at the booth (A01 and A03).



ROOTED IN
INNOVATIVE
SCIENCE.

DRIVEN BY
THE MANY
FACES OF
MULTIPLE
SCLEROSIS.

*Our mission to discover,
develop and deliver
life-enhancing medicines
is focused in areas of
unmet need in hematology,
oncology, immunology
and inflammation.*

**To learn more,
come and visit us
at Booth A05.**



www.celgene.com

© 2018 Celgene Corporation
All rights reserved. 04/18 INT-OZA180004

Satellite Symposia Programmes

13:00 – 14:30
Auditorium I

LILLY:
When migraine is refractory: New approaches to shape the future of patient care

Chairperson:
Messoud Ashina (Copenhagen, Denmark)

- Chairman introduction
Messoud Ashina (Copenhagen, Denmark)
- The treatment resistant migraine patient
Uwe Reuter (Berlin, Germany)
- Assessment of patient reported outcomes
Cristina Tassorelli (Pavia, Italy)
- Panel discussion, questions & answers and closing remarks
All faculty

13:00 – 14:30
Auditorium VI

ROCHE:
Redefining the management of relapsing Multiple Sclerosis & primary progressive Multiple Sclerosis

Chairperson:
Gavin Giovannoni (London, UK)

- Welcome and introduction
Gavin Giovannoni (London, UK)
- Suppressing disease activity and progression in relapsing Multiple Sclerosis and primary progressive Multiple Sclerosis
Gavin Giovannoni (London, UK)
- Ocrelizumab safety across relapsing Multiple Sclerosis and primary progressive Multiple Sclerosis
Ralf Gold (Bochum, Germany)
- Incorporating Ocrelizumab into clinical practice
Aaron Boster (Ohio, United States)
- Q & A
All faculty
- Close
Gavin Giovannoni (London, UK)



Saturday 16 June
13.00 - 14.30

Satellite Symposia Programmes

13:00 – 14:30
Auditorium V

ZAMBON: What's New in the Management of Quality of Life in Parkinson's Disease?

Chairpersons:

Javier Pagonabarraga Mora (Barcelona, Spain)
Angelo Antonini (Padua, Italy)

- Importance of Quality of Life in Parkinson's Disease patients and caregivers
Angelo Antonini (Padua, Italy)
- Role of non-dopaminergic pathways in Parkinson's Disease
Javier Pagonabarraga Mora (Barcelona, Spain)
- The impact of non-motor symptoms on Quality of Life of Parkinson's Disease patients
Heinz Reichmann (Dresden, Germany)
- Impact of pain and pain subtypes on the Quality of Life of patients with Parkinson's Disease: Clinical evidences
Olivier Rascol (Toulouse, France)
- Panel discussion

13:00 – 14:30
Auditorium VIII

BIOMARIN: Turning the tide in misdiagnosis in Myasthenic Syndromes: Increasing the index of suspicion for auto-immune neuromuscular disorders

Chairpersons:

Renato Mantegazza (Milan, Italy)
Luís Negrão (Coimbra, Portugal)

- Welcome and introduction
Luís Negrão (Coimbra, Portugal)
- Current investigations in neuromuscular disease: Role of electrophysiology
Jörn Peter Sieb (Stralsund, Germany)
- A new wave in confirmatory diagnosis of Lambert-Eaton Myasthenic Syndrome? Use of a specific immunoassay
Renato Mantegazza (Milan, Italy)
- Diving deeper: Implications of underdiagnosis of Lambert-Eaton Myasthenic Syndrome – a case series
Sabrina Sacconi (Nice, France)
- Panel discussion
All faculty
- Meeting close
Renato Mantegazza (Milan, Italy)

Satellite Symposium at the 4th EAN Congress

WHEN MIGRAINE IS REFRACTORY: NEW APPROACHES TO SHAPE THE FUTURE OF PATIENT CARE

Saturday, 16 June 2018 | 13:00 to 14:30
Auditorium 1 | Lisboa Congress Centre

SYMPOSIUM OBJECTIVES

- Understand the unmet need in migraine, with a special focus on refractory patients
- Review the burden of untreated patients and approaches to treatment of acute and chronic migraine; patients who are non-responders with initial prevention
- Assessment of patient reported outcomes, disability tools and impact on patient function

SYMPOSIUM CHAIR

Messoud Ashina, MD, PhD (Denmark)

AGENDA

- | | |
|-------------|---|
| 13:00-13:10 | Welcome and Introduction
Messoud Ashina, MD, PhD (Denmark) |
| 13.10-13.40 | The Treatment Resistant Migraine Patient
Uwe Reuter, MD, MBA (Germany) |
| 13.40-14:10 | Assessment of Patient Reported Outcomes
Cristina Tassorelli, MD, PhD (Italy) |
| 14:10-14:30 | Panel Discussion, Questions & Answers and Closing Remarks
All |

Redefining the management of relapsing multiple sclerosis and primary progressive multiple sclerosis

Satellite Symposium at the 4th EAN Congress

Saturday 16 June 2018

13:00–14:30

Auditorium VI, Lisbon Congress Centre

- 13:00–13:15 **Welcome and introduction**
Gavin Giovannoni (Chair)
- 13:15–13:30 **Suppressing disease activity and progression in relapsing multiple sclerosis and primary progressive multiple sclerosis**
Gavin Giovannoni
- 13:30–13:50 **Ocrelizumab safety across relapsing multiple sclerosis and primary progressive multiple sclerosis**
Ralf Gold
- 13:50–14:25 **Incorporating ocrelizumab into clinical practice**
Aaron Boster
- 14:25–14:30 **Q&A and close**
All faculty



Satellite Symposium at the 4th EAN Congress 2018
Lisboa, Portugal, 16-19 June 2018

What's new in the management of quality of life in Parkinson's Disease?

Pain
and mood³

Long term
results¹

Good
ON time²

Motor
functions¹

Please join the
Zambon Satellite Symposium
June 16th 2018, 13.00 - 14.30
Auditorium V

1. Borgohain R, Szasz J, Stanzione P, et al. Two-Year, Randomized, Controlled Study of Safinamide as Add-on to Levodopa in Mid to Late Parkinson's Disease. *Mov Disord*. 2014;29(12):73-80. 2. Kulisevsky J. Emerging role of safinamide in Parkinson's disease therapy. *Eur Neurol Rev*. 2014;9:1-8. 3. Kadish A, Kulisevsky J, Reichmann H, Stocchi F. Safinamide as a valuable add-on therapy: Exploring new approaches to PD management through patient case presentations. *Eur Neurol Rev*. 2017;10(Suppl.6):3-10.



Solve the case of her lifetime

Identifying the link can lead to a crucial diagnosis¹⁻⁵

Hereditary transthyretin-mediated (hATTR) amyloidosis is an inherited, rapidly progressive, life-threatening disease that can cause patients to have cardiomyopathy, sensory-motor neuropathy, and dysautonomia, eventually robbing patients of function—and even their lives.

Being aware of the red-flag symptom clusters will help accurately diagnose patients with this rare disease.

Visit **Booth A12** to learn the red-flag symptoms.



Not an actual patient.

References: 1. Dharmarajan K, Maurer MS. Transthyretin cardiac amyloidosis in older North Americans. *J Am Geriatr Soc.* 2012;60(4):765-774. 2. Hanna M. Novel drugs targeting transthyretin amyloidosis. *Curr Heart Fail Rep.* 2014;11(1):50-57. 3. Adams D, Coelho T, Obici L, et al. Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. *Neurology.* 2015;85(8):675-682. 4. Damy T, Judge DP, Kristen AV, et al. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. *J Cardiovasc Transl Res.* 2015;8(2):117-127. 5. Mohty D, Damy T, Cosnay P, et al. Cardiac amyloidosis: updates in diagnosis and management. *Arch Cardiovasc Dis.* 2013;106(10):528-540.

Satellite Symposia Programmes

Sunday 17 June
12.15 – 13.15

12:15 – 13:15
Auditorium I

ABBVIE: Optimizing care in Advanced Parkinson's Disease: Why, when, and how

Chairperson:

K Ray Chaudhuri (London, UK)

- Introduction
K Ray Chaudhuri (London, UK)
- Burden of Advanced Parkinson's Disease: Individual, societal, and financial aspects
Matej Skorvanek (Kosice, Slovakia)
- Early diagnosis: Why and how we should identify Advanced Parkinson's Disease
Angelo Antonini (Padua, Italy)
- Time to refer: Encouraging multidisciplinary care for patients with Advanced Parkinson's Disease
Bastiaan Roelof Bloem (Nijmegen, Netherlands)
- Q & A
All

12:15 – 13:15
Auditorium VI

NOVARTIS: Our evolving understanding of the Multiple Sclerosis disease continuum: A decade of change

Chairperson:

João Cerqueira (Braga, Portugal)

- Chair's opening and welcome
João Cerqueira (Braga, Portugal)
- Defining treatment success in Multiple Sclerosis: Developing concepts and new approaches
Finn Sellebjerg (Copenhagen, Denmark)
- Expanding the evidence: The impact of long-term and real-world evidence on clinical practice (interactive discussion)
*Tjalf Ziemssen (Dresden, Germany) and
Melinda Magyari (Copenhagen, Denmark)*
- Questions & answers and closing remarks
All faculty



Satellite Symposia Programmes

Sunday 17 June
13.00 – 14.30

13:00 – 14:30
Auditorium V

NOVARTIS: Management of seizures in pediatric patients with Tuberous Sclerosis Complex

Chairperson:

David Neal Franz (Cincinnati, USA)

- Welcome and introduction
David Neal Franz (Cincinnati, USA)
- Identification of Epilepsy in young children with Tuberous Sclerosis Complex
David Neal Franz (Cincinnati, USA)
- Considerations for management of Tuberous Sclerosis Complex and Tuberous Sclerosis Complex-related seizures
Anna Jansen (Brussels, Belgium)
- Neurologic consequences of Tuberous Sclerosis Complex-related seizures and potential implications of treatment
Petrus de Vries (Cape Town, South Africa)
- Panel Discussion and question & answer session
Petrus de Vries (Cape Town, South Africa) (moderator) and faculty

13:00 – 14:30
Auditorium VIII

BIOGEN: Bringing hope for adults with Spinal Muscular Atrophy

Chairpersons:

Claudia Wurster (Ulm, Germany)

Tim Hagenacker (Essen, Germany)

- Welcome and introduction
Claudia Wurster (Ulm, Germany)
- Understanding Spinal Muscular Atrophy: Not just a paediatric disease
Claudia Wurster (Ulm, Germany)
- Considerations in management of Spinal Muscular Atrophy in adult patients
Tim Hagenacker (Essen, Germany)
- Questions from the audience
Claudia Wurster (Ulm, Germany)
Tim Hagenacker (Essen, Germany)
- Conclusions and closing remarks
Tim Hagenacker (Essen, Germany)

Your invitation to a Satellite Symposium at the 4th EAN Congress sponsored by Novartis

Our evolving understanding of the MS disease continuum: a decade of change

Sunday 17 June, 12:15–13:15

Auditorium VI,
Lisbon Congress Centre,
Lisbon, Portugal

Chair's opening and welcome

João José Cerqueira (*Braga, Portugal*)

Defining treatment success in MS: developing concepts and new approaches

Finn Sellebjerg (*Copenhagen, Denmark*)

Expanding the evidence: the impact of long-term and real-world evidence on clinical practice


Tjalf Ziemssen (*Dresden, Germany*) and
Melinda Magyari (*Copenhagen, Denmark*)

Interactive discussion

Q&A and closing remarks

All faculty

Management of Seizures in Paediatric Patients with **TSC**



17 June 2018 / 13:00 – 14:30

Lisbon Congress Centre / Auditorium V / Lisbon, Portugal

PROGRAMME AGENDA

13:00 – 13:15	Welcome and Introduction	CHAIR: David Neal Franz, MD (US)
13:15 – 13:35	Identification of epilepsy in young children with TSC	David Neal Franz, MD (US)
13:35 – 13:50	Considerations for management of TSC and TSC-related seizures	Anna Jansen, MD, PhD (Belgium)
13:50 – 14:10	Neurological consequences of TSC-related seizures and potential implications of treatment	Petrus de Vries, MBChB, MRCPsych, PhD (South Africa)
14:10 – 14:30	Panel Discussion and Q & A	Petrus de Vries, MBChB, MRCPsych, PhD (moderator) and Faculty

FACULTY

CHAIR:
David Neal Franz, MD
*Cincinnati's Children's Hospital,
Cincinnati, Ohio, US*

**Petrus de Vries, MBChB,
MRCPsych, PhD**
*University of Cape Town,
Cape Town, South Africa*

Anna Jansen, MD, PhD
*UZ Brussel, Laarbeeklaan,
Brussels, Belgium*

PROGRAMME OBJECTIVES

- Educate on the neurological aspects of tuberous sclerosis complex (TSC) and review the long-term efficacy and safety profiles of therapies used for managing TSC-associated seizures in children and adolescents
- Discuss the growing body of evidence for management of TSC-associated seizures with mammalian target of rapamycin (mTOR) inhibitors and describe clinical approaches to manage adverse events in children and adolescents
- Explore the potential impact of early treatment on long-term neurological sequelae in children and adolescents with TSC

PROGRAMME OVERVIEW

This 90-minute symposium will focus on the management of treatment-refractory seizures in paediatric patients with TSC. Presentations will be case-based, and will focus on educating the audience about TSC, TSC-associated seizures, and the long-term impact of these seizures and intervention on neurological sequelae in children and adolescents. Topics to be covered will include the diagnosis of TSC-associated seizures, current management strategies, and the emerging role of mTOR inhibitors for TSC-associated seizures. In addition, the symposium will educate on TSC Associated Neuropsychiatric Disorders (TAND) symptomatology and discuss the potential role for early intervention and impact on TAND.

This programme is supported by Novartis.

This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This programme and/or material was developed for use outside of the US, is intended for non-US healthcare professionals, and is to be used in accordance with local laws and regulations.



Satellite Symposia at the 4th EAN Congress

"Bringing hope for adults with Spinal Muscular Atrophy"		Prof. Claudia Wurster and Prof. Tim Hagenacker
Understanding Spinal Muscular Atrophy: not just a paediatric disease		Prof. Claudia Wurster; RKU - Universitäts und Rehabilitationskliniken Ulm, Germany
Considerations in management of Spinal Muscular Atrophy in adult patients		Prof. Tim Hagenacker; Universitätsklinikum, Essen, Germany
Sunday June 17 th	13:00 - 14:00	Auditorium VIII

"The new ECTRIMS / EAN MS guidelines. The journey continues..."		Prof. João de Sá; Santa Maria Hospital, Lisbon, Portugal
...to optimise individual treatment decisions How can we use registry data to personalise therapy?		Prof. Stefan Braune; NeuroTransData Network, Neuburg an der Donau, Germany
...to identify biomarkers of treatment response Is serum neurofilament light chain monitoring ready for clinical practice?		Prof. Jens Kuhle; University Hospital Basel, Basel, Switzerland
...to better understand treatment risk How is long-term safety experience changing patient management?		Prof. Richard Nicholas; Imperial College London, London, United Kingdom
Monday June 18 th	12:15 - 13:15	Auditorium VI

Forum Talks at the 4th EAN Congress

"Progressive supranuclear palsy - Update on diagnostic criteria and clinical research"		Prof. Günter U. Höglinger; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Sunday June 17 th	16:15 - 16:30	Scientific Theatre
"Alzheimer's disease - Current developments in diagnosis and clinical research"		Prof. Giovanni B. Frisoni; University Hospital of Geneva and University of Geneva, Geneva, Switzerland
Monday June 18 th	09:30 - 09:45	Scientific Theatre

These symposia and talks have been organised and funded by Biogen. Biogen products may be discussed - the SPCs will be available at the Biogen stand.



For chronic inflammatory
demyelinating polyneuropathy (CIDP)

FOLLOW THE PATH

DISCOVER the next step in CIDP treatment

VISIT CSL BEHRING AT BOOTH #A14

“Follow the PATH” to the CSL Behring booth and learn about:

- PATH, the largest CIDP study
- The first and only subcutaneous Ig (SCIG) for CIDP
- CSL Behring: over 100 years of expertise in developing and delivering plasma-derived products

Biotherapies for Life® is a registered trademark of CSL Behring LLC.

©2018 CSL Behring LLC

Local representative: CSL Behring Unipessoal Lda. Edifício Mar Vermelho - Av.º D. João II, lote 1.06.2.5 - Piso 3 Frente; 1990-095 Lisboa, Portugal, NIF 503 047 201
www.CSLBehring.com EU/H2V18/-0004

Biotherapies for Life® **CSL Behring**

Satellite Symposia Programmes

Sunday 17 June
13.45 – 14.45

13:45 – 14:45
Auditorium I

SANOFI GENZYME: Demand more from life with Multiple Sclerosis #WomeninMS

Chairperson:

Maria José Sá (Porto, Portugal)

- **Welcome and opening**
Maria José Sá (Porto, Portugal)
- **Family planning and Multiple Sclerosis: 100 key questions answered**
Celia Oreja-Guevara (Madrid, Spain)
- **Teriflunomide #WomeninMS**
How can family planning be managed in a real-life setting?
A Danish example.
Melinda Magyar (Copenhagen, Denmark)
- **Alemtuzumab #WomeninMS**
How can family planning be managed in a real-life setting?
A Norwegian example.
Elisabeth Gulowsen Celius (Oslo, Norway)
- **Questions & answers**

13:45 – 14:45
Auditorium VI

BIAL: Management of Parkinson's Disease: From science to clinical wisdom

Chairperson:

Werner Poewe (Innsbruck, Austria)

- **Chairman's introduction**
Werner Poewe (Innsbruck, Austria)
- **Current treatment of fluctuations**
Fabrizio Stocchi (Rome, Italy)
- **Managing motor fluctuations – a case-based perspective**
Wolfgang Jost (Wolfach, Germany)
- **Facing the challenges of non-motor symptoms**
Francesca Morgante (Messina, Italy)
- **Round table discussion – questions & answers**
All faculty

17

Satellite Symposia Programmes

Sunday 17 June
18.30 – 20.00

18:30 – 20:00
Auditorium I

NOVARTIS: It's time to Act on Migraine: How can we manage the unmet needs?

Chairperson:

Koen Paemeleire (Ghent, Belgium)

- Welcome and introduction
Koen Paemeleire (Ghent, Belgium)
- Migraine from a neurologist's perspective – future advances to raise the profile of the disease
Martin Rutledge (Dublin, Ireland)
- Calcitonin gene-related peptide pathway monoclonal antibodies, from clinical evidence to clinical practice
Anish Bahra (London, United Kingdom)
- Making a meaningful difference for patients with high unmet need
Uwe Reuter (Berlin, Germany)
- Targeted therapy to improve the safety and tolerability profile of prophylactic migraine treatment
Andreas Gantenbein (Bad Zurzach, Switzerland)
- Panel discussion and questions & answers
All faculty
- Closing remarks
Koen Paemeleire (Ghent, Belgium)

18:30 – 20:00
Auditorium VI

MERCK: Foundation and innovation in Multiple Sclerosis treatment – avoiding continuous immunosuppression

Chairperson:

Jiwon Oh (Toronto, Canada)

- The burden of Multiple Sclerosis treatment today
João Cerqueira (Braga, Portugal)
- Solid foundations: 20 years of interferon β -1a
Jiwon Oh (Toronto, Canada)
- Innovatively simple: Avoiding chronic immunosuppression with Cladribine tablets
Bassem Yamout (Beirut, Lebanon)
- Case studies: Exploring treatment approaches
Raymond Hupperts (Sittard-Geleen, The Netherlands)
- Concluding remarks
Jiwon Oh (Toronto, Canada)



ANITA
Relapsing Multiple Sclerosis, Norway

DEMAND MORE FROM LIFE WITH MS

#WomeninMS

VISIT BOOTH A02 TO LEARN MORE

Please join the Sanofi Genzyme Satellite Symposium at the 4th EAN Congress on:
SUNDAY, JUNE 17, 13:45 - 14:45 (AUD. 1)

Chair: Prof. Maria José Sá, Portugal

Speakers: Prof. Celia Oreja-Guevara, Spain
Dr. Melinda Magyari, Denmark
Prof. Elisabeth Gulowsen Celius, Norway

Bial

Keeping life
in mind.

01/14/18/18/004



4TH CONGRESS OF THE EUROPEAN
ACADEMY OF NEUROLOGY, LISBON 2018

MANAGEMENT OF PARKINSON'S DISEASE: FROM SCIENCE TO CLINICAL WISDOM

**SUNDAY 17TH
JUNE 2018**
AUDITORIUM VI
13H45 - 14H45

PROFESSOR
WERNER POEWE
INNSBRUCK, AUSTRIA

CHAIRMAN'S
INTRODUCTION

PROFESSOR
FABRIZIO STOCCHI
ROME, ITALY

CURRENT TREATMENT
OF FLUCTUATIONS

PROFESSOR
WOLFGANG JOST
WOLFACH, GERMANY

MANAGING MOTOR
FLUCTUATIONS
A CASE-BASED PERSPECTIVE

PROFESSOR
FRANCESCA MORGANTE
LONDON, UNITED KINGDOM

FACING THE CHALLENGES
OF NON-MOTOR SYMPTOMS

ROUND TABLE DISCUSSION
QUESTIONS & ANSWERS

Your invitation to a Satellite Symposium at the 4th EAN Congress sponsored by Novartis



It's time to **Act on Migraine:** How can we manage the unmet needs?

Sunday 17 June 2018

18:30–20:00

Auditorium I

Lisbon Congress Centre

Lisbon, Portugal

Welcome and introduction

Koen Paemeleire

Migraine from a neurologist's perspective – future advances to raise the profile of the disease

Martin Rutledge

Calcitonin gene-related peptide pathway monoclonal antibodies, from clinical evidence to clinical practice

Anish Bahra

Making a meaningful difference for patients with high unmet need

Uwe Reuter

Targeted therapy to improve the safety and tolerability profile of prophylactic migraine treatment

Andreas Gantenbein

Panel discussion and Q&A

Moderated by Koen Paemeleire

Closing remarks

Koen Paemeleire



MERCK

Satellite Symposium

at the 4th Congress of the European
Academy of Neurology 2018

FOUNDATION AND INNOVATION IN MS TREATMENT – AVOIDING CONTINUOUS IMMUNOSUPPRESSION

18:30–20:00

Sunday, 17 June 2018

Auditorium VI,
Lisboa Congress Centre (CCL),
Lisbon, Portugal

Chair:

Jiwon Oh, Canada

João Cerqueira, Portugal

Bassem Yamout, Lebanon

Raymond Hupperts,
The Netherlands



This meeting is initiated, funded
and organised by Merck KGaA

GBPMLR/CLA/0418/0077a
Approval date: April 2018

Satellite Symposia Programmes

Sunday 17 June
18.30 – 20.00

18:30 – 20:00
Auditorium V

ALNYLAM PHARMACEUTICALS: Connecting the dots – diagnosing and identifying hATTR Amyloidosis

Chairperson:

Teresa Coelho (Porto, Portugal)

- Welcome and Introductions
Teresa Coelho (Porto, Portugal)
- Clinical presentation of progressive neuropathy
Teresa Coelho (Porto, Portugal)
- Onset of GI manifestations and neuropathy
Lucía Galán (Madrid, Spain)
- A case on cardiac manifestations leading to misdiagnosis
Thibaud Damy (Paris, France)
- Questions & answers
Teresa Coelho (Porto, Portugal)

18:30 – 20:00
Auditorium III

TAKEDA: New insights in treatment and prevention of vascular cognitive impairment

Chairperson:

Alla Guekht (Moscow, Russian Federation)

- Risk factors of cognitive impairment
Ingmar Skoog (Gothenburg, Sweden)
- Questions & answers
- Diabetes mellitus and cognitive impairment
Boris N. Mankovsky (Kiev, Ukraine)
- Questions & answers
- Post-Stroke cognitive impairment: New insights from ARTEMIDA study
Alla Guekht (Moscow, Russian Federation)
- Questions & answers and close

18

Monday 18 June
12.15 - 13.15

Satellite Symposia Programmes

12:15 – 13:15
Auditorium I

AKCEA:
Amyloid Transthyretin (ATTR) Amyloidosis:
One Disease, Many Symptoms

Chairperson:
Teresa Coelho (Porto, Portugal)

- **Diagnosis of Amyloid Transthyretin Amyloidosis**
Teresa Coelho (Porto, Portugal)
- **Relationship between Genotype and Phenotype**
Laura Obici (Pavia, Italy)
- **Cardiac Involvement in Amyloid Transthyretin Amyloidosis**
Arnt Kristen (Heidelberg, Germany)
- **Evaluating Neuropathy Progression**
Violaine Planté-Bordeneuve (Créteil, France)

12:15 – 13:15
Auditorium VI

BIOGEN:
The newECTRIMS / EAN Multiple Sclerosis
guidelines. The journey continues ...

Chairperson:
João de Sá (Lisbon, Portugal)

- ... to optimize individual treatment decisions.
How can we use registry data to personalize therapy?
Stefan Braune (Prien, Germany)
- ... to identify biomarkers of treatment response. Is serum neurofilament light chain monitoring ready for clinical practice?
Jens Kuhle (Basel, Switzerland)
- ... to better understand treatment risk. How is long-term safety experience changing patient management?
Richard Nicholas (London, UK)

To those who say “impossible,
impractical, unrealistic,” we say:

CHALLENGE ACCEPTED

We are relentless in our
pursuit of new treatments.
Because people living with
rare diseases shouldn't
have to wait for hope.

alnylam.com

 Alylam[®]
PHARMACEUTICALS

CHALLENGE ACCEPTED

Satellite Symposium at the 4th EAN Congress

Lunch
will be
provided

Amyloid Transthyretin (ATTR) Amyloidosis: One Disease, Many Symptoms

Monday, 18 June, 2018 | 12:15–13:15
Auditorium 1 | Lisbon Congress Centre



**Chair: Teresa Coelho, MD, Neurologist and Neurophysiologist
at Santo António Hospital, Porto, Portugal**

Join Dr. Teresa Coelho and our expert faculty panel for this 60-minute symposium exploring key topics in ATTR amyloidosis, with an emphasis on polyneuropathy manifestations.

Dr. Coelho will highlight the common clinical presentation of ATTR amyloidosis and provide an overview of characteristic features and symptom combinations that should raise clinical suspicion. Common misdiagnoses will also be outlined, along with an overview of imaging techniques that can assist diagnosis.

We will review the common genotypes in Europe and the clinical spectrum of varying phenotypes observed. Further patient case studies will look at cardiac involvement and the overlap of polyneuropathy and cardiomyopathy phenotypes. The session will conclude with discussion around neuropathy progression and a review of tests/tools to facilitate recognition of neuropathy progression.

Objectives

- To raise awareness of ATTR amyloidosis and common diagnostic challenges
- To describe the multi-systemic nature of ATTR amyloidosis that extends beyond neuropathy
- To provide recommendations for diagnosing and monitoring progression of ATTR amyloidosis

Stop by the Akcea booth B21 for additional information about this important symposium.

Satellite Symposia Programmes

13:00 – 14:30
Auditorium V

SANOFI GENZYME: Latest tales of the unexpected: Illuminating the path to earlier diagnosis in muscle diseases

Chairperson:

Tiziana Mongini (Turin, Italy)

- Introduction and welcome
Tiziana Mongini (Turin, Italy)
- Pathophysiology and the role of muscle biopsy in vacuolar myopathies: Hunting for hidden clues
Josef Čameňák (Praque, Czech Republic)
- Role and risks of magnetic resonance imaging in muscle diseases: A case of mistaken identity?
Cornelia Kornblum (Bochum, Germany)
- A man with limb girdle weakness and respiratory involvement: A clue to an expected diagnosis?
Isabel Conceição (Lisbon, Portugal)
- Pompe disease and differential diagnosis of muscle diseases: An overview
Tiziana Mongini (Turin, Italy)
- Closing remarks
Tiziana Mongini (Turin, Italy)

13:00 – 14:30
Auditorium VIII

TEVA: The role of Calcitonin Gene-Related Peptide in migraine: The latest clinical evidence and its implications in the new era of biologics

Chairperson:

Dimos-Dimitrios D. Mitsikostas (Athens, Greece)

- Welcome and introduction
Dimos-Dimitrios D. Mitsikostas (Athens, Greece)
- Migraine today: Overview and unmet medical needs
Dimos-Dimitrios D. Mitsikostas (Athens, Greece)
- Current treatment options and management of migraine
Patricia Pozo-Rosich (Barcelona, Spain)
- The role of Calcitonin Gene-Related Peptide in Migraine: The latest evidence
Michel D. Ferrari (Den Haag, The Netherlands)
- Panel questions & answers
Dimos-Dimitrios D. Mitsikostas (Athens, Greece) & faculty

18

Monday 18 June
13.45 – 14.45

Satellite Symposia Programmes

13:45 – 14:45
Auditorium I

CELGENE:
The ideal real world in Multiple Sclerosis care – a permanent clinical trial?

Chairperson:
Giancarlo Comi (Milano, Italy)

- Welcome
- A neurologist's perspective: How do you standardise clinical assessment?
Giancarlo Comi (Milano, Italy)
- A radiologist's perspective: How do you standardise imaging techniques?
Mike P. Wattjes (Hannover, Germany)
- A neuropsychologist's perspective: How do you standardise cognitive assessments?
Iris-Katharina Penner (Düsseldorf, Germany)
- Summary and closing

13:45 – 14:45
Auditorium VI

EVERPHARMA:
New evidence for pharmacological treatment in post-stroke recovery

Chairperson:
Andreas Bender (Burgau, Germany)

- Timing, training, and spontaneous recovery after stroke: in animals, in humans
Steven Zeiler (Baltimore, USA)
- Anticorrelated processes in neurobiology - possible consequences for neuro-rehabilitation strategies
Dafin F. Muresanu (Cluj-Napoca, Romania)
- New evidence from a recent meta-analysis in acute ischemic stroke
Natan Bornstein (Tel Aviv, Israel)



LATEST TALES OF THE UNEXPECTED: ILLUMINATING THE PATH TO EARLIER DIAGNOSIS IN MUSCLE DISEASES

MONDAY 18 JUNE 2018, 13:00–14:30
AUDITORIUM V, LISBOA CONGRESS CENTRE, LISBON

Satellite Symposium at the 4th EAN Congress
Lisbon, June 16–19, 2018

A SANOFI
GENZYME
SYMPOSIUM

GE2MEA.PD.18.03.0049
April 2018

SANOFI GENZYME 

Satellite Symposium at
the 4th EAN Congress

Monday 18th June

13:00–14:30

Auditorium VIII
Lisboa Congress Centre
Lisbon, Portugal

The role of CGRP in migraine: the latest clinical evidence and its implications in the new era of biologics

Programme

Time	Title	Speaker
13:00	Welcome and introduction	Dimos-Dimitrios D. Mitsikostas National & Kapodistrian University of Athens, Greece
13:10	Migraine today: Overview and unmet medical needs	Dimos-Dimitrios D. Mitsikostas
13:30	Current treatment options and management of migraine	Patricia Pozo-Rosich Vall d'Hebron University Hospital, Barcelona, Spain
13:50	The role of CGRP in migraine: the latest evidence	Michel D. Ferrari Leiden University Medical Center, The Netherlands
14:10	Panel Q&A	Dimos-Dimitrios D. Mitsikostas & panel
14:30	Close	

teva | Migraine and Headache



3-Days Satellite Session

Programme





**ROOTED IN
INNOVATIVE
SCIENCE.**

**DRIVEN BY
THE MANY
FACES OF
MULTIPLE
SCLEROSIS.**

**Satellite Symposium at
the 4th EAN Congress:
The Ideal Real World In
MS Care—A Permanent
Clinical Trial?**

AUDITORIUM I

Monday, 18 June, 13:45-14:45

*A neurologist's perspective:
How do you standardise
clinical assessment?*

*A radiologist's perspective:
How do you standardise
imaging techniques?*

*A neuropsychologist's
perspective: How do you
standardise cognitive
assessments?*

**3-day Satellite Sessions
at the 4th EAN Congress**

ROOM 0.01

Saturday, 16 June, 10:00-10:30

*The importance of real world
evidence generation in MS*

Sunday, 17 June, 09:30-10:00

*Brain volume loss: From healthy
individuals to MS patients*

Monday, 18 June, 09:30-10:00

*Drug sequencing through platform
and oral therapies: What should
be done?*



www.celgene.com

© 2018 Celgene Corporation
All rights reserved. 04/18 INT-QZA180002

3-Days Satellite Session Programme

CELGENE

10:00 – 10:30
Session Room 0.01

Saturday, 16 June

- The importance of real world evidence generation in Multiple Sclerosis
Tjalf Ziemssen
(Dresden, Germany)

09:30 – 10:00
Session Room 0.01

Sunday, 17 June

- Brain volume loss: From healthy individuals to Multiple Sclerosis patients
Sven Schippling
(Zurich, Switzerland)

09:30 – 10:00
Session Room 0.01

Monday, 18 June

- Drug sequencing through platform and oral therapies: What should be done?
Hans-Peter Hartung
(Duesseldorf, Germany)

Forum Talk

Programmes



**PLEASE JOIN MERCK
FOR THEIR SCIENTIFIC
THEATRE FORUM
TALKS AT THE 4TH
EAN CONGRESS**

Scientific Theatre, Hall 1
Lisboa Congress Centre (CCL), Lisbon, Portugal

**Selective Immune Reconstitution Therapy
in the MS treatment paradigm**

10:15–10:30

Saturday, 16 June 2018

By **Gavin Giovannoni, UK**

**Cladribine Tablets in clinical practice:
switching from platform therapies**

09:45–10:00

Sunday, 17 June 2018

By **Klaus Schmierer, UK**

**Cladribine Tablets in clinical
practice: initiating treatment
in newly diagnosed patients**

09:45–10:00

Monday, 18 June 2018

By **Thomas Müller, Germany**



Forum Talk Programmes

Exhibition – Hall 1 – Scientific Theater

Overview of forum talk programmes organised in the scientific theater within the exhibition area. Additional talks reserved after the date of printing will be announced on-site.

Saturday, June 16

10:15–10:30

MERCK TALK – Multiple Sclerosis

Selective Immune Reconstitution Therapy in the Multiple Sclerosis treatment paradigm

Gavin Giovannoni

(London, UK)

16:30–16:45

ALNYLAM PHARMACEUTICALS TALK

Acute Hepatic Porphyrias – Inherited metabolic diseases with porphyric neuropathy

Case reports:

Jean-Charles Deybach

(Paris, France)

Sunday, June 17

09:30–09:45

ALNYLAM PHARMACEUTICALS TALK

Acute Hepatic Porphyrias – Inherited metabolic diseases with porphyric neuropathy

Case reports:

Jean-Charles Deybach

(Paris, France)

09:45–10:00

MERCK TALK – Multiple Sclerosis

Cladribine Tablets in clinical practice: switching from platform therapies

Klaus Schmierer

(London, UK)

16:15–16:30

BIOGEN TALK

Progressive supranuclear palsy – Update on diagnostic criteria and clinical research

Günter U. Höglinger

(Munich, Germany)

Monday, June 18

09:30–09:45

BIOGEN TALK

Alzheimer's disease – Current developments in diagnosis and clinical research

Giovanni B. Frisoni

(Les Acacias, Switzerland)

09:45–10:00

MERCK TALK – Multiple Sclerosis

Cladribine Tablets in clinical practice: initiating treatment in newly diagnosed patients

Thomas Müller

(Neu-Isenburg, Germany)

Speaker Index

Final Programme



Speaker Index

A	Armentani, E..... 100	Bartenstein, P. 99	Bjerkeli, V. 98
Aamodt, A.H. 80, 98	Arnaldi, D..... 96	Basaia, S..... 98, 113	Bjørk, M.H. 112
Abati, E. 113	Arnold, D.L. 65, 99	Basetti, C. 79, 100	Blamire, A. 67
Abbink, T.E. 66	Arnold, W..... 98	Bassez, G. 59	Blanco, Y. 67
Abdel-Mannan, O. 81	Arntzen, K..... 98	Bastianello, S. 81	Blandiaux, S..... 100
Abel, F. 113	Ashina, M..... 87, 126	Bateman, R.J. 96	Blennow, K..... 82
Abeti, R. 80	Assunta Rocca, M. 86	Battaloglu, E. 66	Blin, O. 96
Acevedo-Arozena, A..... 80	Atar, D..... 98	Bauckneht, M..... 96	Bloem B.R. 132
Adams, D..... 64, 66	Attal, N..... 78	Baumgartner, C..... 71	Bloomer, J..... 64
Adler, C. 64	Attarian, S. 66	Bäzner, H. 73	Blumenfeld, A. 112
Ægidius, K.L. 98	Audoin, B. 67	Beach, T. 64	Boirie, Y. 64
Agosta, F. 60, 96, 98, 113	Auger, F..... 97	Beccaria, K. 81	Bolino, A. 66
Aguilar, C. 67	Aurora, S.K. 112	Bede, P. 60	Bombardi, R..... 67
Al-Ajlan, F..... 98	Aurrand Lyons, M..... 80	Bedetti, C. 81	Bonello-Palot, N. 66
Albanese, A. 59	Aviv, R..... 98	Bednarik, J..... 66	Bonetti, B. 97
Albani, G. 100	Awada, A. 73	Belden, C..... 64	Bonkovsky, H..... 64
Alberti, D..... 67	Ayrignac, X. 67	Bellatache, M. 66	Bonnet, A. 80
Alfano, L..... 98	Azevedo, E..... 79	Belvisi, D..... 80	Boon, P..... 37, 54, 81, 108
Alonso, I..... 113	Azarin, I. 113	Ben-Shlomo, Y. 64	Bordet, R..... 96, 97
Alsagob, M. 66	Azulay, J.-P. 113	Benabdeljlil, M..... 73	Bornstein, N..... 79, 149
Al-Tawil, N..... 64		Benabid, A..... 89	Boster, A..... 126
Alteheld, L..... 80	B	Bender, A. 149	Bottlaender, M..... 99
Alvarez, V..... 91	Bacigaluppi, M..... 80	Benedetti, L..... 97	Bouchoux, G..... 81
Alvarsson, M. 96	Bacon, C.J. 66	Benedetti, M.D..... 67	Bouckaert, C..... 81
Alves, C. 97	Bahra, A. 58, 139	Beniczky, S..... 54, 93	Boulouis, G..... 98
Alves, P.N..... 80	Baig, F. 64	Bennett, D..... 50	Boumédiène, F..... 98
Al-Zaidy, S. 98	Baker, I..... 50	Benson, M. 66	Bourdain, F. 81
Amin, F.M. 82	Ballabriga, J. 67	Berardelli, A..... 80	Boutin, E. 113
Anderson, C. 98	Balwani, M..... 64	Berezcki, D. 88	Bouzidi, A..... 81
Anderson, K. 64	Banwell, B. 65	Berk, J. 64, 66	Bovi, P. 97
Andersson, T..... 96	Bar-or, A. 65, 99, 100	Berlit, P. 106	Boyko, A. 65
Andres, D. 100	Barabino, S..... 98	Berry, K. 98	Branco, M..... 97
Angelini, C. 51	Baralle, F..... 80	Bertini, E..... 66	Brandão, A.F..... 113
Annovazzi, P. 97	Barber, T. 64	Berzero, G. 81	Brandner, S. 80
Antelmi, E. 100	Barboni, P. 67	Bettencourt, A..... 67, 81	Brandt, T. 91, 99, 112
Antonini, A..... 61, 88, 127, 132	Barbot, C. 113	Bettencourt, C..... 80	Brannagan, T. 66
Antonio, S. 80	Barceló, M.I. 67	Bhatia, K. 59	Brás, P. 64
Anzalone, N..... 80	Bardins, S..... 99	Bianchi Marzoli, S..... 67	Braune, S..... 145
Arévalo, M.J..... 99	Barkhof, F. 65, 99, 100	Bianchini, E. 80	Braun, K. 80
Argov, Z..... 61	Barloese, M. 112	Bierhals, T..... 66	Braunstein, J.B. 96
Ariatti, A..... 66	Baron, J.C. 107	Bigoni, M..... 100	Breitenfeld, T. 73
Ariño, H. 86	Barro, C. 65	Biotti, D..... 67	Bresolin, N. 98, 113
Armangué, T. 67	Barros, J..... 113	Bisdorff, A. 112	Bril, V. 66
	Barroso, F. 66	Bissell, D. 64	Brizzi, T. 113
		Bjekić, J..... 99	Brouwer, M. 112

Speaker Index

Brouwer, O.....	80	Cascavilla, M.L.....	67	Cock, H.....	39, 53, 73, 96	Damier, P.G.	71
Brownlee, W.....	70	Case, M.G.....	112	Coelho, M.....	77, 108	Damy, T.....	144
Brück, W.	65	Caso, F.....	96	Coelho, T.....	52, 64, 66,97, 144, 145	Dankiewicz, J.....	82
Bruna, J.....	67	Caso, V.	20, 78, 97	Cohen, J.A.....	65, 99	Dankwa, L.....	66
Brunelli, M.C.....	81	Cassol, H.	99	Colamarino, E.....	82	Davis, K.....	64
Bruno, F.	81	Cavaco, S.	67	Cole, J.	20	De Angelis, F.....	65, 99
Büchner, B.	67	Cavaliere, L.	96	Čolić, M.	99	De Carvalho, M.A.....	57
Budur, K.....	96	Cencini, F.....	64	Collins, D.L.	80	De Giglio, L.	100
Buratti, E.....	80	Cerliani, L.	80	Collongues, N.....	67	De Grandis, M.....	80
Burch, M.	113	Ceroni, M.	81	Colombo, B.	65, 96	De Koning-Tijssen, M.....	109
Burghes, A.....	98	Cerqueira, J.....	108, 132, 139	Colosimo, C.....	53	De Leeuw, F.E.....	53
Burgunder, J.M.....	66, 90	Chan, A.....	64	Comi, G.	54, 65, 77, 80,96, 98, 99,108, 113, 149	De Marchis, G.M.....	97
Burn, D.J.....	88	Chan, E.....	113	Conceição, I.....	52, 66, 148	De Meo, E.....	96
Burtscher, M.	100	Chan, K.H.	67	Condette Auliac, S.	81	De Negri, A.M.	67
Buse, D.....	112	Chandler, H.....	20	Connick, P.....	65, 99, 100	De Reuck, J.	80, 97
Buttari, F.....	97	Chandran, S.	65, 99, 100	Cordonnier, C.	97	De Rojas Leal, C.....	112
<hr/>							
C		Chang, Y.....	98	Correia, M.....	75	De Sá, J.	145
Calabresi, P.....	81	Chard, D.....	106	Corrochano, S.	80	De Seze, J.	65
Calandriello, L.	98	Chataway, J.....	65, 99, 100	Cortis, S.	98, 113	De Stefano, N.....	60, 99
Calvi, A.....	65, 99	Chatelle, C.....	99	Costa, C.	81	De Visser, M.....	61
Camargo, A.	100	Chaudhuri, K Ray	132	Costa, J.....	113	De Vries, J.....	67
Campistol, J.	66	Chaves, J.M.M.	81	Costa, P.	81	De Vries, P.	133
Campos, F.	81	Chelban, V.....	66	Costa, R.....	108	Deangelis, F.	100
Canhao, P.....	96, 108	Chen, J.	64	Coutinho, E.P.....	80	Debette, S.....	53
Canney, M.....	81	Chiavazza, C.....	81	Coutinho, P.	113	Del Bo, R.	98
Cantalupo, G.....	67	Chincarini, A.....	96	Cras, P.	20, 96	Del Sorbo, F.	64
Canu, E.....	96	Chinnery, P.	67	Cree, B.....	100	Delattre, J.-Y.....	81
Capobianco, M.....	97	Chinot, O.L.....	81	Cree, B.A.C.....	99	Delbeke, J.	81
Caporali, L.....	67	Chinoy, H.....	113	Cremascoli, R.....	100	Delogu, R.	67
Cappellari, M.	97	Chiò, A.....	98	Crombez, E.....	96	Deluca, G.....	97
Capra, R.	67	Chirita-Emandi, A.	66	Cronberg, T.....	82	Demarin, V.....	73
Carbonelli, M.	67	Chitnis, T.....	65	Cruccu, G.	109	Demchuk, A.	98
Cardoso, M.....	97	Chumillas, M.J.....	97	Cuccarini, V.....	81	Demeret, S.	87
Carelli, V.	67	Church, K.....	98	Cunha, C.....	67	Deramecourt, V.....	97
Carpentier, A.....	81	Ciccarelli, O.....	65, 99	<hr/>			
Carreño, M.....	71	Cincotti, F.	82	D		Desnick, R.....	64
Carrette, E.....	81	Ciranni, A.....	113	Dahlke, F.....	100	Desnick, R.J.....	64
Carrière, M.....	99	Ciron, J.....	67	Daizadeh, N.	65	Deuschl, G.....	37, 75, 108
Carron, R.....	113	Claeys, K.....	86	Dalmau, J.....	67	Dewaele, F.....	81
Carta, A.	67	Classen, J.	77, 79	Damásio, J.	113	Deybach, J.-C.....	64, 159
Carvalheiras, G.	67	Clavier, L.....	107	D'ambrosio, A.	99	Di Fonzo, A.	113
Carvalho, C.....	81	Cletheroe, D.	113	Damian, M.	61, 82	Di Liberto, G.	20
Carvalho, M.....	77, 108	Cloughesy, T.....	81			Di Stefano, A.L.....	81
		Cobo-Calvo, A.	67			Di Vito, L.	67
		Cocco, E.	97			Diamanti, L.	81
						Dias, M.....	64

- Dickson, G..... 113
- Didic, M. 96
- Diener, H.-C..... 80
- Dieterich, M. 70, 99, 112
- Dietz, V..... 72
- Dinh, Q..... 64
- Diodato, D..... 66
- Dioni, L. 98
- Diserens, K..... 90
- Divisova, S. 66
- Dodel, R. 89
- Doglioni, C. 80
- Dojčáková, D..... 66
- Domingos, J. 113
- Donadio, V. 64
- Donati, M.A..... 67
- Doornebal, N..... 80
- Doshi, A..... 65, 99, 100
- Dowlatshahi, D. 98
- Drachman, B. 66
- Dragancea, I..... 82
- Drapier, S..... 80
- Dréan, A..... 81
- Driver-Dunckley, E..... 64
- Duarte, G..... 113
- Dubois, B..... 96
- Ducray, F..... 81, 106
- Durand Dubief, F..... 67
- Durand, E..... 64
- Durieux, N. 97
- Durif, F..... 64
- Durn, B.L. 66
- Dutheil, F. 64
- Dyck, P. 66
- E**
- Ebentheuer, J..... 65
- Edwards, M..... 109
- Efeturk, H. 96
- Efthymiou, S. 66
- Eisner, W. 97
- El Alaoui Faris, M..... 107
- Eldøen, G. 98
- Elia, A..... 64
- Emmet, W..... 80
- Emre, M. 88
- Engelter, S..... 97
- Enzinger, C..... 80, 99, 107
- Eoli, M..... 81
- Eriksdotter, M..... 96
- Eriksen, E..... 80
- Erlinge, D..... 82
- Eschenfelder, C..... 80
- Eschlböck, S..... 97
- Escudero, D..... 67
- Eshaghi, A. 65, 99
- Esiri, M. 97
- Espinos, C. 97
- Esposito, F. 65
- Eubanks, J. 99
- Eusebio, A. 113
- Eusebi, P. 81
- Evangelista, T. 61
- Evers, S. 91, 109
- Evoli, A..... 110
- F**
- Fabbrini, A. 80
- Falini, A..... 80, 96, 98
- Falzone, Y..... 98
- Fanciulli, A..... 58, 70
- Fanning, K. 112
- Fantini, M.L. 64
- Faravelli, I. 98
- Farias Serratos, B.M. 81
- Farias Serratos, C.V. 81
- Farias Serratos, F..... 81
- Farina, L.M. 81
- Farotti, L. 81
- Farrugia, M. 67
- Fastbom, J. 96
- Faulhaber, M..... 100
- Fawzi, N. 80
- Fazekas, F. 70
- Federico, A. 61, 107
- Fenton, M..... 113
- Fernandes, J. 97
- Ferrante, M. 98
- Ferrari, C..... 96
- Ferrari, M..... 87, 148
- Ferrari, S..... 67
- Ferreira, A..... 113
- Ferreira, C..... 71
- Ferreira, J. 37, 71, 108, 113
- Ferreira, P. 80
- Ferreira, R..... 81
- Ferro, J..... 53, 73, 77, 88, 90, 97
- Fetoni, V..... 67
- Fileccia, E..... 64
- Filipovic, S. 99
- Filippi, M. 65, 96, 98, 99, 113
- Filosa, G. 98
- Fior, A. 80
- Fisher, E..... 80
- Flamand-Roze, E. 112
- Florian, H..... 96
- Focke, N. 65
- Foltynie, T..... 113
- Fonseca, C..... 88
- Fontana, A..... 96
- Fontao, L..... 97
- Forbes, R..... 80
- Forloni, G.L..... 96
- Foulon, C..... 80
- Foust, K..... 98
- Fox, E.J. 99
- Fox, R. 100
- Fradette, C. 67
- Franchino, F..... 81
- Frank, D. 113
- Franz, D. 133
- Frasquet Carrera, M. 97
- Fratta, P. 80
- Frau, J..... 97
- Freitas, J. 81
- Friberg, M.P.H..... 82
- Frisoni, G. 96
- Frisoni, G.B..... 159
- Fromm, A. 80
- Fronczek, R..... 110
- Fuhr, P. 77
- Fukumura, R..... 80
- G**
- Gadeyne, S. 81
- Gagliardi, D..... 98
- Gajofatto, A..... 67
- Galán, L..... 144
- Galassi, G. 66
- Galego, S. 80
- Galitzky, M..... 65
- Gallo, A. 99
- Gallo, F..... 97
- Gamez, J. 66
- Gandhi, P. 64
- Gandini Wheeler-Kingshott, C.A..... 65, 99
- Gantenbein, A. 139
- Garcez, D..... 81
- Garcia, A. 65
- Garcia-Garcia, J..... 97
- Garcia-Ptacek, S..... 96
- Garcia-Sobrinho, T. 97
- Gärtner, J..... 65
- Gaspard, N..... 91
- Gasperini, C. 100
- Gasser, T. 72
- Gatterer, H..... 100
- Gaudio, E. 80
- Gazdulska, J..... 81
- Genbrugge, E. 81
- Geraldes, R..... 97
- Gertz, M. 66
- Ghariq, M..... 112
- Ghezzi, A. 65, 96
- Giacomotti, E. 100
- Giannoccaro, M.P. 80
- Gil-Gouveia, R. 91, 112
- Gilhus, N.E..... 76
- Gilo, F..... 67
- Giometto, B..... 81
- Giovannoni, G..... 51, 65, 99, 100, 126, 159
- Girtler, N..... 96
- Giunti, P. 80
- Goadsby, P.J. 109, 112
- Gold, R. 100, 106, 126

Speaker Index

Goldstein, J..... 98	Hanna, M..... 67		Karin, I..... 67
Goldwirt, L..... 81	Hardiman, O..... 50	I	Karlsson, G..... 100
Goli, L..... 81	Häring, D..... 65	Idbaih, A..... 81	Karlsson, W..... 82
Gollob, J..... 64	Harper, P..... 64	Ihle-Hansen, H..... 98	Karolis, S..... 80
Gomez, L..... 113	Hartung, H.-P... 65, 66, 99, 155	Imperiale, F..... 96	Kaspar, B..... 98
Gomis, C..... 113	Hassager, C..... 82	Incensi, A..... 64	Kawai, K..... 81
Gondo, Y..... 80	Havrdova, E..... 73, 99, 108	Infante, R..... 64	Kaya, N..... 66
Gonzalez-Duarte, A..... 64	Hawkins, C.P..... 65, 99, 100	Inglese, M..... 99	Kelderman, T..... 96
Gordon, K..... 107	Hayflick, S.J..... 67	Insel, P.S..... 82	Kerkhof, F.I..... 112
Gorevic, P..... 66	Healy, D..... 109	Irani, S..... 86	Kermer, P..... 80
Gorlia, T..... 81	Hecker, C..... 97	Irving, S..... 99	Khatami, R..... 100
Gorman, G..... 67	Heide, W..... 72	Isaacs, A..... 80	Killer-Oberpfalzer, M..... 97
Gosseries, O..... 99, 100	Heitner, S..... 66		Kilner, J..... 113
Gouya, L..... 64	Helbok, R..... 92		Kissel, J..... 98
Goyal, S..... 64	Herholz, K..... 113	J	Kjaergaard, J..... 82
Graessner, H..... 61	Herrmann, DN..... 66	Jaarsma, J..... 20, 89	Klein, C..... 59
Graus, F..... 67	Hidalgo de la Cruz, M..... 65	Jacobson, L..... 80	Klein, J.C..... 64
Grazian, L..... 67	Hilz, M..... 58, 112	Jaeger Wanscher, M.C..... 82	Klingenhofer, L..... 20
Greenberg, B..... 65	Hinz, R..... 113	Jahn, K..... 72, 82, 112	Klopstock, T..... 66, 67
Greenberg, S..... 98	Hirsch, E..... 71	Janes, F..... 67	Kloth, K..... 66
Greensmith, L..... 80	Hobart, J..... 51	Jansen, A..... 133	Klucken, J..... 54
Grisold, W..... 81	Hodgson, R..... 113	Jansen, F..... 80	Kmiec, T..... 67
Grond, M..... 80	Hoffmann, J..... 109	Jaunmuktane, Z..... 80	Kobelt, G..... 51
Guedes, L..... 108	Höftberger, R..... 110	Jelic, V..... 96	Koenig, T..... 96
Guehenec, J..... 81	Hogarth, P..... 67	Jennum, P.J..... 110	Koga, M..... 97
Guekht, A..... 144	Högl, B..... 100	Jensen, R.H..... 58, 78, 112	Koini, M..... 99
Guglieri, M..... 113	Höglinger, G.U..... 53, 159	John, N..... 65, 99, 100	Konziella, D..... 90
Guillonnet, C..... 112	Holtzman, D.M..... 96	Johnell, K..... 96	Kong, X.Y..... 98
Guimarães-Costa, R..... 66	Holzknacht, E..... 100	Jonsson Laukka, E..... 96	Koopmans, M..... 112
Gullotta, G..... 80	Horakova, M..... 66	José Sá, M..... 70	Korlipara, P..... 113
Gulowsen, E..... 138	Horn, J..... 82	Jost, W..... 138	Kornblum, C..... 148
Gurary, N.M..... 112	Hort, J..... 99	Jovicich, J..... 96	
Gurol, E..... 98	Horváth, R..... 51, 66, 67		Körv, J..... 71
	Hösl, K..... 112		Kostic, V.S..... 113
	Houlden, H..... 66, 72, 80		Kovalova, I..... 66
H	Housman, D..... 80	K	Kozubski, W..... 81
Hackner, H..... 100	Howard, J..... 113	Kalaydjieva, L..... 66	Krarup, C..... 66, 94
Hadzhikolev, H..... 112	Hu, M..... 64	Kalina, A..... 99	Kristen, A..... 64, 145
Hagberg, G..... 98	Huang, V..... 99	Kallmünzer, B..... 97	Krogias, C..... 110
Hagedorn, A..... 112	Hughes, D..... 80	Kallweit, U..... 100, 110	Krogseth, S.B..... 98
Hagenacker, T..... 133	Hulst, H..... 99	Kalmar, B..... 80	Kropshofer, H..... 65
Hall, J..... 67	Humphrey, J..... 80	Kalpouzos, G..... 96	Kruja, J..... 38
Hallett, Mark..... 76	Hupperts, R..... 139	Kälviäinen, R..... 53, 61	Krupp, L..... 65
Halvorsen, B..... 98	Husain, M..... 72	Kappelle, J.L..... 78	Kruuse, C..... 98
Hamilton, E.M..... 66	Hynčicová, E..... 99	Kappos, L..... 54, 65, 99, 100	Kubala Havrdova, E..... 65
		Karamyan, A..... 97	Kuca, B..... 112

Kuhle, J.	65, 145	Lerstad, H.	98	Mafra, M.	81	Massa, F.	96
Kuiper, M.A.	82	Leys, D.	77, 97	Magis, D.	78	Massa, R.	57
Kuks, J.	20	Liao, P.	80	Magnani, G.	96	Massacesi, L.	106
Kurz, M.	80, 98	Liguori, C.	81	Magnusson, B.	100	Mataluni, G.	97
Kynman, S.	20	Liguori, R.	64, 67, 80	Magyari, M.	132, 138	Matej 132	
Kyriakides, T.	113	Likhite, S.	98	Mahlknecht, P.	97	Mathis, A.	100
		Lilja, G.	82	Maillart, E.	67, 112	Mathis, J.	52, 100
		Lilleker, J.	113	Mair, K.	97	Mattia, D.	77, 82
		Limousin, P.	113	Malucchi, S.	97	Mattsson, N.	82
L		Lin, K.-P.	64	Man, W.K.	112	Maurage, C.	97
La Morgia, C.	67	Lindelof, M.	82	Manack Adams, A.	112	Mauro, A.	100
Laczó, J.	72, 99	Linker, R.A.	112	Mancinelli, C.R.	67	Mayordomo, F.	113
Laforêt, P.	78	Lipton, R.	112	Mancinelli, R.	80	Mazzoli, M.	66
Lagarde, J.	99	Lisý, J.	99	Manconi, M.	100	McCombe, P.	65
Lambercy, O.	72	L'italien, J.	98	Mancuso, M.	67	McDonnell, G.V.	80
Lamberink, H.	80	Liu, M.	112	Manfioli, V.	67	McFarland, R.	67
Landis, T.	64	Llufriu, S.	67	Manganelli, F.	66	Mc Govern, E.	112
Lang, B.	80	Lo, C.	64	Manita, M.	64	McKinley, J.	80
Lang, E.	65	Lo, K.	80	Mankovsky, Boris N.	144	Meani, A.	96
Lanzavecchia, A.	100	Lo Fermo, S.	98	Mantegazza, R.	127	Megarbane, A.	66
Larkin, P.	54	Logallo, N.	80	Mantovani, C.	81	Mehta, S.	64
Laroni, A.	97	Logoteta, A.	100	Manzato, E.	112	Meinert, R.	65
Latorre, D.	100	Loh, K.Y.	80	Manzur, A.	113	Meissner, W.	65
Latour, P.	66	Lopes, J.M.C.F.	81	Marchioni, E.	81	Melanson, M.	65
Laurà, M.	66	Lopes, M.	97	Maresh, K.	113	Melo Pires, M.	97
Laureys, S.	90, 99, 100	Lopes de Sousa, A.S.	80	Mari, F.	67	Meluzinová, E.	99
Lawo, J.-P.	66	Losito, Silvana	52	Mariano, M.	80	Melzi, V.	98
Lawton, M.	64	Lovett-Racke, A.	99	Marignier, R.	67	Menassa, D.A.	80
Le Ber, I.	53	Loves, L.	98	Marine, B.	112	Mendell, J.R.	98
Le Jeune, F.	80	Lubetzki, C.	38, 77	Mariotto, S.	67	Mendonça, A.	108
Le Rhun, E.	81	Ludolph, A.	98, 108	Marizzoni, M.	96	Mendonca, N.	96
Leal, B.	81	Luigetti, M.	66	Marković, V.	113	Mercuri, E.	113
Leal Rato, M.	113	Lund, N.	112	Markus, H.	53	Mercuri, N.B.	81
Lebedeva, E.	112	Lundberg, C.	52	Marlion, M.	20	Merkies, I.S.	66
Lee, D.-H.	112	Lunn, M.	93	Marques, A.	64	Merlini, G.	66
Lee, J.	112	Lupo, V.	97	Marson, T.	52	Merschhemke, M.	65
Lee, R.Z.	80	Lythgoe, M.	80	Martens, G.	99	Mestre, T.	113
Léger, J.-M.	93			Marti, P.	113	Meyer, K.	98
Lehericy, S.	99			Martin, V.T.	112	Michalak, S.	81
Lehmann, D.	113			Martinkovic, L.	99	Michel, B.	112
Lemaire, N.	81	M		Martino, G.	80	Michel, P.	71
Lemstra, E.	90	Macerollo, A.	99, 113	Martins da Silva, A.	81, 97	Mielke, O.	66
Leocani, L.	94	Macha, K.	97	Martins da Silva, B.	81	Migliorato, A.	113
Leonard-Louis, S.	66	Machado, M.	64	Martins Silva, A.	67	Milanović, S.	99
Leone, M.	20	Maciel, P.	89	Mascia, M.T.	66	Miller, D.	54
Leppert, D.	65	Macmanus, D.	65, 99, 100				

Speaker Index

Millesi, K. 97	Musumeci, O. 113	Orejudos, A. 112	Pearl, P.L. 73
Misiego, M. 97	Mutzenbach, J. 97	O’riordan, W. 64	Peball, M. 97
Mitsikostas, D.-D. 148	Mykland, M.S. 112	Otte, W. 80	Pelayo-Negro, A.L. 97
Mo, F. 81		Ourselin, S. 65, 99, 100	Pellerino, A. 81
Mochel, F. 112		Outeiro, Tiago F. 53	Pellis, T. 82
Modugno, N. 64		Outeiro, Tiago Fleming... 96	Penner, I.K. 149
Möhwald, K. 112		Öztürk, S. 107	Penz, C. 64
Moiola, L. 96	N		Peralta, C. 97
Mok, K. 99	Nabors, L.B. 81		Péran, P. 65
Mokhtari, K. 81	Nadjar, Y. 79		Perren, F. 110
Molinuevo Guix, J.L. 96	Naess, H. 80, 98	P	Petersson, J. 78
Mollenhauer, B. 65	Nagendran, S. 98	Pace, A. 81	Petri, S. 60
Molnar, Judith. 97	Nandedkar, S. 57	Paciaroni, M. 97	Petrović, I. 113
Monaco, S. 67	Nardocci, N. 67	Padua, L. 62	Pfausler, B. 108
Mondello, S. 113	Negrão, L. 127	Paemeleire, K. 96, 139	Pfister, S. 106
Mongini, T. 113, 148	Nesbitt, V. 67	Pagani, M. 96	Phillips, J. 64
Monia, B. 66	Neumayr, L. 67	Pagonabarraga Mora, J. . 127	Piani Meier, D. 100
Montalban, X. 65, 99, 106	Neuteboom, R. 67	Paiva Nunes, A. 80	Piarulli, A. 100
Montaner, J. 88	Neuwirth, C. 57	Palace, J. 76, 97, 110	Picconi, R. 100
Montcuquet, A. 67	Ng, Y.S. 67	Pamblanco, Y. 113	Pichiecchio, A. 81
Monteiro, C. 97	Nichelli, P. 66	Pandolfo, M. 90	Pichiorri, F. 82
Monteverdi, A. 100	Nicholas, R. 145	Panicker, J. 20	Pikija, S. 97
Monzio Compagnoni, G.. 113	Nicoletti, A. 98	Panni, P. 80	Pina, S. 113
Moody, J. 113	Nielsen, N. 82	Papathanasiou, E. 91	Pisciotta, C. 66
Moonen, G. 82	Nikolai, T. 99	Papp, V. 20, 64	Pitceathly, R. 67
Morar, B. 66	Nizzardo, M. 98	Pardini, M. 96	Pittman, A. 80
Morbelli, S.D. 96	Noachtar, S. 93	Pardo Fernandez, J. 97	Piva, R. 96
Moreira, I. 67	Nobile-Orazio, E. 93	Pareto, D. 99	Plagnol, V. 80
Morgante, F. 138	Nobili, F. 96	Pareyson, D. 66, 97	Planté-Bordeneuve, V. 66, 145
Morotti, A. 98	Nocker, M. 97	Parisi, D. 113	Plantone, D. 65, 99, 100
Morra, I. 81	Notermans, N.C. 97	Parker, C. 64	Plazzi, G. 100, 110
Morrison, P.J. 80	Novi, G. 97	Parker, R. 65, 99, 100	Plesnila, N. 82
Mosca, V. 113	Nunes, S. 81	Parman, Y. 66	Podnar, S. 62
Moseby Knappe, M. 82		Parnetti, L. 81, 96	Poewe, W. 77, 97, 138
Muelas, M.M.N. 113	O	Pascual, J. 58	Polydefkis, M. 66
Muhler, N. 99	Oberndorfer, S. 106	Pasquier, F. 97	Poore, C.P. 80
Müller, F. 82	Obici, L. 52, 64, 145	Passos, J. 81	Popkirov, S. 67
Müller, T. 159	Oertel, W. 20, 65, 89	Patti, F. 98	Poulton, J. 67
Mulliez, A. 64	Oh, Jiwon. 139	Paulus, W. 51, 99	Poyatos, J. 113
Munot, P. 113	Oleaga, L. 67	Pauws, E. 80	Pozo-Rosich, P. 148
Muntean, M.-L. 65	Olesen, J. 75, 112	Pavao Martins, I. 108	Pozzato, M. 80
Muntoni, F. 113	Olesen, J. 75, 112	Pavitt, S. 65, 99, 100	Pozzilli, C. 65, 100
Murakami, T. 66	Oliveira, H. 80	Pavone, A. 67	Pozzoli, U. 98
Muresanu, D. 77, 149	Oliveira, V. 89	Pavy-Le Traon, A. 65	Pradhan, C. 99
Musicco, M. 108	Oliver, D. 20, 50, 54	Payoux, P. 96	
	Olivieri, P. 99	Pearce, G.L. 65	
	Oreja-Guevara, C. 20, 138		

Prados, F.	65, 99, 100	Rektor, I.	80	Rothwell, J.C.	51	Santoro, L.	66
Preux, P.M.	50	Religa, D.	96	Rothwell, P.M.	80	Santos, C.	97
Previtali, S.	66	Rendenbach-Mueller, B. ...	96	Rouyrre, N.	100	Santos, E.	67
Priano, L.	100	Reuter, U.	87, 126, 139	Roveri, L.	80	Sanvito, F.	80
Prior, T.	98	Ribaldi, F.	96	Roveta, F.	81	Saraiva, M.J.	90
Probst, P.	82	Ribo, M.	107	Rowe, J.	108	Sarazin, M.	99
Proesmans, S.	81	Ricci, G.	66	Roy, S.	112	Sardh, E.	64
Prokisch, H.	66	Ricketts, T.	80	Rudà, R.	81	Sardoeira, A.	113
Prosperini, L.	100	Ridout, D.	113	Rüegg, S.	87	Sargento Freitas, J.	110
Prüss, H.	87	Rieu, I.	64	Rufa, A.	67	Sarkozy, A.	113
Pugliatti, M.	20, 50, 89	Righi, C.	80	Ruffmann, C.	64	Sastre-Garriga, J.	54
Puybasset, L.	90	Riley, M.	113	Ruggieri, S.	100	Saul, G.	113
<hr/>		Riou, A.	80	Ruiz, A.	67	Scaglione, C.L.	64
Q		Riva, N.	98	Russell, D.	98	Schaedelin, S.	97
Quattrone, A.	66	Rizzo, F.	98	Ruttledge, M.	139	Schaefer, A.	67
Querbes, W.	64	Rizzo, G.	64	Růžička, E.	64, 71, 76, 92	Schäfer, J.	86
Querol Gutierrez, L.A.	51	Rizzuti, M.	98	Rybacka-Mossakowska, J. ...	81	Schanda, K.	67
Quinlivan, R.	113	Robb, S.	113	Rylander, C.	82	Schäpers, B.	82
Quintanilha, A.	37	Roberts, M.	67	Ryvlin, P.	50	Schapira, A.	52
Qureshi, A.	98	Roberts, M.E.	113	<hr/>		Schaumburg, M.	65
<hr/>		Robieson, W.	96	S		Scheinberg, M.	66
R		Rocca, M.A.	65, 96, 99	Sá, Maria José.	138	Scheltens, P.	75
Raedt, R.	81	Rocha, I.	70	Saal, D.P.	112	Schenone, A.	66
Rafiq, S.	98	Rocha, M.	113	Sabatelli, M.	66	Scherer, SS.	66
Rajdova, A.	66	Rock, S.	64	Sacconi, S.	66, 127	Schippling, S.	155
Ramalheira, J.E.D.P.	81	Rodegher, M.	96	Sadun, F.	67	Schmidt, H.	64, 66
Ramesmayer, C.	97	Rodino-Klapac, L.	98	Said Inshasi, J.	65	Schmidt, R.	90
Ramlau, R.	81	Rodolico, C.	113	Saiz, A.	67	Schmierer, K.	159
Raputová, J.	66	Rodrigues, C.	97	Salazar-Lopez, E.	112	Schmitt, C.	81
Rascol, O.	65, 88, 127	Rodrigues, D.	81	Sales, F.	93	Schmitt, W.	100
Rascunà, C.	98	Rodrigues, R.	97	Salgado, D.	81	Schmutzhard, E. ...	91, 93, 112
Ratajczak-Tretel, B.	98	Rodriguez, C.	65	Sallusto, F.	100	Schneider, E.	99
Rauen, K.	82	Rolinski, M.	64	Salmaggi, A.	81	Schöberl, F.	99
Reardon, D.A.	81	Rollot, F.	67	Saloheimo, P.	20, 52	Schoenen, J.	79
Reed, M.	112	Romero, J.	98	Salsano, E.	79	Schonknecht, P.	96
Rees, D.	64	Romoli, M.	81	Sambuceti, G.	96	Schoonheim, M.	86
Regis, J.	113	Rosa, H.	113	Samões, R.	67	Schordan, E.	98
Reichelt, L.	82	Rosa, J.	64	Sampaio, C.	72	Schoser, B.	59
Reichmann, H.	57, 71, 127	Rosa, M.M.	108	Sánchez-Monteaquedo, A. ...	97	Schott, J.	90, 108
Reijntjes, R.H.	112	Rosand, J.	98	Sandor, P.	91	Schottlaender, L.V.	80
Reilly, M.M.	66	Rossetti, A.	92	Sandset, E.C.	98	Schreier, D.	100
Reimao, S.	80, 108	Rossi, F.	67	Sand, T.	112	Schwab, K.	98
Reindl, M.	67	Rossini, P.M.	51, 96	Sanford, R.	80	Schwab, S.	93, 97
		Rossi, S.	97	Sanson, M.	81	Schwertner, E.	96
		Rostasy, K.	65			Scigliano, H.	97

Scomazzoni, F.	80	Snoer, A.	112	Struhal, W.	58	Tournev, I.	64
Sechi, E.	67	Soares, H.	96	Strupp, M.	76, 91	Toyka, K.	20, 39, 73,79, 96
Sechi, G.	67	Sobrido, M.-J.	97	Stupp, R.	81	Toyoda, K.	97
Secnik, J.	96	Sobue, G.	66	Stutters, J.	65, 99, 100	Trad, M.	107
Seelose, N.	100	Soelberg Sørensen, P. .	54, 77	Su, W.	99	Trapp, C.	99
Seferian, A.M.	113	Soffietti, R.	106	Sue, L.	64	Trenkwalder, C.	38, 65, 92
Seiffge, D.J.	97	Solà Valls, N.	67	Suhr, O.	64	Tricta, F.	67
Sellebjerg, F.	132	Solanky, B.	100	Sutcliffe, A.	81	Trinka, E.	50
Sellitti, L.	100	Solari, A.	20	Swayne, O.	80	Troiano, M.	106
Selmaj, K.	65	Sømark, J.	98	Sweetser, M.	64	Truelsen, T.C.	98
Selmaj, K.W.	99	Sommer, C.	70, 80, 93	Swiniuch, D.	81	Tsvigoulis, G.	110
Selzler, K.J.	112	Sørensen, C.G.	82			Tsolaki, M.	96
Semerano, A.	80	Soricelli, A.	96			Tuna, M.	78, 80
Seppi, K.	60, 97	Sormani, M.P.	97	T		Tur, C.	65, 100
Sepulveda, M.	67	Sottilini, F.	81	Taba, P.	80, 92, 113	Turnbull, D.	67, 113
Sequeiros, J.	90, 113	Sousa, A.	64	Tafti, M.	100	Turner, M.R.	60
Serodio, J.	67	Soutar, M.	80	Tagliavini, F.	67	Twyman, C.	99
Serrano, G.	64	Sperli, F.	97	Taiana, M.	98		
Serratos, J.	53, 71	Spinelli, E.G.	98	Taipa, R.	97		
Servais, L.	113	Spino, M.	67	Takagi, M.	97	U	
Sevilla, T.	97	Sproule, D.	98	Talbot, K.	90	Uitdehaag, B.	65
Shakeshaft, C.	97	Stadelmann, C.	54	Tan, J.	66	Ule, A.	80
Sharrack, B.	65, 99, 100	Stallard, N.	65, 99, 100	Tanasescu, R.	67	Ulfberg, J.	100
Sheffield, J.K.	99	Stamelou, M.	92	Tancin Lambert, A.	98	Unterberger, I.	79, 91
Shell, R.	98	Stammet, P.	82	Tanel, R.	67	Ursino, G.	66
Shill, H.	64	Stanier, P.	80	Tardieu, M.	65	Urso, D.	67
Shorvon, S.D.	53	Stanković, I.	113	Tassorelli, C.	126		
Shubin, R.	99	Staykov, D.	93	Tay, C.G.	113		
Shy, ME.	66	Steele, H.	67	Taylor, R.W.	67, 113	V	
Sica, F.	97	Stefani, A.	100	Tazir, M.	66	Valabrègue, R.	99
Siciliano, G.	86	Stefanova, E.	113	Tedeschi, G.	78, 86, 99	Valdúeza, J.	79
Sieb, J.P.	127	Stein, P.	64	Teodoro, T.	113	Valente Fernandes, M.	81
Signori, A.	97	Steiner, I.	91, 108	Tepper, S.	112	Valentino, M.L.	67
Silani, V.	60	Steinman, L.	99	Terwindt, G.	78	Valentino, P.	66
Siliquini, S.	81	Stenton, S.	66	Thibaut, A.	99	Vallat, J.M.	73
Sillevis Smitt, P.A.	67	Stites, T.	65	Thiebaut de Schotten, M.	80	Valls Seron, M.	112
Silvani, A.	81	Stjern, M.	112	Thijs, R.D.	112	Valls-Solé, J.	77
Simionato, F.	80	Stocchi, F.	138	Thompson, A.	77	Valsasina, P.	65, 99
Simon, A.	64	Stojkovic, T.	66, 113	Thouvenot, E.	67	Valzania, F.	66
Siva, A.	70, 108	Storstein, A.	81	Tilikete, C.	76	Van Broeckhoven, C.	87
Sivakumar, P.	80	Stourac, P.	67	Tinelli, E.	100	Van Damme, P.	60
Sixel-Döring, F.	65	Strambo, D.	80	Tinelli, M.	89	Van de Beek, D.	91, 108, 112
Skjelland, M.	98	Straub, V.	113	Titulaer, M.	67, 73, 86, 110	Van den Bergh, P.	66, 88
Skoog, I.	144	Strom, T.-M.	66	Tomic, D.	65, 100	Van der Knaap, M.S.	66
Smailovic, U.	96	Stromillo, M.L.	99	Toscano, A.	59, 113		

Van der Worp, B.	93
Van Diessen, E.	80
Van Dijk, G.	70, 112
Van Doorn, P.A.	78, 88
Van Engelen, B.	108
Van Geloven, N.	66
Van Wijmeersch, B.	65
Vandi, S.	100
Vandrovcova, J.	66
Vanschoenbeek, G.	96
Vasta, R.	98
Vaugoyeau, M.	113
Vázquez-Costa, J.	97
Vega Hernandez, J.	113
Ventura, P.	64
Verdelho, A.	78, 87
Verdijk, R.	67
Vérin, M.	80
Vermersch, P.	65, 100
Vernooij, M.W.	67
Veronese, S.	54
Verreault, M.	81
Verschuuren, J.J.G.M.	76
Vichinsky, E.	67
Vidailhet, M.	59, 61
Vidiri, A.	81
Vilchez, J.J.	59, 113
Vílchez, R.	113
Villarejo-Galende, A.	67
Villar, N.	113
Vincent, A.	80
Vincent, A.E.	113
Visser, N.	97
Visser, P. J.	87, 96
Vissing, J.	57
Viswanathan, A.	98
Vita, G.	66, 113
Vivacqua, G.	80
Vlckova, E.	66
Vodušek, D.	89
Volanti, P.	98
Voltz, R.	54
Von Oertzen, T.	50, 80
Vonck, K.	81
Vrancken, A.	61, 97
Vukusic, S.	67
Vyhnaek, M.	99
<hr style="width: 50px; margin-left: 0;"/>	
W	
Waddington Cruz, M.	66
Wagner, M.	66
Waisfisz, Q.	66
Walker, M.C.	93
Wallis, C.	113
Wang, A.	66
Wang, D.	96
Wang, E.	80
Wang, R.	112
Wannez, S.	99
Warendorf, J.	97
Wattjes, Mike P.	149
Waubant, E.	65
Weber, K.P.	76
Weber, M.	57
Weckhuysen, S.	53
Weir, C.J.	65, 99, 100
Wekerle, H.	75
Weller, M.	81, 106
Wells, C.	98
Wenning, G.	58
Wenning, G.K.	92, 97
Werkmann, M.	97
Werring, D.	97
Westhall, E.	82
Wetterslev, J.	82
Wheeler-Kingshott, C.	100
Whelan, C.	66
Wicke, T.	65
Wick, W.	81
Wietecha, L.A.	112
Wildt, T.	100
Willeit, P.	97
Willison, H. J.	88
Wilson, D.	97
Wilson, M.-C.	112
Wiltfang, J.	96
Winblad, B.	96
Wise, M.P.	82
Witjas, T.	113
Wolf, N.	66
Wolinsky, J.	65
Wood, N.W.	66
Wurster, C.	133
<hr style="width: 50px; margin-left: 0;"/>	
Y	
Yamashita, T.	64
Yamout, B.	139
Yang, C.-C.	64
Yick, L.W.	67
Yu, L.	98
<hr style="width: 50px; margin-left: 0;"/>	
Z	
Zahedmanesh, H.	113
Žamečnik, J.	148
Zamrini, E.	64
Zappia, M.	98
Zeiler, S.	149
Zephir, H.	67
Zepper, P.	50
Zetterberg, H.	82
Zhang, H.	113
Zhang, N.	64
Zhao, F.	67
Ziemssen, T.	132, 155
Zierz, S.	113
Zimmermann, J.	65
Živanović, M.	99
Zoccarato, M.	67
Zorzi, G.	67
Zuliani, L.	67, 97
Zwergal, A.	99, 112

Notes

The official journal of the
**European Academy
of Neurology**



**FREE
Guidelines**

Impact Factor
3.988

Free Online Access for EAN Members



FREE Guidelines



Reviews



High Impact
Research Articles



Topical Virtual
Issues

**Discover how you can read -
and write for *European Journal of Neurology***

Publish Your Next Paper With Us

Visit the EAN or Wiley Congress booths to find out why and how

Discover more at

wileyonlinelibrary.com/journal/ene or www.ean.org

ean
congress

5th Congress of the
European Academy
of Neurology

Oslo
2019

June 29 – July 2



Abstract submission deadline
23 January 2019
Early registration deadline
10 April 2019

Neuroinflammation

Science. Synergies. Solutions.



www.ean.org/oslo2019
#ean2019   